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ABSTRACT 
Described herein is the chemoenzymatic total synthesis of several 
Amaryllidaceae constituents and their unnatural C-I analogues. A new approach 
to pancratistatin and related compounds will be discussed along with the 
completed total synthesis of 7 -deoxypancratistatin and trans-dihydrolycoricidine. 
Evaluation of all new C-l analogues as cancer cell growth inhibitory agents is 
described. 
The enzymatic oxidation of dibromobenzenes by Escherichia coli 1M 109 
(pDTG60 1) is presented along with conversion of their metabolites to (-)-conduritol 
E. Investigation into the steric and functional factors governing the enzymatic 
dihydroxylation of various benzoates by the same organism is also discussed. The 
synthetic utility of these metabolites is demonstrated through their conversion to 
pseudo-sugars, aminocyclitols, and complex bicyclic ring systems. 
The current work on the total synthesis of some morphine alkaloids is also 
presented. Highlighted will be the synthesis of several model systems related to 
the efficient total synthesis of thebaine. 
11 
ACKNOWLEDGEMENTS 
There are a number of individuals to whom I would like to express my 
thanks for their support and assistance in the course of preparing this manuscript. 
I would first like to express my gratitude to my research advisor Professor Tomas 
Hudlicky. His career-long dedication to the training of young professionals is 
inspirational and I feel fortunate to have been given the opportunity to apprentice 
in his laboratory. 
I would like to thank the members of my graduate committee: Professor Georgii 
Nikonov and Professor Tony Van. Professor Jeffrey Atkinson and Professor 
Stuart Rothstein are thanked for their participation in my candidacy examination. 
I would like to thank Razvan Simionescu and Tim Jones for their help with 
collection and analysis ofNMR spectroscopic and mass spectroscopic data. 
I am forever in debt to my many talented colleagues in the Hudlicky lab both past 
and present. I particular I would like to thank Dr. Kevin Finn, Dr. Michael 
Moser, Dr. Uwe Rinner, Dr. Bradford Sullivan, Dr. Hannes Leisch, Dr. Fabrizio 
Fabris, Melissa Drouin, and Leon Sun for their collaboration on various projects. 
I would like to thank my parents Tim and Brenda Collins for their endless support 
and enthusiasm through these seemingly endless years of schooling. 
Finally, I would like to express my appreciation to my wife Dottie. Her patience 
and understanding for the demands of my studies has been nothing short of 
amazing. I chose chemistry for the love of science but my work is and will 
always be for her. 
111 
TABLE OF CONTENTS 
ABSTRACT 
ACKNOWLEDGEMENTS 
LIST OF TABLES 
LIST OF SCHEMES 
LIST OF FIGURES 
LIST OF ABBREVIATIONS 
CHAPTERS 
I. Introduction 
II. Historical 
II -1 Aromatic Dioxygenases 
II -1.1 History of Microbial Oxidation of Aromatics 
11-1.2 On the Mechanism of Arene Oxidation by 
Oxidoreductase Enzymes 
11-1.3 Diversity of Known Dihydroarenediols and 
Their Utility in Synthesis 
11-2 Amaryllidaceae alkaloids 
II -2.1 Biosynthesis of Amaryllidaceae Alkaloids 
11-2.2 Biological Activity and Pharmacophore Studies 
II -2.3 Selected Synthesis of Amaryllidaceae Alkaloids 
11-3 Morphine Alkaloids 
11-3.1 Biosynthesis of Morphine Alkaloids 
11-3.2 Selected Syntheses of Thebaine 
and its Use in Semi-synthesis 
III. Discussion 
III -1 Introduction 
111-2 Dihydroxylation of 0- and m-Dibromobenzene and 
Total Synthesis of (-)-Conduritol E 
111-3 Dihydroxylation of Benzoate Esters 
111-3.1 Synthesis of Pseudo-sugars, Amino Cyclitols, and 
Bicyclic Ring Systems 
111-4 Intramolecular Aziridine Opening Approach to 
the Amaryllidaceae Alkaloids 
111-4.1 Synthesis ofC-1 Analogues of7-Deoxypancratistatin 
111-4.2 Total Synthesis oftrans-Dihydrolycoricidine 
111-4.3 Formal Total Synthesis of7-Deoxypancratistatin 
111-4.4 Biological Evaluation of Intermediates 
111-5 Latent Symmetry, Diels-Alder Approach to Thebaine 
IV. Conclusions and Future Work 
V. Experimental Section 
V-I General Experimental Details 
V -2 Detailed Experimental Procedures 
VI. Selected Spectra 
VII. References 
vm. Vita 
11 
111 
V 
VI 
IX 
Xl 
I 
4 
4 
4 
5 
11 
16 
18 
20 
24 
39 
44 
48 
55 
55 
58 
62 
65 
69 
69 
84 
85 
97 
104 
115 
117 
118 
122 
190 
222 
240 
IV 
LIST OF TABLES 
Table 1. Dihydroxylation of Benzoate Esters. . 64 
Table 2. Hydrogenation of Alkyne 223. 73 
Table 3. Attempted Reductive Amination Reactions. 83 
Table 4. Conditions Attempted for Formation of Silver Salt 264. 90 
Table 5. Attempted Grob Fragmentations and Oxetane Formation. 93 
Table 6. Human Cancer Cell Line and Murine P-388 Lyphocytic 
Inhibitory Activities. 99 
Table 7 Formation of Furan Tether. 109 
v 
LIST OF SCHEMES 
Scheme 1. Proposed pathway for the metabolism of p-chlorotoluene 
by toluene-grown cells of P. Putida. 6 
Scheme 2. Isotope labelling experiments in the oxidation of arenes. 7 
Scheme 3. Metabolism of toluene by soil bacteria and 
recombinant strains of E. coli. 8 
Scheme 4. Danishefsky's synthesis ofpancratistatin. 25 
Scheme 5. Hudlicky's synthesis ofpancratistatin. 26 
Scheme 6. Li' s synthesis of pancratistatin. 28 
Scheme 7. Pettit's relay synthesis ofpancratistatin. 29 
Scheme 8. Ohtas and Kimotos synthesis of 7 -deoxypancratistatin. 30 
Scheme 9. Paulsen and Stubbes synthesis of7-deoxypancratistatin. 31 
Scheme 10. Hudlicky's synthesis of7-deoxypancratistatin. 33 
Scheme 11. Padwa's synthesis of7-deoxypancratistatin. 34 
Scheme 12. Gabrielsen's relay synthesis of trans-dihydrolycoricidine. 35 
Scheme 13. Chida's synthesis of trans-dihydrolycoricidine. 36 
Scheme 14. Ogasawara's and Iwabuchi's synthesis of 
trans-dihydrolycoricidine. 38 
Scheme 15. Rapoport's synthesis of thebaine. 49 
Scheme 16. Schwartz's synthesis of thebaine. 49 
Scheme 17. Stork's synthesis of thebaine. 51 
Scheme 18. Synthesis of oxycodone from thebaine. 52 
Scheme 19. Synthesis of hydro cod one from thebaine. 53 
Scheme 20. Synthesis of naltrexone and naloxone from thebaine. 54 
Scheme 21. Synthesis of (-)-conduritol E (162). 61 
Scheme 22. Synthesis of Mosher ester 183. 62 
Scheme 23. Conversion of diene carboxylates to ester 199 and 
proof of absolute configuration. 
Scheme 24. Synthesis of carba-a-L-galactopryanose (164). 
65 
66 
VI 
Scheme 25. Application of Die Is-Alder reactions to 
benzoate-derived diols. 
Scheme 26. Synthesis ofepoxy-aziridine (217) and selective 
oxirane opening. 
Scheme 27. Synthesis of acetylene 222. 
Scheme 28. Intramolecular aziridine opening and synthesis 
of C-l aldehyde by oxidative phenanthrene cleavage. 
Scheme 29. Ozonolysis route to aldehyde 169 and 
68 
71 
72 
74 
proposed oxidative cleavage of hydroxyl-ketone 235. 77 
Scheme 30. Conversion of C-l aldehyde 169 to 
C-l ester 172 and acid 171. 78 
Scheme 31. Alternate oxidative cleavage of olefm 215. 79 
Scheme 32. Conversion of C-l aldehyde 166 
to alcohol 167 and acetoxymethylene derivative 170. 80 
Scheme 33. Alternative approaches to alcohol 238. 81 
Scheme 34. Attempted synthesis of C-l amines. 82 
Scheme 35. Displacement of C-l mesylate and synthesis of amide 251. 84 
Scheme 36. Synthesis of trans-dihydrolycoricidine (3). 85 
Scheme 37. Investigation of Baeyer-Villiger oxidation 
for C-l functionalization. 87 
Scheme 38. Hunsdiecker conditions employed toward synthesis of263. 89 
Scheme 39. Attempted synthesis of epoxide 267 through 
C-2 hydroxyl elimination. 90 
Scheme 40. Attempted olefm formation by Grobb fragmentation 
or through elimination oxetane 269. 91 
Scheme 41. Synthesis ofmesylate 268. 92 
Scheme 42. Approaches toward olefin 270 by decarboxylation. 94 
Scheme 43. Additional approaches to olefm 270 through acid 277. 95 
Scheme 44. Further attempts at C-2 hydroxyl elimination 
and formation of olefm 282. 96 
Scheme 45. Formal synthesis of7-deoxypancratistatin (2). 97 
Vll 
Scheme 46. Synthesis ofpyridazine 291. 
Scheme 47. Synthesis of furan tether 290. 
Scheme 48. Synthesis of dihydrofuran 292. 
Scheme 49. Hydroamination of bis(pyridazines) 6. 
Scheme 50. Synthesis of hydroa min at ion catalyst 312. 
Scheme 51. Sonagashira coupling ofTMS acetylene 
with chlorpyridazine 313. 
Scheme 52. Tethering of dihydrofuran 292 to amine 309. 
108 
109 
110 
111 
112 
112 
113 
V111 
LIST OF FIGURES 
Figure 1. General strategy for synthesis ofAmaryllidaceae constituents. 1 
Figure 2. Retrosynthetic analysis of thebaine. . 3 
Figure 3. Proposed pathway for catechol formation from benzene. 5 
Figure 4. Model for regio- and stereo selectivity of the 
oxidation of single ring aromatics. 10 
Figure 5. Ley's synthesis of(±)-pinitol. 11 
Figure 6. Hudlicky's formal synthesis ofPGE2a. 12 
Figure 7. Hudlicky's synthesis of Con dura mine A-I. 13 
Figure 8. Banwell's formal synthesis ofPlatencin. 14 
Figure 9. Micalizio's use ofmetalo-[3,3] rearrangement 
in the synthesis of (+ )-phorbacin C. 15 
Figure 10. Representative Amaryllidaceae constituents. 17 
Figure 11. Biosynthesis of O-methylnorbelladine (49). 19 
Figure 12. Biosynthesis of Amaryllidaceae alkaloids. 20 
Figure 13. Known 60S ribosomal subunit binders 
trichodermin (60) and anisomycin (61). 21 
Figure 14. Pancratistatin as a model for required pharmacophore 
in the Amaryllidaceae alkaloids as proposed by Pettit. 23 
Figure 15. Naturally occurring morphine alkaloids. 41 
Figure 16. Semisynthetic opiods. 44 
Figure 17. Biosynthesis of (R)-reticuline (134). 45 
Figure 18. Biosynthesis of thebaine, codeine, and morphine. 46 
Figure 19. Alternate biosynthesis of morphine. 47 
Figure 20. Enzymatic oxidation of substituted benzenes in the 
synthesis of cyclitols. 56 
Figure 21. Chemoenzymatic synthesis of7-deoxypancratistatin (2), 
trans-dihydrolycoricidine (3), and various C-l analogues of 
7-deoxypancratistatin (167-170). 57 
Figure 22. Proposed model system and the total synthesis ofthebaine. 58 
IX 
Figure 23. Symmetry of dibromobenzenes and the metabolism to diols. 60 
Figure 24. Enzymatic dihydroxylation of benzoate esters. 63 
Figure 25. Retrosynthetic analysis for the synthesis 
of Amaryllidaceae alkaloids and their C-l analogues. 
Figure 26. Full assignment ofNMR chemical shifts for 
the acetate of keto alcohol 232. 
Figure 27. Baeryer Villiger reaction in the synthesis of 
7 -deoxypancratistatin (2). 
Figure 28. Evaluation ofapoptosis induced by 167 and 170 
after 72 hours with Hoechst staining. 
Figure 29. Evaluation of apotosis induced by 167 and 170 
after 48 hours and Annexin-V binding. 
Figure 30. Apoptosis induced by 167 after 72 hours and 
determination of ED 50. 
Figure 31. Apoptosis induced by 170 after 72 hours and 
determination of ED50. 
Figure 32. Screening of 170 against non-cancerous human cells 
70 
76 
86 
101 
101 
102 
102 
with Hoechst staining. 104 
Figure 33. Retrosynthetic analysis of latent symmetry approach 
to thebaine (4). 105 
Figure 34. Proposed model systems for the synthesis of thebaine (4). 106 
x 
LIST OF ABBREVIATIONS 
Ac Acetyl 
AIBN 2,2' -Azob(isobutyronitrile) 
Bn Benzyl 
Bz Benzoyl 
CDI Carbonyl diimidazole 
COSY (proton) Correlated spectroscopy 
DBU 1,8-Diazobicyclo[5.4.0]undec-7-ene 
DCC dicyclohexylcarbodiimide 
DDQ 2,3-Dichloro-5,6-dicyano-l,4-benzoquinone 
DIAD Diisopropyl azodicarboxylate 
DMAP 4-(Dimethylamino )pyridine 
DME 1,2-Dimethoxyethane 
DMF N,N-Dimethylformamide 
DMP 2,2-Dimethoxypropane 
DMS Dimethylsulfide 
DMSO Dimethylsulfoxide 
HRMS High resolution mass spectrometry 
IBX 2-Iodoxybenzoic acid 
IMDA Intramolecular Diels-Alder (reaction) 
Imid Imidazole 
IR Infrared 
KHMDS Potassium hexamethyldisilazide 
LAH Lithium aluminum hydride 
m-CPBA m-Chloroperoxybenzoic acid 
MOM methoxymethyl 
mp melting point 
Ms mesyl (methanesulfonyl) 
NADPH nicotinamide adenine dinucleotide phosphate 
NMO N-methylmorpholine-N-oxide 
NMR Nuclear magnetic resonance (spectroscopy) 
Xl 
nOe 
PAD 
PCC 
Py 
SMEAH 
TBAF 
TBS 
Tf 
TDO 
TEA 
THF 
THS 
TLC 
TMS 
Ts 
Nuclear Overhauser effect 
Potassium azodicarboxylate 
Pyridinium chlorochromate 
Pyridine 
bis(2-methoxyethoxy)aluminum hydride 
Tetrabutylammonium fluoride 
t-Butyldimethylsilyl 
Triflyl (trifluoromethanesulfonyl) 
Toluene dioxygenase 
Triethylamine 
Tetrahydrofuran 
Thexyl (dimethyl-(2,3-dimethyl-2-butyl)silyl) 
Thin layer chromatography 
Trimethylsilyl 
Tosyl (p-toluenesulfonyl) 
XlI 
I. Introduction 
The ideal synthetic target for any organic chemist is one that incorporates both 
structural complexity and prospective utility. Intricate molecules provide 
interesting synthetic problems for chemists to tackle in addition to encouraging 
the development of new methods. The envisioned utility of a chosen target 
provides synthetic organic chemists with real-world relevance with which to 
ground their intellectual pursuits. One group of natural products which fulfill 
both criteria is the Amaryllidaceae constituents. The synthesis of these 
biologically active compounds and their unnatural analogues has a rich history in 
the Hudlicky group. Our current strategy relies on construction of the highly 
oxygenated C ring of 7-deoxypancratistatin (2) and trans-dihydrolycoricidine (3) 
from chiral cis-cyc1ohexadienediols. We arrive at these building blocks through 
an enzymatic dihydroxylation of substituted benzenes (Figure 1). 
x X 
OH 
.. 
.. OH 
~ ___ ~~ -tv0H __ ---... ~ (0 ~OH 0 OH 
R1 0 
R1 = OH, R2 = OH, pancratistatin (1) 
R1 = H, R2 = OH, 7-deoxypancratistatin (2) 
R1 = H, R2 = H, trans-dihydrolycoricidine (3) 
R1 = C-1 analogues 
Figure 1. General strategy for synthesis of Amaryllidaceae constituents. 
The biooxidation is high yielding and allows for the subsequent construction of 
the isocarbostyril framework in an enantioselective fashion while at the same time 
I 
reducing the environmental impact of the synthesis. Natural supply of the most 
active congeners is often lacking, so the development of a truly efficient synthesis 
is crucial to their further advancement as candidates for the treatment of cancer. 
The flexibility of these synthetic designs has the added benefit of allowing 
for ready synthesis of unnatural analogues of the targeted Amaryllidaceae 
constituents. This work represents an important contribution given the 
remarkable activity associated with many of these natural targets and their 
sometimes less than desirable bioavailability characteristics. The synthesis and 
biological evaluation of a variety of C-l analogues has been pursued in parallel 
with total synthetic efforts and constitutes a significant portion of this manuscript. 
In addition to their application in the synthesis of Amaryllidaceae 
constituents we also set out to further explore the utility of new cis-
cyc1ohexadienediols. We desired to investigate various dibromobenzenes as 
substrates for the above mentioned enzymatic dihydroxylation with the hope of 
producing new and synthetically useful materials. In the same vein, we also 
endeavored to establish the scope and limitations of the chemoenzymatic 
transformation of benzoate esters. This work was undertaken at the time for its 
intended use in the synthesis of cyc1itols and the antiviral agent Oseltamivir 
(Tamiflu). 
Another group of natural products that present interesting synthetic 
challenges is the opiates. The design and execution of a synthesis genuinely 
adaptable to large-scale preparation of morphine alkaloids has been a long 
standing goal in the Hudlicky group. This has led to the development of a number 
2 
of approaches and total synthesis efforts. 1 Given the increasing importance of 
thebaine in recent years we have elected to pursue its total synthesis through a 
cascade Diels-Alder route (Figure 2). Initial investigation of this strategy utilized 
thiophene as a diene partner in an intramolecular cycloadditions but recent reports 
by Boger and Bodwell3 have inspired us to incorporate nitrogen-containing 
heterocycles as the diene component. The results of our efforts in this endeavor 
are presented as the third component of this manuscript. 
thebaine (4) 
5 
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Figure 2. Retrosynthetic analysis of thebaine. 
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A unifying theme in the work of the Hudlicky group is the use of 
chemoenzymatic processes to generate chiral building blocks useful in synthesis. 
As enzymatic oxidation of arenes is a component in the majority of the work 
contained here, the next section begins with a review of this key dihydroxylation 
reaction. 
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II. Historical 
11-1 Aromatic Dioxygenases 
11-1.1 History of Microbial Oxidation of Aromatics 
While the use of various microorganisms in the production of foodstuffs 
predates recorded history, the first use of biocatalysis is credited to Brown.4 
While this early work demonstrated that biocatalysis could be used to effect 
chemical transformations systematic study of microbial metabolism of 
hydrocarbons did not begin until the early 20th century. 5 Degradation of 
aromatics by bacteria has been described as early as 1908 when the bacterium 
Bacillus hexacarbavorum was shown to grow on toluene and benzene. 6 Five 
years later a report by Sohngen described a bacterium that tolerated various 
concentrations of benzene.7 The first isolated product of these fermentations was 
shown to be catechol. 8 In this study the gram-negative Pseudomonas aeruginosa 
was shown to grow in the presence of both benzene and catechol. A long debated 
question of the possible intermediacy of phenol in the oxidation of benzene was 
put to rest when Marr and Stone demonstrated that these bacteria did not 
metabolize phenol effectively. 9 With their proposed intermediate, 3,5-
cyc1ohexadiene-l,2-diol, being described as "unavailable" they nonetheless 
reasoned its existence along with the presence of the required dehydrogenase by 
analogy with mammalian systems such as the I ,2-dihydronaphthalene-1 ,2-diol 
isolated following rat metabolism of naphthalene. 
The continued study of bacteria-mediated arene metabolism led to the 
1968 seminal paper by Gibson in which he described a strain of Pseudomonas 
4 
putida that utilized toluene and benzene as a carbon source. IO It was 
demonstrated that benzene and toluene were oxidized at equal rates and that one 
mole of oxygen was taken up per mole of substrate en route to the formation of 
catechol. The possibility of an epoxidation as the first step in the pathway was 
discounted when it was shown that trans-benzene glycol was not effectively 
metabolized by cells that were shown to rapidly transformed the cis isomer (cis-
cyc1ohexa-3,5-diene-l,2-diol). Gibson eventually proposed a mechanism for the 
transformation of benzene to catechol that involved dioxobicyle 10 (Figure 3). 
(X0H ----:.~ I ~ OH 
9 10 11 12 
Figure 3. Proposed pathway for catechol formation from benzene. 
In an effort to provide stronger evidence for intermediate 10 Gibson began work 
on the oxidation of more diversely substituted aromatics. 
11-1.2 On the Mechanism of Arene Oxidation by Oxido-reductase Enzymes 
In the fall of 1968 Gibson reported the oxidation of halogenated benzenes 
and p-chlorotoluene by the soil bacteria P. putida. II Gibson was able to show that 
the halogenated benzenes were metabolized at decreasing rates with increase of 
halogen substituent size. In each case the halogenated catechols were isolated. In 
the case of the p-chlorotoluene (13) a mixture of compounds was isolated 
(Scheme 1). The initial biotransformation of 13 yielded a mixture of catechol 15 
5 
and at that time unknown 2,3-dihydroarenedioI14. Treatment of diol14 with 2 N 
Hel gave rapid conversion to phenols 16 and 17. This observation combined with 
a variety of spectroscopic methods led Gibson to propose the correct structure of 
4-chloro-2,3-dihydroxy-I-methylcyclohexa-4,6-diene (14). Isolation of the first 
cis-2,3-dihydroarenediol derived from toluene was reported less than a year later 
through the action of the mutant P. putida 39/D.12 
¢ O2 ¢CoH NAD+ ¢roH .. .. ~ OH ~ OH 
CI CI CI 
13 14 15 
HCI 
A 
¥OH 
CI 
16 
Scheme 1. Proposed pathway for the metabolism of p-chlorotoluene by toluene-
grown cells of P. Putida. 
The absolute stereochemistry of (+)-cis-2,3-dihydroxy-I-methylcyc1ohexa-
4,6-diene was later assigned by its conversion to (R)-( -)-2-methyladipic acid. 13 In 
this proof the stereocenters of the cis-diol were destroyed leaving assignment to 
be inferred from the assumed face-selectivity of a hydrogenation step. It was not 
until 15 years later that unambiguous assignment of absolute configuration would 
be demonstrated in the synthesis ofPGE2a.14 
6 
The diverse pathways by which oxo-reductase enzymes process aromatic 
substrates have been a subject of study since the mid 1930s. The first dihydrodiol 
derived from aromatics to be isolated was trans-l ,2-dihydroxy-l ,2-
dihydroanthracene, the product of cytochrome P-450 epoxidation of anthracene. 15 
In 1962 Boyland and Booth demonstrated that only one atom of 180 2 was 
incorporated in the dihydroxylation of benzene (18), (Scheme 2).16 In a similar 
experiment, Gibson demonstrated that both atoms of 180 2 are incorporated in the 
cis-dihydroxylation of naphthalene (23).17 
[ 
18 ] o epoxide o _rome P-45,2 d hydrolase. 189H : OH o 
18 19 20 
P. putida 
.. 
18 0H 
00'18 catechol I ~ OH dehydrogenase .. h h 
23 24 
21 22 
o:r
180H 18 
~ ~ OH 
I h h 
25 
Scheme 2. Isotope labeling experiments in the oxidation of arenes. 
In the oxidation of arenes by eukaryotic organisms the aromatic substrates 
are converted to catechols through their epoxide intermediates. Arene oxides 
formed in this manner either undergo rearrangement or trans-opening by various 
nuc1eophiles. In the case of prokaryotic organisms, such as soil bacteria, 
dioxygenase enzymes introduce two oxygen atoms. Intermediates such as 24 then 
usually undergo re-aromatization through the action of catechol dehydrogenases, 
a pathway later established by Gibson in his characterization of mutant P. putida 
strains. 
7 
The identification and characterization of the mutant P. putida 39/D was a 
major breakthrough in the development of arene cis-diol research. 12 The blocked 
mutant lacked the ability to further metabolize the intermediate dihydroarene diols 
and so allowed for their accumulation and isolation. Extensive study of this and 
other mutant strains led to the identification of the nucleotide sequence of the 
genes responsible for coding the toluene catabolic pathway. 18 The elaborate 
electron transport chain enabling this metabolism was also identified. These 
genes were actively expressed in E. coli hosts creating a variety of organisms 
which reproduce either part of or the entire catabolic pathway (Scheme 3). 
I 
wild type P. put/da I I mutant strain l P. put/da 39/0 
0 
0 toluene (x00 c/s-dihydrodiol Oc001~- ~ dioxygenase .. dehydrogenase .. :1 ._ ...... " 1 (TOO) ~ OH 00 ~OHl 
26 27 H02e 28 
JM109(pOTG601) t I JM109(pOTG602) t acetate 
(todC1C2BA) (todC1C2BAD) recombinant 
JM 109 (pOTG602) strains 
(todC1C2BAD) 
Scheme 3. Metabolism of toluene by soil bacteria and recombinant strains of E. 
coli 
The recombinant organism JMl09(pDTG601) was created to over-express 
the first part of the pathway allowing for efficient production of cis-
dihydrodiols. 18 The recombinant organism JM109(pDTG602) was also created 
allowing for the chemoenzymatic synthesis of catechols from either arenes or the 
isolated cis-dihydrodiols 26. A third organism JM109(pDTG603) was also 
8 
created which expressed 1,2-catechol dehydrogenase and metabolized toluene to 
2-hydroxy-6-oxo-2,4-heptadienoate (28). To this day, the least understood aspect 
of the pathway remains the remarkable dihydroxylation catalyzed by the toluene 
dioxygenase enzyme (TDO). Several mechanisms have been proposed17,19,2o and 
despite reporting of the X-ray crystal structure of naphthalene dioxygenase,21 a 
related enzyme, the exact mechanism remains elusive. 
Even without the availability of exact mechanistic details of the key 
dihydroxylation these biocatalysts have become readily available tools in 
synthetic organic chemistry.22 Whole-cell fermentation protocols facilitate these 
transformations without the need to account for the complex electron-transport 
chains and cofactors associated with isolated oxidoreductase enzymes. The use of 
recombinant E. coli in these transformations provides several advantages over the 
same transformations done using the wild or mutant strains. Protocols for use of 
blocked mutants require toluene or chlorobenzene as inducers for protein 
synthesis. The complication of having the inducer also be a substrate is avoided 
In the recombinant organIsm where the sugar analogue, fJ-
isopropylthiogalactopyranoside (IPTG) is used to induce enzyme production. 
Also recombinant cells contain multiple copies of the plasmid allowing for higher 
concentrations of the desired enzyme and greater space/time yields of diols. 
In the little over forty years since Gibson's isolation of the first stable cis-
cyclohexadienediol the matebolic pathway has been mapped, the recombinant 
organisms engineered, and more than 400 substrates of toluene dioxygenase and 
related enzymes have been identified. With such a large substrate library it is 
9 
surprising that only a fraction of these richly functionalized compounds have been 
exploited in synthesis. Listings of known metabolites and their synthetic 
applications have been extensively reviewed?3 The broad number of metabolites 
with varying substitution patterns has allowed for the development of an 
empirical model for the regio- and stereo selectivity of the oxidation (Figure 4)?4 
R(large) 
Figure 4. Model for regio- and stereo selectivity of the oxidation of single ring 
aromatics. 
In the model, oxidation proceeds as shown according to the orientation of the ring 
substitution. It is proposed that the smaller group of disubstituted, single ring 
aromatics is more easily accommodated into the active site to provide oxidation 
products as shown. This predictive model has helped in the incorporation of new 
cis-dihydrodiols into synthetic schemes, in some cases before the diols are even 
confirmed metabolites. 
10 
11-1.3 Diversity of Known Dihydroarenediols and Their Utility in 
Synthesis 
The first application of these cis-dihydrodiol metabolites in synthesis was 
the preparation of polyphenylene using benzene cis-dihydrodiol11 in 1983.25 In 
this seminal publication researchers at lei exploited the diene functionality in a 
radical polymerization reaction. Elimination of the protected diols followed to 
provide polyphenylene fibers and films. It is important to note that the diol 
functionality was destroyed in this process reforming the arene. The first true 
exploitation of the diol functionality would have to wait until accademic interest 
in the same meso diol (11) was initiated by Ley with his synthesis of (±)-pinitol 
(44).26 In Ley's synthesis, the diols were retained and utilized in their protected 
form to facially direct epoxidation of the diene (Figure 5). Selective opening of 
the resulting vinyl epoxide with methanol set the stage for the introduction of the 
final oxygenation with OS04. The use of the diol functionality to direct · further 
transformations and the steric and electronic differentiation of the olefins would 
prove to be standard strategies in the application of these cis-dienediols in 
synthesis. 
protected 
d· ct d form used to Ire . e . direct 
epoxldatlon and oxidations 
selective opening ) 
~(X0H 5 steps 
directed ~ ~ 
dihydroxylatV OH 
11 
Figure 5. Ley's synthesis of(±)-pinitol. 
OH 
Me0yYoH 
HO,,·l00H 
OH 
(±)-pinitol (29) 
11 
Oxidative Cleavage of Arene cis-Diols 
The first enantiose1ective synthesis that incorporated arene cis-diols was 
the fonnal synthesis of PGE2a (32) by Hudlicky.14 The use of the chiral cis-diol 
(30) derived from enzymatic oxidation of toluene differentiated this synthesis 
from the previous work by Ley. It is also noteworthy for its adaptation of 
oxidative cleavage protocols to the dihydroarene diol framework (Figure 6). 
oxidative 
cleavage & 
recYlizftiO~OH __ ---. 
",-UOH • lev 
30 31 0'\ 
Figure 6. Hudlicky's fonnal synthesis ofPGE2a. 
The Pseudomonas putida mutant strain 391D was used to transfonn toluene to its 
corresponding cis-diol in a yield of 3 giL of culture. The diol was protected as its 
acetonide prior to oxidative cleavage of both olefms with ozone. The resulting 
ketoaldehyde underwent intramolecular aldol condensation to provide enone 31, a 
fonnal intennediate in the synthesis ofprostiglandins.27 The fonnal synthesis was 
completed in four steps, a substantial improvement upon reported synthesis at the 
time.23a 
Use of Arene cis-Diols as Cycloaddition Partners 
Other classes of transfonnations that have been applied to cis-dienediols 
include cycloadditions. The ability of these diol intennediates to behave as the 
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diene component in Diels-Alder reactions was fIrst demonstrated by Gibson. 12 
The fIrst application of Diels-Alder reactions to cis-dihydrodiol metabolites in 
total synthesis was Hudlicky's preparation of Con dura mine A-I (36) (Figure 7). 
used to impart protected form used to 
regioselectivity direct selectivity of 
to CYCload~{n£~:j_ vo~ ccOH OH 
cycloadditions U
OH 
.:-... 0 ----:l.~ I OH 
X = CI or Br \ NH2 
33 34 35 ~ Conduramine A-1 (36) 
Figure 7. Hudlicky's synthesis of Con dura mine A-I. 
Chloro- or bromo-dienediol 33 or 34 were protected as their acetonides prior to 
facial and regioselective [4+2] cycloadditions with nitrosyl dienophiles to yield 
35. Reductive cleavage of the N -0 bond with sodium amalgam also resulted in 
dehalogenation with retention of stereochemistry at the three asymmetric 
positions. The synthesis of conduramine A-I (36) was completed in fIve steps 
from bromo- or chlorobenzene with complete regio- and stereocontrol of the 
Diels-Alder reaction being achieved by exploiting key functionality of the cis-
, I 
dienediols 33 and 34. 
Use of Arene cis-Diols as Cross-Coupling Partners 
In addition to Diels-Alder reactions these diols have also been employed 
in a variety of coupling reactions en route to natural products. In their synthesis 
of platencin (40i8, the Banwell group combined an intramolecular cycloaddition 
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with a cross-coupling protocol to provide an intermediate synthesized by 
Nicolaou (Figure 8).29 
CCYclOadditiOn r~~~'l'\OH _. --l .... 
Y"'OH (137 
cross-coupling 
.,,0\/ 
"'0/\ 
38 
OTBDMS 
TBDMSO~ 
.. 'I 
o 
39 01 
Figure 8. Banwell' s formal synthesis of Platencin. 
HOrQ-°~ 
HO HN 
o 
Platencin (40) 
Diol 37 was derived from the enzymatic oxidation of iodobenzene by 
recombinant organisms expressmg TDO. The tethered dieneophile 38 was 
generated using a Negishi cross-coupling reaction.3o This was followed by a 
facially selective intramolecular Diels-Alder reaction to provide adduct 39, a 
formal intermediate in the synthesis of platencin (40). 
Application of Rearrangements to the Arene cis-Diol Framework 
In addition to coupling reactions, the cis-dienediols have been transformed 
using various transpositions and sigmatropic rearrangements. One noteworthy 
example is provided by Micalizio in the total synthesis of phorbasin C (44), 
(Figure 9).31 The starting material was cis-dihydroarenediol 34 derived from 
oxidation of bromobenzene by TDO. Dihydroxylation of the distal olefin was 
followed by radical debromination yielding 41. The key step relied upon a 
reductive cross-coupling of diol 41 with TMS-propyne. The alkylative 
transposition of the remaining olefm proceeds through a metalo-[3,3] 
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rearrangement (42) to give the 1,4-diene 43. This new diene was then taken on to 
(+ )-phorbacin C (44). 
protected form 
. directs sigmatropic 
selectIVe t 
dihydroxylationrearrangemen OH 
'-(I",OHJ ~O~,,\O _---.. . 
Y-"OH V-"OX: (Br 
radical 34 41 
dehalogenation 
R=~)AcO ~ 
R 
o 
~OH .. \OX .. I -"0 ~ Me /TMS .. 
(+)-Phorbacin C (44) 
Figure 9. Micalizio's use of metalo-[3,3] rearrangement in the synthesis of (+)-
phorbacin C. 
The examples highlighted above represent only a fraction of the known 
metabolites and their synthetic applications. In the time since Gibson's original 
disclosure, over 400 metabolites of TDO or related enzymes have been reported. 
These metabolites and their use as synthetic intermediates have been extensively 
reviewed.23 More recently cis-dihydroarenediols have been used in the synthesis 
of codiene32, various montanine alkaloids,33 and oseltamivir (Tamiflu).34 The cis-
dihydrodiols derived from 4-chloroquinolines have also been used in the synthesis 
of chiral 2,2' -and 4,4' -bipyridyl ligands for use in asymmetric transition-metal 
catalysis.35 
When considering the design and execution of future synthesis using cis-
dihydroarenediols, it is helpful to study previous synthetic efforts. Many of the 
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targets generated to date contain highly oxygenated cores or amino-cyclitol 
moieties. As epoxide or aziridine scaffolds are readily accessible from the cis-
dihydrodiol framework, their coupling with various nudeophiles is also well 
established. One group of natural products which contain a highly oxygenated 
core that can efficiently be constructed using this motif is the Amaryllidaceae 
alkaloids. These structurally complex constituents have a rich history both in 
their use as medicinal agents and in the efforts applied toward their synthesis. 
11-2 Amaryllidaceae alkaloids 
The application of several plants of the Amaryllidaceae family to the 
treatment of illness related to cancer has been known since antiquity.36 The first 
recorded treatments specifically designed for cancerous conditions were 
prescribed by Hippokrates of Cos (ca. B.C. 460-370).37 This "Father of 
medicine" and founder of the school of medicine bearing his name recommended 
application of narcissus oil (most likely from Narcissus poeticus L.) for the 
treatment of tumors of the uterus. Topical treatments prepared from Narcissus 
poeticus L. and Narcissus pseudonarcissus were prescribed by Gaius Plinius 
Secundus (A.D. 23_79).38 Hippokrates' treatment for uterine cancer was 
continued by Soranos of Ephesos, physician and prominent gynaecologist, who 
taught in Rome and Alexandria under Trajan and Hadrian (98-138 A.D).37 In 
fact, historical use of plants from over 30 members of the Amaryllidaceae family 
in remedies for cancer is reported well into the 19th and 20th century, at which 
point individual congeners began to be isolated and tested for anti-tumor activity. 
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The first alkaloid to . be isolated from an Amaryllidaceae plant was 
lycorine (45) in 1877.39 As lycorine is the major constituent of N. poeticus L., it 
was suspected that it was also responsible for the therapeutic benefits of these 
plants in herbal treatments of cancer. This theory was seemingly confirmed in 
1958 with the disclosure of lycorine's antitumor activity.40 Since that time 
interest has intensified and more than 100 structurally diverse constituents from a 
variety of Amaryllidaceae plant species have been isolated. 
OH 
OH 
Iycorine (45) 
OH 
o 
9H 
OH 
OH 
R 0 
R = OH narciclasine (46) 
R = H Iycoricidine (47) 
R 0 
OH 
R = OH pancratistatin (1) 
R = H 7 -deoxypancratistatin (2) 
R = OH trans-dihydronarciclasine (48) 
R = H trans-dihydrolycoricidine (3) 
Figure 10. Representative Amaryllidaceae constituents. 
The most active congeners have proven to be the isocarbostyril grouping, 
represented by select members above (Figure 10). Narciclasine (46) and 
lycoricidine (47) were isolated from the bulbs of Lycoris radiate and were 
reported to have potent cytotoxic activities.41 In 1984 Pettit and coworkers 
isolated isocarbostyril 1 from the bulbs of Hawaiian Hymenocallis littoralis 42 and 
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named it pancratistatin.43 A pattern of isolation of 7 -hydroxy and 7 -deoxy pairs 
of isocarbostyril congeners began to emerge with the isolation of 7-
deoxypancratistatin (2) in 1989.44 The last pair to be isolated was trans-
dihydronarcic1asine (48) and trans-dihydrolycoricidine (3) (7 -deoxy-trans-
dihydronarcic1asine).45,46 
The interesting biological activity of these congeners and their structural 
complexity has made them appealing targets for synthetic chemists. The total 
synthesis of lycorine (45)47, pancratistatin (1)48, 7-deoxypancratistatin (2)49, 
narcic1asine (46iO, lycoricidine (47it. trans-dihydronarcic1asine (48)52, and 
trans-dihydrolycoricidine (3i3 have been completed and made the subject of a 
number of excellent reviews. 54 
11-2.1 Biosynthesis of Amaryllidaceae alkaloids 
The biosynthesis of the Amaryllidaceae alkaloids can vary widely 
according the type of ring subgroup being produced.55,56 In the majority of cases 
a common intermediate in the biosynthesis of these molecules has been shown to 
be O-methylnorbelladine (49), (Figure 11). The core of this central intermediate, 
imine 50, is formed from a condensation reaction between protocatechuic 
aldehyde (51) and tyramine (52) which are derived from phenylalanine (53) and 
tyrosine (54) respectively. 
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phenylalanine (53) 
Figure 11. Biosynthesis of O-methylnorbelladine (49) 
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~ 
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Two main pathways are proposed for formation of the various constituents 
comprising the Amaryllidaceae alkaloids. The first consists of para-ortho 
oxidative coupling of O-methylnorbelladine (49) to give intermediate 55 which 
then undergoes conjugate attack of the amine to form norpluvine (56),57 a known 
precursor to lycorine (45), (Figure 12).58 The second pathway begins with a para-
para oxidative coupling yielding intermediate 57, which undergoes 
intramolecular Michael addition to form noroxomaritidine (58). Conversion of 58 
to narcic1asine (46) was elucidated in a series of experiments using 14C and 3H 
labeled O-methylnorbelladine (49) and ll-hydroxyvittatine (59).58,59 The 
transition from 59 to narcic1asine (46) is hypothesized to proceed through a retro-
Prins reaction followed by oxidation steps. 56 
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Figure 12. Biosynthesis of Amaryllidaceae alkaloids. 
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The true biosynthesis of pancratistatin has yet to be reported, but the two 
pathways described above account for the general skeleton of many of the most 
biologically active congeners of this family. 
11-2.2 Biological Activity and Pharmacophore Studies 
Members of the Amaryllidaceae alkaloid family have been recognized for 
generations for their utility as folk medicines, particularly with regards to the 
treatment of illness related to cancer. It was not until 1958 that the antitumor 
properties of lycorine (1) were formally reported.60 In addition to its strong 
activity against murine P-388 lymphoceutic leukemia lycorine (1) has also been 
shown to possess antiviral activity.61 The antitumor activity of narciclasine (46) 
was reported following its screening against the mouse Sarcoma 180 cell line.62 
The murine P-388 lymphocytic leukemia, cell line has been used as the initial 
screening bioassay for many of the most potent Amaryllidaceae alkaloids. 
Pancratistatin (1), 7 -deoxypancratistatin (2), narciclasine (46), lycoricidine (47), 
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trans-dihydronarciclasine (48), and trans-dihydrolycoricidine (3) have registered 
GI50 values as low as 0.01 % .ug/mL.63,64,65,66 These isocarbostyril-type congeners 
were also tested against the NCI (National Cancer Institute) 60 human cancer cell 
line in vitro screen and were shown to be most effective against the melanoma 
subgroup.67 Strong activity was also documented within the other subpanels 
(NCS lung, colon, brain, and renal), but activities varied by as much as 1000 fold 
between different cells lines in each group. 
The mechanism of action for these strongly anti-cancer agents has been 
studied with narciclasine as a model. In initial studies by Carrasco it was shown 
that narciclasine inhibited poly V-directed incorporation of l4C labeled 
phenylalanine in rabbit reticulocyte ribosomes.68 Narciclasine was also shown to 
inhibit association of [I4C]trichodermin (60) and eH]anisomycin (61), two known 
inhibitors of protein synthesis by eukaryotic ribosomes (Figure 13). 
trichodermin (60) 
0)-
o~ -O~ . ..-'- ~d HO NH 
anisomycin (61) 
Figure 13. Known 60S ribosomal subunit binders trichodermin (60) and 
anisomycin (61). 
As 60 and 61 are known to shut down protein biosynthesis by binding to the 60S 
ribosome subunit, experiments were conducted using the mutant Saccharomyces 
cerevistae TRI strain. This mutant is resistant to 60 and 61 through alteration of 
the peptidyl transferase center of the 60S riboso~al subunit.69,70 Narciclasine (46) 
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was shown to be ineffective in suppressing protein biosynthesis in the resistant 
mutant leading to assignment of the 60S eukaryotic ribosome subunit as the 
location of narciclasine's activity. While similar experiments have not been 
conducted with pancratistatin (1) and other congeners, it can be argued that a 
similar mode of action exists for these compounds. 
Specific studies investigating the mechanism of action of pancratistatin 
have recently been reported. Selective apoptosis in the Jurkat cell leukemia 
model vs normal nucleated blood cells was induced by pancratistatin.71 Pandey 
postulated that the selectivity was because of pancratistatin's ability to 
differentiate between mitochondria from cancer cells and those of healthy cells.72 
This approach is currently being explored in more complicated systems.73 It is 
unclear whether this new mode of action represents the primary source of activity 
for these congeners or if the previously established protein synthesis inhibition 
predominates. It is highly possible that the two modes of action are 
complimentary, combining for strong biological activity and selectivity in 
initiation of apoptosis in cancer cells. 
Initial attempts to determine the cytotoxic pharmacophore of the 
Amaryllidaceae alkaloids relied on comparison of isocarbostyrils in the natural 
series andlor analogs derived from semisynthesis. In general, the constituents 
containing C-7 hydroxylation are more potent by an order of magnitude or 
more.64,74 Dihydronarciclasine has been generated in both its cis- and trans- form 
with the trans- (trans B/C ring juncture) displaying significantly more potent 
activity.75 Analogs containing the amide functionality of the B ring as opposed 
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to the semisynthetic amine are more active by up to two orders of magnitude. 64 
With these studies a general view of the pharmacophore of this Amaryllidaceae 
isocarbostyril subgroup begins to take shape (Figure 14). 
Essential 
Essential 
Figure 14. Pancratistatin as a model for required pharmacophore III the 
Amaryllidaceae alkaloids as proposed by Pettit. 
Modification of the A nng has included replacement of the 
dioxymethylene moiety to form singly oxygenated derivatives of 7-
deoxypancratistatin,76 indole mimics,77 and bis-silylated analogues,78 all 
displaying significantly reduced or no activity. Ring B modifications have 
yielded various seco-analogues,79 lactones80 and the semisynthetic amines 
mentioned above. All have been shown to be inactive. The necessity of the trans 
B/C ring juncture has also been demonstrated by the C IOb-epimer of 7-
deoxypancratistatin prepared by Hudlicky.81 This cis-fused analogue proved 
completely inactive in screens against cancer cell panels. Possibilities for ring C 
modifications are numerous because of its rich substitution pattern. A host of C 
ring analogues, bearing a variety of hydroxylation patterns, have been synthesized 
to date.82,76 These studies have demonstrated the necessity of having at least three 
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of the four hydroxyl groups present in ring C. Of these oxygenated positions, it 
has been shown that the 2,3, and 4 hydroxylation patterns are most important for 
strong biological activity. Most recently, reports detailing the synthesis of several 
B,C-seco-analogues have appeared.83,84 These derivatives failed to provide 
substantial activity, but again confirmed the importance of intact B and C rings 
for strong antitumor response. 
In the course of their semi-synthesis of pancratistatin, Pettit and coworkers 
generated a C-l benzoyl derivative of pancratistatin that displayed remarkably 
potent activity.48h In an effort to improve the aqueous solubility of various 
Amaryllidaceae constituents, the Pettit group has synthesized 7 -O-phosphate 
prodrug analogues of 1,85 3,4-0-cyclic phosphate analogues of 1, 3, 46-48 and a 
C-l benzoyl analog.86 These phosphate prodrugs are currently being evaluated on 
a preclinical level. 
Synthetic efforts to generate meaningful analgues have provided much 
needed information concerning the minimal structure requirements detailed 
above. With continued development in this field reliant upon supplies of 
relatively scarce natural congeners, synthetic efforts will no doubt persist in this 
area of research. 
11-2.3 Selected Syntheses of Amaryllidaceae Alkaloids 
Pancratistatin 
The first total synthesis of pancratistatin was reported by Danishefsky and 
Lee in 1989.48a The synthesis begins with pyrogallol 62 as the precursor to the A 
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ring of pancratistatin (Scheme 4.). Further functionalization provided amide 63, 
which contained all of the 14 skeletal carbons in pancratistatin. Iodolactonization 
to form 64 was achieved only after cleavage of the silyl-ether and stannylation of 
the phenol. 
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HNACCI3 OH 0 68 69 pancratistatin (1) 
Reaction conditions: (a) HC(OEth, Amberlyst-15, C6H6, 86%; (b) NaH, Et2NCOCI, THF, 
then MeOH, TsOH, rt 86%; (c) K2C03, CH2Br2, CuO, DMF, 70%; (d) s-BuLi, TMEDA, 
THF, 58%; (e) TBSCI, imidazole, CH2CI2, 86%; (f) s-BuLi, TMEDA, THF, 70%; (g) 
allylmagnesium bromide, Et20, 92%; (h) (i) CH3S02CI, Et3N, CH2CI2; (ii) DBU, 54%; (i) 1-(benzenesulfonyl)-2-nitroethene, CHCI3, 96%; BU3SnH, AIBN, PhCH3, 72%; 0) TBAF, 
THF, 79%; (k) (i) (Bu3Sn)O, C6H5CH3, (ii) 12, THF, 67%; (I) BnBr, Ag20, DMF, 85%; (m) 
OS04, NMO, CH2CI2, THF, H20, 90%; (n) DBU, C6H6 , 88%; (c) 2-acetoxyisobutyryl 
bromide, CH3CN, 88%; (p) OS04, NMO, CH2CI2, THF, H20, 88%; (q) BU2SnO, 
C6H5CH3, 4-methoxybenzyl bromide, n-Bu4NI, (r) BnBr, A920, DMF, 95%; (s) DDQ, 
CH2CI2, H20, 75%; (t) Zn, AcOH, H20, CH2CI2, 81%; (u) NaH, CCI3CN, THF, 74%; (v) 
100-105 °C, 0.05-0.1mm Hg, 56%; (w) OS04, NMO, THF, H20, 75%; (x) K2C03, MeOH, 
CH2CI2, DCC, 82%; (y) H2, Pd(OHh, EtOAc, 90%. 
Scheme 4. Danishefsky's synthesis ofpancratistatin. 
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The needed regio-selective formation of imidate 68 necessitated a lengthy series 
of manipulations to achieve but the required Overman rearrangement provided 
amino moiety 69 in fair yield. Dihydroxylation was followed by rearrangement of 
the lactone to the phenanthredone core. With the final hydrogenation, the racemic 
synthesis of pancratistatin (2) was completed in 26 steps and in an approximate 
overall yield of 0.13%. 
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Reaction conditions: (a) DMP. p-TsOH. acetone; (b) PhINTs. Cu(acach. CH3CN. 27% (over 2 steps). (c) BU3SnH. AIBN. THF. reflux. 78%; (d) (i) 74. s-BuLi. TMEDA. THF. ( ii) 
CuCN. (iii) 70. BF3.Et20. 49%; (e) s-BuLi. (BOChO. THF. 68%; (f) Na I anthracene. 
DME. 62%; (g) morpholine-SMEAH. THF. 72%; (h) BnBr. K2C03• DMF. 83%; (i) 
NaCI02• KH2P04• 2-methyl-2-butene. t-BuOH. H20. CH2N2, 98%; m HOAc, THF. H20. 
73%; (k) t-BuOOH. VO(acac)2. CeHe. 53%; (I) CeH5COONa. H20, 100°C, 51%. 
Scheme 5. Hudlicky's synthesis ofpancratistatin. 
The first asymmetric total synthesis of pancratistatin was reported in 1995 
by Hudlicky.48b Chirality in this synthesis was derived from the microbial 
dihydroxylatoin of bromo benzene which provided cis-dioI34. Aziridination of the 
acetonide of 34 using Yamada's iodonium ylide followed by radical 
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debromination provided vinyl aziridine 70 (Scheme 5). Trans-diaxial opening of 
the aziridine with the higher order cuprate of 74 coupled the A and C rings. At 
this stage all attempts at a transamidation reaction failed and additional functional 
group transformations were required (71-73). The remaining C-ring oxygenation 
was installed by opening of epoxide 73. Additionally it was discovered that in the 
course of this final step cleavage of the benzyl ether, cleavage of the the Boc 
group, debenzylation, and formation of the lactam all occurred to provide 
pancratistatin (1) in a single operation. 
The shortest total synthesis ofpancratistatin to date (12 steps) is that ofLi 
and coworkers.48j The starting material for this asymmetric synthesis is D-pinitol 
(74), an expensive starting material ($145/gram)87 but one containing all 
necessary oxygenation of the final C-ring (Scheme 6). Several protection and 
deprotection steps in addition to installation of the C4a nitrogen of pancratistatin 
were required to arrive at cyclic-sulfate 75. The A-ring fragment 78 was 
introduced by a phosgene mediated coupling with amine 75. Protection of the 
phenol and amide with MOMCI provided cyclization precursor 76. The crux of 
the synthesis was the intramolecular opening of this cyclic-sulfate to close the B-
ring and complete the skeleton. Various conditions were attempted by the authors 
to effect this transformation but initial trials with aryllithium or arylmagnesium 
bromide provided complex mixtures of products. It was not until generation of 
the organocerium that meaningful yields of phenathridone 77 were observed. 
Interestingly, this reaction was later optimized to include ultrasonication during 
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the generation of the organocerium intermediate to provide 77 in good yield. 
Subsequent deprotection occurred uneventfully to provide pancratistatin (1). 
OMe OMe OMe 
HOnOH a-g ° 0::(X0 . h, i O\S°::(X~>< \' / .. 
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Reaction conditions: (a) TIPDSCI2, imidazole, DMAP, CH2CI2, 94%; (b) (MeO)2C(CH3h, 
p-TsOH, 81%; (c) (i) PPh3, DEAD, CH3S03H, CH2CI2, 0 °C to rt; (ii) NaN3, DMF, 60°C, 
72%; (d) TBAF, THF, 0 °C to rt, 100%; (e) SOCI2, Et3N, CH2CI2, 0 °C; (f) Na104, RuCI3, 
aq. CH3CN, 87% over two steps; (g) PPh3, aq THF, 0 °C to rt, 94%; (h) 78, MgBr2"OEt2, 
COCI2, ether, 0 °C, 75, 64%; (i) K2C03, MOMCI, DMF, rt, 84%; 0) t-BuLi, CeCI3, 
ultrasound, THF, -78°C to rt, 72%; (k) (i) BBr3' CH2CI2, -78 to 0 °C, 1 h; (ii) MeOH, 78 to 
o °C, 2 h, 52%. 
Scheme 6. Li' s synthesis of pancratistatin. 
The synthesis of medicinally important targets by relay from more readily 
available natural products is commonly accepted in the pharmaceutical industry. 
The greater availability of narciclasine (46) in the bulbs of Amaryllidaceae plants 
compared with that of pancratistatin prompted Pettit to explore synthesis of 
pancratistatin (1) using narcic1asine (46) as a precursor (Scheme 7).48h The free 
hydroxyl groups were protected as their acetoni~e and acetates before epoxidation 
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with mCPBA to provide derivative 79. Hydrogenation of the epoxide was 
followed by removal of the acetate protecting groups to provide a mixture of 
compounds from which 80 was isolated in 28% yield. Formation of the cyclic 
sulfate 81, opening with benzoate, and deprotection provided pancratistatin (1) in 
10 steps and an overall yield of3.6%. 
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paneratistatin (1) 82 81 
Reaction conditions: (a) DMF, DMP, p-TSOH, 97%; (b) A~O, pyr, 81%; (e) mCPBA, 
phosphate puffer, CH2CI2, H20, 52%; (d) (i) H2, Pd/C 10%, (ii) K2C03, CH30H, H20, 
28%; (e) SOCI2, Et3N, THF; (f) RuCI3"3H20,NaI04, CH3CN, CCI4, H20, 45% (over 2 
steps); (g) (i) PhC02H, CsC03, DMF, (ii) THF, H20, H2S04, 74%; (h) K2C03, CH30H, 
75%. 
Scheme 7. Pettit's relay synthesis ofpancratistatin. 
7-Deoxypancratistatin 
The first preparation of 7 -deoxypancratistatin occurred prior to its isolation from 
natural sources and was reported by Ohta as an intermediate in the synthesis of 
lycoricidine (Scheme 8).49a Installation of the C-ring carbons proceeded through a 
Diels-Alder cycloaddition between the diene derived from precursor 83 and ethyl 
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acrylate. Hydrolysis of the intermediate ester provided acid 84, which was 
converted to an isocyanate before formation of lactam 85 under Lewis acid 
catalysis. The lactam-Iactone transformation occurred through a protection, 
hydrolysis, and bromolactonization sequence to give bromide 86. Elimination of 
the bromide was followed by a lactone-Iactam transform, protection, and 
oxidation to epoxide 88. Further elaboration to allylic acetate 89 allowed for 
installation of the final C-ring hydroxylation via OS04. Removal of the acetate 
provided 7-deoxypancratistatin (2). 
<0:vC =cf2 a,b o ~ c-e ~ .. ~ I ~ t02H .. o ~ 
83 84 85 0 
~f-h 
AcHNn 
0 k, I 0 i, j <°=0:;0 Br < .. < .. 0 0 o ~ I 0 . 
88 0 87 0 86 0 
~m, n 
OAc 9H 
OH 
~ o-q .. ~ OH 
0 0 
89 7 -deoxypancratistatin (2) 
Reaction conditions: (a) ethyl acrylate, p-TsOH, 180 'C, 56%; (b) NaOEt, EtOH, reflux, 
then H20, reflux, 74%; (c) CIC02Et, Et3N, acetone, H20; (d) NaN3, H20, then 
CsHsCH3' reflux; (e) BF3.Et20, 89% (over 3 steps); (f) A~O, pyr, reflux, 83%; (g) 1 N 
KOH, CH30H, 68%; (h) NBS, THF, 96%; (i) DBU, pyr, reflux, 98%; 0) 20% NaOH, 
EtOH, 90 'C, 90%; (k) 2,3-dihydropyrane, p-TsOH, reflux, 75%; (I) mCPBA, CHCI3, 
85%; (m) diphenyldiselenide, EtOH, NaBH4, reflux, then H20 2, 63%; (n) A~O, pyr, 
97%; (0) p-TsOH, AcOH, MeOH, reflux, 59%; (p) OS04, pyr, 87%; (q) 1 N KOH, 
CH30H, reflux, 49%. 
Scheme 8. Ohta and Kimoto's synthesis of 7 -deoxypancratistatin. 
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The first asymmetric total synthesis of 7 -deoxypancratistatin was also 
completed in the course of a total synthesis of lycoricidine.49c Chirality in the 
synthesis was derived from glucose, which was used to make nitro olefin 90 
(Scheme 9). Introduction of the A-ring was accomplished by metal-halogen 
exchange of the appropriate bromobenzoate and Michael addition to the nitro 
olefin to afford furanose derivative 91. The acetonide was removed and the 
lactone 92 formed upon treating with base. Reduction of the nitro group and 
cleavage of the benzyl ether was followed by lacone-Iactam rearrangement to give 
7 -deoxypancratistatin(2). 
OBn 
. OH 
a 
90 
OH 
OH 
OH .. 
o 
7-deoxypancratistatin (2) 
b 
OH 
d 
93 
Reaction conditions: (a) (i) isopropyl (6-bromo-3,4-(methylenedioxy»benzoate, n-BuLi, 
THF, -110 °C, (ii) 90, 77%; (b) (i) HOAc, H20, reflux, (ii) K2C03, CH30H, 34%; (c) H2, 
Pd/C, CH30H, 77%; (d) K2C03, CH30H, reflux, 72%. 
Scheme 9. Paulsen and Stubbe's synthesis of7-deoxypancratistatin. 
OH 
92 
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Hudlicky continued exploration of chemoenzymatic synthesis of these 
constituents in his asymmetric total synthesis of 7 -deoxypancratistatin. As in the 
previous synthesis of pancratistatin, vinyl aziridine 70 was opened with a 
cyanocuprate to couple the A and C rings (Scheme 10). The tosyl moiety of 
intermediate 94 was replaced with methyl carbamate before the removal of the 
acetonide and the directed epoxidation that provided diol 95. The replacement of 
the N-tosyl protecting group with methyl carbamate was needed in order to avoid 
the difficulties experienced in closure of the B ring in Hudlicky's first generation 
synthesis ofpancratistatin (discussed previously). Stereos elective opening of the 
epoxide and protection of all free alcohols as their acetates provided cyc1ization 
precursor 96. The B ring was closed using Bischler-Napieralki conditions 
reported by Banwell, completing the core ring structure 97 with all necessary 
chirals centers set. Final deprotection occurred without incident to give 7-
deoxypancratistain (2). 
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70 94 95 
~f' 9 
OH OAe OAe 
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o 
7 -deoxypaneratistatin (2) 97 96 
Reaction conditions: (a) (i) 4-bromo-1,2-(methylenedioxy) benzene, n-BuLi, THF, -78 
°C, (ii) CuCN, (iii) 70, BF3.Et20, 32%; (b) s-BuLi, THF, (BOChO, 76%; (e) 
Nalanthracene, DME, -78 °C; 69%; (d) AeOH, THF, H20, 65 °C, 94%; (e) t-BuOOH, 
VO(acaeh, CeHe, 85%; (f) H20, BzONa, 100 °C, 82%; (9) A~O, DMP, pyr, 84%; (h) 
Tf20, DMAP, CH2CI2, 5 °C, 61%; (i) NaOCH3, CH30H, 72%. 
Scheme 10. Hudlicky's synthesis of7-deoxypancratistatin. 
OAe 
A recent total synthesis of 7 -deoxypancratistatin was accomplished by 
Padwa utilizing a Stille coupling/intramolecular Diels-Alder cascade (Scheme 
11). Furan-2-ylcarbamic acid tert-butyl ester was coupled with A-ring fragment 
98 via its carbamate anion to give amidofuran 99. BOC protection on the 
nitrogen was exchanged for a p-methoxybenzyl group. Stille coupling between 
the newly formed iodo derivative and methyl 2-tri-n-butyl stannylacrylate was 
followed by a spontaneous intramolecular [4+2]-cyc1oaddition to furnish 
cyc10adduct 100 in good yield over the two step cascade. 
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Reaction Conditions: (a) (i) furan-2-ylcarbamic acid 2-tert-butyl ester, n-BuLi, 98, THF, 
o DC, (ii) Mg(CI04~' CH3CN, 50 DC, 75%; (b) NaH, 4-methoxybenzyl chloride, DMF, 0 
DC, 83%; (c) LiCI, Pd(PPh3)4, CuCI, 2-(tri-n-butylstannyl)acrylate, DMSO, -78 - 60 DC, 
82%; (d) (i) 4-methylmorpholine-N-oxide, OS04, rt, CH3CN/H20, (ii) 2,2-
dimethoxypropane, pyridinium p-toluenesulfonate, DMF, rt, 80%; (e) (i) Zn(BH4~' 
TMSOTf -78 DC - rt, CH2CI2, (ii) TBAF, rt, THF, 74%; (f) NaH, benzyl bromide, 0 DC - rt, 
DMF, 91%; (g) (i) LiOH, reflux, THF/MeOH/H20, (ii) (COCI)2, DMF, CH2CI2, (iii) 
Zn(BH4)2, 0 DC - rt, CH2CI2, (iv) molecular sieves, NMO, TPAP, rt, CH2CI2, 77%; (h) 
RHCI(PPh3h, reflux, benzonitrile, 63%; (i) (i) H2, Pd(OH~, rt, EtOAc, (ii) NaH, CS2, Mel, 
o DC - rt, (iii) reflux, o-dicholobenzene, 85%; 0) NMO, OS04, rt, acetone, 68%; (k) (i) 
Et3N, SOCI2, 0 DC - rt, CH2CI2, (ii) RuCI3"3H20, Na104, CH3CN/H20, 82%; (I) (i) benzoic 
acid, CS2C03, DMF, (ii) 40% H2S04, 80 DC, THF, 75%; (m) (i) NaOMe, 25 DC, THF, (ii) 
Pd(OH~, H2, rt, THF, 80% 
Scheme 11. Padwa's synthesis of7-deoxypancratistatin. 
Dihydroxylation of the olefin was followed by acetonide protection, and final 
cleavage of the oxo-bridge under Lewis acid catalysis gave alcohol 101. Multiple 
functional group manipulations were required to arrive at olefin 102 which was 
converted to 7 -deoxypancratistatin (2) by dihydroxylation, formation of the 
cyclicsulfate, opening with benzoate, and deprotection steps. 
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Trans-dihydrolycoricidine 
Synthetic trans-dihydrolycoricidine was prepared by Gabrielsen and Pettit 
In 1992.53f In this synthesis the more readily available lycoricidine (47) was 
converted to its dihydro analog through catalytic hydrogenation with Adams' 
catalyst (Scheme 12). The mixture of cis and trans-dihydrolycoricidine 103 was 
only seperable by first protection as its triacetate and then column 
chromatography. Cleavage of the acetate groups under basic conditions yielded 
synthetic trans-dihydrolycoricidine (3), which was screened in a variety of 
antiviral assays.53f 
9H 9H 
a b 
o 
\, o \, 
o 
Iycoricidine (47) 
o 
103 
o 
trans-dihydrolycoricidine (3) 
Reaction Conditions: (a) (i) Pt02, rt, MeOH, (ii) A~O, pyridine, rt, 10%; (b) Ba(OH)2' rt, 
MeOH,83% 
Scheme 12. Gabrielsen's relay synthesis of trans-dihydrolycoricidine. 
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Reaction conditions: (a) MOMCI, i-Pr2NEt, CH2CI2, 87%; (b) DBU, CeH5CH3, 73%; (c) 
Hg(OCOCF3)2, acetone, H20; (d) MsCI, Et3N, CH2CI2, 63%; (e) NaBH4' CeCI3.7H20, 
CH30H, 86%; (f) NaH, MPMCI, DMF, 69%; (g) (i) LAH, Et20, (ii) 6-bromopiperonylic 
acid, (EtO)2P(0)CN, Et3N, DMF, 89%; (h) NaH, MPMCI, DMF, quant.; (i) Pd(OAcn, 1,2-
bis(diphenylphosphino)ethane, TIOAc, DMF, 68%; 0> H2, 5% Pd/C, EtOH/EtOAc, rt, 
87%; (k) Tf20, pyridine, 0 °C, Ch2C12; (I) KOAc, 18-crown-6, benzene, rt, 81%; (m) (i) 1 
N HCI, THF, 50°C, (ii) Ac-;.O, pyridine, rt, 93%; (n) TFAlCHCI3, rt, 85%; (0) NaOMe, 
MeOH, 0 °C, 83%. 
Scheme 13. Chida's synthesis of trans-dihydrolycoricidine. 
Chida's asymmetric synthesis of trans-dihydrolycoricidine (3) was 
completed by protocols developed in his previously reported total synthesis of 
lycoricidine (47).51e,53b Glucose derived diol104 was fIrst protected as its MOM 
ether before formation of the vinyl ether and a Ferrier rearrangement to give 
ketone 105. The hydroxyl moiety was eliminated giving the enone. Luche 
reduction of the ketone and protection of the resulting alcohol afforded 106, 
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which underwent azide reduction and coupling with the A-ring fragment. The 
nitrogen of cyclization precursor 107 was protected and the B ring was closed 
using an intramolecular Heck reaction. The Heck product 108 marked a point of 
divergence in the synthesis. This material was used as a common intermediate in 
the total synthesis of 7 -deoxypancratistatin (2) and lycoricidine (47). 
Hydrogenation ofl08 gave the trans isomer 109 as the sole product in 87% yield. 
This transformation was remarkably selective when compared to other 
hydrogenation reactions involving narciclasine and its analogues. In the process 
of hydrogenation the O-MPM group was also cleaved and the resulting C-2 
hydroxyl was inverted via displacement of its triflate. Deprotection occurred 
uneventfully to provide trans-dihydrolycoricidine (3). 
Ogasawara and Iwabuchi introduced chirality into their synthesis of trans-
dihydrolycoricidine by use of cyclohexanoid building block 110, generated from 
the free diol by a lipase-mediated de symmetrization. 53c This intermediate was 
converted to iodoenone 111 before the coupling with the aromatic A-ring via the 
Stille protocol (Scheme 14). Reduction of the enone gave 112. A Mitsunobu 
reaction using azide gave exclusively the SNi product which was convert to 
carbamate 113 over several steps. Cleavage of the tetrahydrofuran and 
elimination of bromine was mediated by Zn. Protection of the resulting alcohol 
allowed for a facile retro Diels-Alder reaction to provide cyclohexene 114. The 
TBS group was exchanged for the bulkier naphthoyl and a Bischler-Napieralski 
reaction closed ring B of the skeleton (l1S). Cyclic sulfate 116 was formed using 
standard conditions and was opened selectively at the more hindered C-3 position 
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by assistance of the naphthoyl group. Acidic hydrolysis and subsequent treatment 
with NaOMe provided trans-dihydrolycoricidine (3) in 21 steps and 3.2% overall 
yield from 110. 
110 
o 115 
q-S~ 
o 
116 
n-p 
....--
OR <0 
o 
R = 2-naphthoyl 
t, u 
~ 
111 
e-f 
~ 
OH 
o 
trans-dihydrolycoricidine (3) 
Br 
Reaction conditions: (a) NBS, CH2CI2, -30°C, 62%; (b) K2C03, MeOH, rt, 99%; (c) 
POC, CH2CI2, rt, 96%; (d) 12, pyridine/CCI4, rt; (e) (3,4-methylenedioxy-
phenyl}tributylstannane, PdCI2(PPh3}2, PhaAs, CuCl, THF, rt, 63%; (f) OIBAl, 2,6-di-
tert-butyl-4-methylphenol, CH2CI2 , -78°C, 86%; (9) OPPA, PPh3, DIAD, rt, 76%; (h) 
H2, 10% Pd/C, EtOAc, rt, 95%; (i) CIC02Me, 1 N NaOH, THF, rt, 95%; 0) H2, 50% 
Pd(OHh/C, MeOH, rt, 92%; (k) Zn, MeOH/AcOHITHF, reflux, 94%; (I) TBSOTf, Et3N, 
CH2CI2, -78°C, 95%; (m) NaHC03, Ph20, reflux, 87%; (n) TBAF, THF, 97%; (o) 2-
naphthoyl chloride, pyridine, OMAP, rt, 97%; (p) Tf20, OMAP, CH2CI2, 0 °C, 84%; (q) 
0804 , NMO, THF/H20, 92%; (r) SOCI2 , pyridine, -30 - -20°C; (s) RuCI3H 20, Nal04, 
CCIJMeCN, rt, 52%; (t) (i) pyridine, reflux, (ii) 2N H2SOJCHCI3, 70°C, 64%; (u) 
NaOMe, MeOH, rt, 84%. 
Scheme 14. Ogasawara and Iwabuchi's synthesis oftrans-dihydrolycoricidine. 
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The selected approaches to Amaryllidaceae consitutents presented above 
represents only a small portion of the work published on the synthesis of these 
complex natural products. Despite this large body of synthetic work the 
attainment of a truly efficient synthesis has yet to be realized. Another category 
of natural products that suffer a similar lack of efficient synthetic supply is the 
opiates. Those compounds related to morphine have · a rich history that predates 
even that of the Amaryllidaceae constitutents. 
11-3 Morphine Alkaloids 
The use of opium and morphine alkaloids predates even recorded history. 
Evidence for the cultivation of poppies in the 6th millennium B.C., most likely for 
their seeds, has recently been uncovered at Neolithic archeological sites in what 
are modem day Spain, France, and Germany.88,89 It is often difficult to identify 
instances of poppy cultivation and use from early written records because of 
ambiguity in individual accounts. Historians generally agree that the Sumerians, 
living in what is today Iraq, not only cultivated poppies but isolated opium from 
their seed capsules at the end of the third millennium B.C.90 The plant they 
cultivated was Papaver Somniferum but to the Sumerians it was known as "hul 
gil" the ''joy plant.,,9o The Ebers Papyrus, one of the oldest known medical texts, 
makes a mention around 1500 B.C. of opium as an additive in a concoction used 
to quiet the excessive crying of children. The text even goes as far as to make the 
guarantee that "the crying will stop at once" if the treatment, which includes paste 
made from flies, is administered on four successive days. Use of opium in 
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religious rituals as a pain killer arid as a sleep inducing agent is well recorded 
through much of Greek and Roman history.91 
In the eighth century A.D. opium was introduced to India and China by 
Arab traders and quickly became popular.92 Opium use as we know it today then 
migrated west, back into Europe between the tenth and thirteenth century. By the 
sixteenth century the problems of addiction and tolerance development were well 
known and were recorded in text throughout Europe. 90 
In the mid eighteenth century, amid growing trade deficits with China, the 
British Empire began the massive importation of opium from India to China. 
Even after a ban on opium smoking by the Yangzheng Emperor, the British 
smugglers increased opium exports from 15 tons in 1730 to over 75 tons in 
1773.93 By the 1820s more than 900 tons of Indian opium was flooding into 
China every year. The tension of this situation resulted in two conflicts 
collectively known as the Opium Wars. The defeat of China in both conflicts 
resulted in almost complete destruction of Chinese sovereignty and subjugation of 
the Qin Dynasty by Britain and France. The anti imperialist (western) sentiment 
bred from this led to future conflicts and the eventual fall of dynastic China in 
1911. 
While the East India Company was tightening its grip on the opium 
trade, work was ongoing to isolate the components responsible for the strong 
biological activity of opium. Friedrich Wilhelm Sertiimer isolated the alkaloid 
morphine (117) from raw opium in 1805.94 He named the compound after 
Morpheus, the Greek God of Dreams. Morphine (117) accounts for 10-16% of 
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the mass of raw opium ill addition to the alkaloids codeine (118) 1-3%, 
papaverine (119) 0.8-1 %, thebaine (4) 0.5-2%, and narcotine (120) 1-7% (Figure 
15). 
NMe NMe NMe 
morphine (117) codeine (118) 
OMe 
OMe 
OMe 
papaverin (119) narcotine (120) 
Figure 15. Naturally occurring morphine alkaloids. 
The process by which opiates are extracted from poppy plants begins with 
harvesting of the raw opium latex. This is done by scoring the ripening seed pod 
with a sharp blade, traditionally in the afternoon and at a time to avoid rain, wind, 
or dew. In many opium producing regions a special4-bladed tool called a nishtar 
is used to score the pod in intervals (3 times over 3 days). Raw latex dries to a 
sticky resin and is usually collected the following morning. Illicit drug traders 
often process the raw opium into morphine base in field processing labs. The 
morphine base is pressed into bricks and dried in the sun. This crude product can 
be smoked directly but is often converted to heroin. 
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Sertiiroer's initial isolation of morphine in 1805 occurred only with his 
knowledge of its basic character.94 More than forty years would pass before the 
correct empirical formula (C17HI9N03) was established by Laurent.95 The most 
important work in the elucidation of morphine's oxygenation is credited to 
Wright.96 It is interesting to note that in the course of his work Wright was the 
first to synthesize diacetylmorphine or heroin. It would be more than twenty 
years later before heroin would be "discovered" by chemists at Bayer and 
marketed as an over-the-counter, non-addictive substitute for morphine. 
The presence of an oxygenated phenanthrene was established by 
numerous degradation studies by Greichten, Hofmann, and Pschorr.97 The correct 
structure of morphine was proposed in 1925 by Robinson98 and confirmed in 1952 
with the first total synthesis of morphine by Gates.99 With the emergence of x-
ray diffraction analysis around that time, the relative configuration of morphine 
was established by MacKay and Hodgkin.loo The story of the isolation, structure 
elucidation, and eventual synthesis of morphine is one that spans more than 150 
years and has been made the subject of several reviews. 101 It is an 
accomplishment that is to be both admired for its sound science and also its 
representation of a classic subdicipline in organic chemistry, structure 
determination by degradation, which has all but disappeared in the modem day. It 
is interesting to imagine what might be accomplished if those same researchers, 
so trained in the academic rigor of structure proof by chemical degradation, were 
given access to modem equipment and spectroscopic techniques. 
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If any group of natural products could be said to possess the power to 
affect events on an international scale, it would undoubtedly be the opiates. The 
sheer scale of opium production and proceeds from its sale are staggering. In 
2007 alone raw opium production was estimated at 8,200 tons and proceeds from 
illicit sales totaled more than $760 billion.102 This figure alone is a testament to 
the influence of the opium trade at a global level. Opium production occurs in 
many locations around the world, but is centered in India, Turkey, Tasmania, 
Pakistan, and Afghanistan. The raw opium harvested in these regions primarily 
contains morphine, thebaine, codeine, papaverin, and narcotine. 103 While some 
of the more unstable countries, such as Afghanistan, are responsible primarily for 
illicit production of opiates, world supply for morphine alkaloids and their 
semisynthetic derivatives is still deepened upon natural isolation. This means that 
access to reliable supply for medical purposes is subject to environmental change, 
various pathogens, and geopolitical upheaval. One way to assure steady supply is 
the development of a truly practical synthesis route. Since the first synthesis of 
morphine by Gates in 1952 more than 30 total syntheses of morphine alkaloids 
have been reported. I04 The attainment of a truly efficient synthesis, capable of 
competing with natural production, has remained elusive. 
Starting in the first quarter of the 20th century, thebaine has increasingly gained 
notoriety as an important semisynthetic intermediate. Oxycodone (121), 
oxymorphone (123), naloxone (125), naltrexone (126), etorphine (124), and 
buprenorphine (127) are all manufactured through semisynthesis from thebaine 
(Figure 16). In addition to use as anelgesics (oxycodone, oxymorphone), these 
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synthetic opiates have a range of applications from the treatment of alcohol 
dependency (naltrexone) to use as elephant and rhino tranquilizers (etorphine). 
NMe 
oxycodone (121) hydrocodone (122) oxymorphone (123) 
NMe 
R = allyl, naloxone (125) 
etorphine (124) R = CPM, naltrexone(126) buprenorphine (127) 
Figure 16. Semisynthetic opiods. 
11-3.1 Biosynthesis of morphine alkaloids 
The importance of the morphine alkaloids has also placed great value on 
elucidation of their biosynthesis. The Mechanistic pathway by which these 
benzylisoquinoline alkaloids are synthesized by nature is fairly well understood 
and documented. 105,106 The efficiency of nature is made obvious with the 
realization that all but one carbon atom of the morphine alkaloid skeleton is 
derived solely from the amino acid L-tyrosine (128) shown in Figure 17. Through 
a series of enzymatic transformation the L-tyrosine is converted to dopamine 
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(129) and 4-hydroxyphenylacetaldehyde (130), the precursors to the C and A 
rings respectively. 
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Figure 17. Biosynthesis of (R)-reticuline (134). 
The formation of (S)-norcoclaurine (131) is accomplished by an asymmetric 
Pictet-Spengler condensation between 129 and 130. This is followed by N-
methylation and further oxidation to (S)-3'-hydroxy-N-methylcoclaurine (132). 
Further methylation of each catechol provides (S)-reticuline (133), the precursor 
to more than 2500 benzylisoquinoline alkaloids. Conversion of 133 to its 
enantiomer (R)-reticuline (134) is accomplished via reduction of its Schiff base. 
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Figure 18. Biosynthesis of thebaine, codeine, and morphine. 
The most radical transformation in the biosynthesis of these molecules is 
undoubtedly the C-12/C-13 oxidative phenolic coupling to form salutaridine (135) 
(Figure 18). This reaction is catalyzed by salutaridine synthase, a NADPH-
dependent cytochrome enzyme. t07 In this case, P-450 enzyme behaves as an 
oxidase, as opposed to a mono oxygenase, an atypical role compared with other 
alkaloid biosynthetic pathways. The ketone of salutaridine (135) is reduced to 
(7S)-salutaridinol which is subsequently converted to its acetate 137. 
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Displacement of the acetate by the phenolic hydroxyl in an SN2' fashion gives 
thebaine (4). Demethylation of the C-6 enol ether provides neopinone (138) and 
subsequently codeinone (139). Reduction of the C-6 ketone gives codeine (118), 
which is demethylated to give morphine (117). 
The 19-step biosynthetic pathway by which plants make morphine and 
other congeners is considered to be well understood. 105 Nevertheless alternative 
biosynthetic pathways and natural sources of morphine alkaloids have been 
reported. The synthesis of morphine (117) from thebaine (4) with oripavine (140) 
as an intermediate has been proposed (Figure 19).108 The existence of the poppy 
mutant thebaine oripavine poppy 1 (top)), which accumulates oripavine (140) and 
thebaine (4) but not codeine (118) and morphine (117) lends credence to this 
theory. 109 It was speculated that mutation of the enzyme responsible for 
demethylation of thebaine (C-6 oxygen) is responsible for the arrest of the 
morphine biosynthetic pathway. The cultivation of this same mutant has also 
provided a means of producing oripavine (140) and thebaine (4) in a cost effective 
manner. This in turn has increased the availability of many medicinally important 
semi-synthetic opioids. 
HO 
NMe ----1.~ NMe 
thebaine (4) oripavine (140) morphine (117) 
Figure 19. Alternative biosynthesis of morphine. 
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11-3.2 Selected Syntheses of thebaine and its use in semi-synthesis 
Few classes of synthetic targets have the combination of medicinal utility 
and structural complexity present in morphine alkaloids. Congeners such as 
morphine and codeine have enjoyed wide recognition both within the synthetic 
community and among the general public. llo While thebaine does not enjoy the 
celebrity status of its cousins it nonetheless has enjoyed considerable attention 
from synthetic chemists. Its lack of useful medicinal activity, but availability as 
a natural congener has contributed to its use in a number of semisynthetic routes 
to more desirable alkaloids. This concept of turning trash into treasure is not new 
and was first applied to thebaine in Freund and Speyer's semisynthesis of 
oxycodone.11l The importance of thebaine as a semisynthetic intermediatell1 has 
fueled enthusiasm for its total synthesis ll2 as a means to supplement or replace 
natural supply. With no fully synthetic, commercial route currently in existence 
for morphine and its congeners this goal has yet to be met. The following section 
summarizes several syntheses of thebaine followed by an overview of several 
semisyntheses of morphine congeners which feature thebaine as a key 
intermediate. 
The first synthetic preparation of thebaine (4) by any means was disclosed 
by Rapoport in 1956.112a Dihydrothebaine (141) was obtained by enol ether 
formation of dihydrocodeinone and was treated with methyl hypobromite to give 
bromoacetal142 (Scheme 15). Elimination of the bromide and hydrolysis yielded 
thebaine (4). 
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Am,102 °C, 80%; (c)p-TSA, CH2CI2, H20, rt, 40% 
Scheme 15. Rapoport's synthesis of thebaine. 
NMe 
The first total synthesis of thebaine was published in 1975 by Schwartz 
(Scheme 16).112f Protection of (±)-N-norreticuline (144) as its trifluoroacetate was 
followed by oxidative para-ortho coupling to gIVe (±)-N-
trifluoroacetyInorsalutaridine (145). Replacement of the triflouroacetate moiety 
with an ethyl carbamate and then reduction provided alcohol 146 which was 
converted to (±)-thebaine under acidic conditions. 
MeO 
MeO 
OH 
144 
MeO 
HO 
MeO 
o 
145 
MeO 
HO 
c-e 
N ----.. y CF3 
o MeO 
OH 
146 
thebaine (4) 
Reaction conditions: (a) trifluoroacetic anhydride, K2C03, CH2CI2, rt; (b) 
thallium tris(trifluoro)acetate, CH2CI2, -78°C, 11%; (c) K2C03, MeOH, rt, 86%; (d) EtOCOCl, Et3N, CHCI3, rt; (e) LAH, THF, reflux, ~1 % (3 steps); (f) 1 N HCI, rt 
Scheme 16. Schwartz's synthesis of thebaine. 
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While the majority of synthetic routes to thebaine utilize other opiates as 
semisynthetic intermediates, work in the area of total synthesis is ongoing. Most 
recently a total synthesis of thebaine (4) has been reported by Stork, who took 
advantage of an intramolecular cyc1oaddition between a benzofuran and a tethered 
diene (Scheme 17).112i The benzofuran cyc1oaddition precursor 151 was 
constructed over a number of steps starting from iodoisovanillin (147). Most 
notably, the formation of benzofuran 149 was accomplished by intramolecular 
Heck coupling of iodide 148. The ketal was removed and the aldehyde chain 
extended under Wittig conditions to give 150. Homologation of aldehyde 150 
using an alkoxyalkenylzirconocene was mediated by silver triflate. The [4+2] 
cyc1oaddition of 151 required somewhat harsh conditions but proceeded to give 
phenanthrofuran 152 in good yield. Cleavage of the silyl ether, oxidation to the 
C-9 ketone, and conversion of the methyl ester to its enol ether gave intermediate 
153. The C-9 ketone was reduced and converted to its mesylate prior to 
introduction of methylamine via reductive amination. The resulting basic 
nitrogen smoothly displaced the mesylate to give (+)-condeine methyl ether (154) 
which had been previously converted to thebaine by Rapoport. 112e 
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Reaction conditions: (a) HO(CH2hOH, p-TsOH, toluene, 85%; (b) methyl 
propiolate, Et3N, THF, 89%; (c) Pd(OAc)2, Ph3P, NaOAc, n-Bu4NCI, DMF, 125 
°C, 84%; (d) HCI, THF, 98%; (e) (i) Ph3PCH20CH3CI, KHMDS, THF, (ii) HCI, 
THF, 95%; (f) (i) 4-methoxy-3-butene-1-yne, ZrCP2(H)CI, AgOTf, CH2CI2, (ii) 
TESCI, imidazole, 95%; (g) decalin, Et3N, 240°C, 24 h, 69%; (h) (i) Super 
hydride, THF, (ii) Dess-Martin, CH2CI2, (iii) Ph3PCH20CH3CI, KHMDS, CH2Clr 
THF, (iv)TBAF, THF, (v) Dess-Martin periodane, CH2CI2, 0 °C, 51%; (i) (i) L-
Selectride, THF, 0 °e, (ii) MsCl, Et3N, CH2CI2, 0 °C, 34%; m (i) HCI, THF,(ii) 
MeNH2 . HCI, Et3N, Ti(OiPr)4, MeOH, (iii) NaBH4, 80% (k) K2C03, benzene, 75 
°C, 24 h. (I) Reference 113e 
Scheme 17. Stork's synthesis of thebaine. 
As mentioned previously, thebaine (4) is a common starting material for 
the semi synthesis of more active and more commercially valuable opioids. 
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Oxycodone (121) is a synthetic opiate that possesses much of the analgesic 
properties of morphine (117) and is used in the treatment of medium to severe 
pain.113 Oxycodone was ftrst synthesized from thebaine in 1916 by a two step 
process (Scheme 18).111 The C-ring of thebaine (4) is ftrst oxidized to 
oxycodeinone 155 by treatment with acidic hydrogen peroxide. A subsequent 
hydrogenation gives the 14-hydroxylated, oxycodone (121). Interest in this 
commonly prescribed analgesic has prompted optimization of this net 
transformation by a number of academic and industrial researchers. 114 
thebaine (4) 
oxidation 
• 
NMe 
reduction • 
o 
155 
Scheme 18. Synthesis of oxycodone from thebaine. 
oxycodone (121) 
The analgesic and antitussive (cough suppressant) hydrocodone (122) is a 
semisynthetic opioid derived from either codeine (118)115 or thebaine (4).116 The 
synthesis, starting from thebaine (4), begins with diimide reduction of the C-8/C-
14 olefm. The intermediate enol ether 156 is then subjected to hydrolysis to 
provide hydrocodone (122) (Scheme 19). 
A variety of opioid receptor antagonists have been developed for the 
treatment of opiate dependency and overdose. The semisynthetic opioids 
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naltrexone (126) and naloxone (125) are two such antagonists which are produced 
commercially from thebaine (4)y7 
MeO 
NMe NMe NMe 
o 
thebaine (4) 156 hydrocodone (122) 
Scheme 19. Synthesis of hydrocodone from thebaine. 
Thebaine is converted to oxycodone (121) which is a common 
intermediate for both opioids (Scheme 20). Demethylation of the nitrogen is 
followed by alkylation with the appropriate chain to provide intermediates 157 or 
158. These derivatives then undergo 3-0-demethylation to provide antagonists 
naltrexone (126) and naloxone (125). 
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Scheme 20. Synthesis of naltrexone and naloxone from thebaine. 
The preceeding chapter has described previous contributions to the areas 
of enzymatic dihydroxylation of arenes, study of Amaryllidaceae constitutents, 
and preparation of opiates related to thebaine. It is hoped that this will serve to 
frame our recent work in these areas and provide emphesis for the relevance of 
the presented research. As our progress in the synthesis of Amaryllidaceae 
constituent is built upon the chemoenzymatic oxidation of substituted benzenes, 
our work entailing TDO mediated oxidation of arenes is discussed first. 
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III. Discussion 
111-1 Introduction 
The development of methods to enhance brevity, selectivity, and 
efficiency in synthetic processes is one of the cornerstones of modem organic 
chemistry. Despite continued developments in catalysis, the prowess of enzymes 
in all three of the aforementioned areas remains unmatched. The availability of 
enzymatic methods/reactions which have direct equivalents in traditional organic 
chemistry is still lacking and this has contributed greatly to the slow· adoption of 
these methods. Problems also exist with enzymatic reactions being "too specific" 
and lacking the generality needed for widespread acceptance. As part of our 
research in the direct application of enzymatic methods to total synthesis we have 
continually pursued exploration of the limits of the chiral dihydroxylation of 
arenes using various whole-cell fermentation processes. Our recent work in this 
area will be discussed. Highlighted will be the recent investigation of 
chemoenzymatic oxidation of various dibromobenzenes and their application to 
the total synthesis of (-)-conduritol E (162) (Figure 20). This will be followed by 
a discussion of our investigations into the steric factors governing the oxidation of 
benzoates by the TDO enzyme. The utility of these previously unidentified 
metabolites will be demonstrated by their application in the synthesis of pseudo-
sugars, aminocyc1itols, and various bicyc1ic ring systems. 
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R2 = C02Me 160 
Br 
Br~OH 
U OH 
161 
163 
(X0H 
HO"': OH 
OH 
(+conduritol E (162) 
-OH 
carba-a-L-galactopryanose 
(164) 
Figure 20. Enzymatic oxidation of substituted benzenes in the synthesis of 
cyclitols. 
The Amaryllidaceae constituents have garnered considerable attention 
from the scientific community for both their structural complexity and their 
intriguing biological activities. Several of the most important members of this 
family, pancratistatin (1), 7-deoxypancratistatin (2), narcic1asine (46), and trans-
dihydrolycoricidine (3) are available only in minute quantities. The future of 
these constituents as potential treatments for cancer is dependent on adequate 
supply. There have been many elegant approaches to the synthesis of these 
constituents over the years but few, if any, approach the brevity or efficiency 
required to advance these compounds as therapeutics. 
In addition to the issue of supply, the above mentioned Amaryllidaceae 
constituents suffer from poor solubility profiles. While this issue has been 
partially addressed through the synthesis of various phosphate prodrug analogues, 
the generation of these derivatives is still dependent on supply of the natural 
product. A major portion of this discussion will focus on our efforts to both 
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provide general methods for the synthesis of the isocarbostyril skeleton and 
synthetic routes to novel C-l analogues of 7 -deoxypancratistatin. The total 
synthesis of 7 -deoxypancratistatin (2) and trans-dihydrolycoricidine (3) were 
achieved from a common C-l aldehyde analogue of 7-deoxypancratistatin (166) 
(Figure 21). This C-l aldehyde was also used to synthesize several C-l 
derivatives (167 - 170). These new analogues were evaluated for their efficacy 
against a number of human and nonhuman cancer cell lines providing strong 
evidence of the positive influence of C-l derivatization on the activity profiles of 
these compounds. 
Br 6 _e_nzy....:....-m_a_tic_d_ih--'y_d_ro_xy.;;....l_at_io_n--:l ... 
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OH 
o 
7-deoxypancratislatin (2) / 
o 
OH 
OH o 
<0 
Br 
h OH 
U OH 
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o 
~ tranS-di~drOIYCOriCidine (3) 
'\... )lo 9H 
OH - OH 
OH 
o R = H, 168 0 167 0 170 
R= Me, 169 
Figure 21. Chemoenzymatic synthesis of7-deoxypancratistatin (2), trans-
dihydrolycoricidine (3) and various C-l analogues of7-deoxypancratistatin (167-
170). 
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In the last section of this discussion an approach to the synthesis of 
morphine alkaloids is presented. This double Diels-Alder approach is reliant on 
the latent symmetry contained in morphine alkaloids and is intended as a general 
entry to the synthesis of many medicinally vital opioids. A detailed 
investigation of various model systems will be discussed in addition to progress 
toward the total synthesis of thebaine (4) (Figure 22). 
¢----., .. ~ OMe 
CI 
8 6 171 
: 1st 
: Diels-Alder 
I 
thebaine (4) 172 
Figure 22. Proposed model system and the total synthesis of thebaine. 
111-2 Dihydroxylation of 0- and m-Dibromobenzene and Total Synthesis of 
(-)-Conduritol E 
The use of whole-cell fermentation techniques in the production of cis-
dienediols and the application of these metabolites to total synthesis has proven to 
be a powerful combination.23 As part of our ongoing research in this area we 
have become interested in the discovery of new substrates of the toluene 
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dioxygenase enzyme. Focus has been placed on elucidation of new metabolites 
that provide data on the mechanism of oxidation, materials suitable for total 
synthesis, or both. As disubstituted aromatics (ortho, meta, and para) account for 
some of the most richly functionalized compounds accepted by TDO we elected 
to investigate dibromobenzenes as possible substrates. 
In general, m-substituted aromatics give lower yields of the corresponding 
diol compared their ortho and para counterparts. One exception to this is m-
dibromobenzene, which is transformed to diene diol (174) in yields of up to 4 gIL 
fermentation broth.1I8 This provided access to the diol (174) in sufficient enough 
quantity to allow for its use in the total synthesis of narciclasine (46). 50c In order 
to complete the series, an investigation of the enzymatic oxidation of the 
remaining two isomers (ortho and para) was undertaken. 119 p-Dibromobenzene 
(175) was converted to its corresponding dienediol (176) in 55 mgIL on a 
shakeflask scale (Figure 23). While the resulting diol is a meso compound, it is 
theoretically possible to incorporate it into asymmetric synthesis via subsequent 
desymmetrization steps. 
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Figure 23. Symmetry of dibromobenzenes and the metabolism to diols. 
o-Dibromobenzene (159) was converted to the corresponding dienediol 
161 by enzymatic oxidation with recombinant E. coli JM 109 (pDTG601). The 
scale of the reaction was increased from 0.5 L to 15 L to give an eventual yield of 
4.1 gIL of the diol. This oxidation occurred selectively to provide only the 1,2-
regioisomer as opposed to the meso 3,4-hydroxyl regioisomer. The absolute 
configuration of diol 161 was established by its conversion to (-)-conduritol E 
(162) (Scheme 21).120 The optical purity of (-)-conduritol E (162) was compared 
to a literature value and found to be within 3% error.120b 
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Br Br Br B''-(x0H a B''6::>< b B'X:x~>< .. .. ~ OH HO' : 0 
OH 
161 177 178 
1c (:C0H d 
, .. (:C:>< .. 
HO" ' : OH HO : 
OH OH 
(-)-conduritol E (162) 179 
[0.]021 -285 (c 1.0, H2O) 
lit: [0.]02°-294 (c 1.0, H20)ref119b 
Reaction conditions: (a) 2,2-DMP, pTsOH, rt, 95%; (b) OS04, NMO, acetone-
H20, rt, 71%; (c) nBu3SnH, AIBN, THF, reflux, 64%; (d) 3% cone HCL, MeOH, 
rt,81% 
Scheme 21. Synthesis of (-)-conduritol E (162). 
The enantiomeric excess of diol 161 was also determined by its conversion to 
Mosher ester derived from monoprotected diol 182, (Scheme 22). This Mosher 
derivative 183 was previously prepared from homochiral and racemic alcohols 
182.121 Examination of the 19F NMR spectrum showed a single peak at -72.8 
ppm, indicating enantioselectivity ~ 95% in the original biooxidation of 0-
dibromobenzene. 
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0 1e 
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Reaction conditions: (a) potassium azodicarboxylate, AcOH, MeOH, 0 DC, 95%; 
(b) THSCL, imidazole, OCM, 0 DC, 86%; (c) H2, Pt02, Et3N, rt, 52%; (d) Mosher's 
acid chloride, Et3N, OCM 
Scheme 22. Synthesis of Mosher ester 183. 
111-3 Dihydroxylation of Benzoate Esters 
The further exploration of new diols amenable to synthesis led us to 
investigate the processing of various benzoates by the toluene dioxygenase 
enzyme. 122 Initial investigation into the precedent for dihydroxylation of 
benzoate esters revealed a single example of enzymatic oxidation of methyl 
benzoate (160) by Pseudomonas putida wild strains NCIB 1176 and NCIB 11680 
or Pseudomonas putida UV4.123 In this report diol 163 was only partially 
characterized eH-NMR, MS, optical rotation), and so a more thorough 
investigation of the steric and functional limits for the processing of these 
benzoate esters by TDO was undertaken (Figure 24). 
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Figure 24. Enzymatic dihydroxylation of benzoate esters. 
All of the required benzoate esters were either commercially available or 
prepared by standard procedures. 124 Each benzoate (entries 1-8, Table 1) was 
screened on small scale in Femach shake flasks with cells harvested from a 15 L 
fermentor. In cases where benzoates were substrates the resulting metabolites 
were isolated and characterized prior to preparative fermentation (15 L scale). 
Diols 163, 191, 196, and 197 were isolated in approximately 1 gIL. The slightly 
larger or more branched benzoates, n-Pr and i-Pr, were shown to be poor 
substrates, while n-Bu and I-Bu benzoates provided no detectable quantity of 
metabolites. 
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Table 1. Dihydroxylation of benzoate esters. 
Entry Substrate (benzoate) Product Conversion (%) Yield (gIL) 
I Me 163 95 1.30 
2 Et 191 56 0.80 
3 n-Pr 192 78 0.07 
4 i-Pr 193 41 0.05 
5 n-Bu 194 
6 t-Bu 195 
7 allyl 196 89 0.60 
8 propargyl 197 91 1.0 
The stability of the isolated diols proved to be quite remarkable when compared 
with their more labile CI, Br, I, Me cousins. This stability allowed for purification 
of the diols by crystallization or chromatography and even permitted their 
combustion analysis. The absolute configuration of the new diols was established 
by stereochemical proof (Scheme 23). Diol 191 underwent PAD reduction to 
give vinyl ester 199. The structure of 199 was matched by chemical synthesis 
performed by Bradford Sullivan. I22 Vinyl ester 199 was generated from diol 34 in 
4 steps which included a carbonylation of vinyl bromide 202. The remaining 
diols (163, 192-193, 196-197) were saturated at the site of the olefin prior to 
trans esterification to ethyl ester 199. In the case of allyl and prop argyl diols 196 
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and 197 the additional unsaturation was reduced with excess PAD to provide 
vinyl ester 200, a compound previously converted and matched to ester 199. The 
conversion of all diols to intermediate 199 allowed for assignment of absolute 
stereochemistry as identical to that of well established diol 
~OH a aOH b O:~H ~ ~ ~ OH OH OH 
163 R= Me 198 R= Me 199 
191 R = Et 199 R= Et 
192 R = n-Pr 200 R=n-Pr 
193 R = i-Pr 201 R = i-Pr 
196 R = allyl 
197 R = propargyl 
Br Br 
Cc°H c,a 6::>< ~ ~ OH 
34 202 
Reaction conditions: (a) potassium azodicarboxylate, AcOH, MeOH, 0 DC; (b) 
H2S04, EtOH, rt; (c) 2,2-DMP, p-TsOH, acetone, rt; (d) (i) t-BuLi, Et20, -78°C, (ii) CO2, -78°C - rt; (e) EtOH, EDC, DMAP, CH2CI2, 0 °C 
34. 
Scheme 23. Conversion of diene carboxylates to ester 199 and proof of absolute 
configuration. 
ill-3.1 Synthesis of Pseudo-sugars, Amino Cyclitols, and Bicyclic Ring 
Systems 
The substitution of these new diols provides ready access to vanous 
pseudo-sugars. To demonstrate this utility, carba-a-L-galactopyranose (164) was 
synthesized in five steps starting with diol163 (Scheme 24). Facial control of the 
dihydroxylation of the distal olefm was achieved by protection of the diol as its 
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acetonide prior to treatment with OS04. The isolation of the free diol from this 
oxidation was confounded by its polarity and decomposition during purification. 
Protection of the crude diols as their acetates allowed for isolation of intermediate 
203 in good yield over the three steps. The acrylate 203 was reduced under 
hydrogenation conditions to provide 204 and 205 as a mixture of diastereomers 
(4:1). Separation of these isomers by chromatography allowed for reduction of 
ester 204 to give triol 206, an intermediate in the synthesis of carba-a-L-
galactopyranose (164).125 Protected carbasugar 206 was identical in every respect 
to the previously prepared material, save for a slightly higher optical rotation 
([a]D20 -57.08 vs. [a]D -47). 
C02Me 
a &~>< C02Me g02Me O:0H b :0, .. 6::>< :o, .. CX:>< ~ OH :cO"·. 0 
-
-
OAc OAc OAc 
163 203 204 4: 1 205 
&OH 
Ie 
HO 
HO"2x:>< .. HO"·. OH 
OH OH 
carba-a-L-galactopryanose (164) 206 
Reaction conditions (a) (i) 2,2-DMP, acetone, p-TsOH, rt, (ii) OS04, NMO, 
acetone/H20, rt, (iii) A~O, pyridine, rt, 70%; (b) H2 60 psi, Rh/AI20 3, EtOH, 69% 
of 206; (c) LAH, THF, reflux, 86% 
Scheme 24. Synthesis of carba-a-L-galactopyranose (164). 
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In an effort to explore the synthetic possibilities afforded by these diols 
their utility in a number of cyc1oaddition reactions was investigated (Scheme 25.). 
The facile dimerization of acetonides derived from diol 34 is well known and 
documented. 126 We first sought to explore the tendency of these new substrates to 
undergo a similar cyc1oaddition with the hope that it would likewise proceed with 
high regio- and stereo selectivity. The acetonides 207 and 208 derived from diols 
191 and 197 smoothly underwent an analogous [4 + 2] cyc1oaddition when 
maintained at room temperature for prolonged periods of time (7 days) giving 
dimers 209 and 210, respectively. This same dimerization could be accelerated 
by heating a concentrated solution of each acetonide in toluene (6 hours). In each 
case, the cyc10adducts were formed by an apparent endo-approach of the 
dieneophile to the less hindered face of both cyc1oaddition partners. The dimers 
209 and 210 were formed as single diastereomers whose structurers were 
confirmed by NOESY spectroscopy_ The dimerization of the free diol 191 was 
also explored at a variety of temperatures and concentrations. Heating of the free 
diol at rt or 60°C provided no change in composition, even after prolonged 
reaction times (3 days). On the other hand, heating the same diol191 at 110°C 
for 12 hours prompted the loss of water and the formation of the corresponding 
phenol. 
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Reaction conditions: (a) 2,2-DMP, p-TsOH, acetone, R = ethyl 92%, R = 
propargyl63%; (b) rt, neat, 7 d, R = ethyl, 93%, R = propargyl82%; (c) DMAD, 
toluene, 57%; (d) (i) 2,2-DMP, p-TsOH, (ii) AcNHOH, Na104, MeOH, rt, 70% 
(over 2 steps); (e) Mo(CO)6, CH3CN/H20, reflux, 75% 
Scheme 25. Application of Diels-Alder reactions to benzoate-derived diols. 
Acetonide 207 was also reacted with electron poor dieneophile 
dimethylacetylenedicarboxylate (DMAD). The cyc1oaddition between electron 
poor diene 207 and DMAD afforded mixtures of cyc1oaddition product 211 and 
dimer 209 (2:1 ratio). 
Finally, these dienes were used in a series of inverse electron demand 
Diels-Alder reactions with an in situ-generated acetyl nitroso dieneophile. The 
cycloaddition proceeded with complete regio- and stereo selectivity to provide 
dihydrooxazine 212.127 The labile N-O bond in this highly functionalized 
68 
intermediate was cleaved to provide hydroxyl ester 213, a potential precursor to 
amino pseudo-sugars and aminocyclitols. Most recently this intermediate has 
been used in the total synthesis of the antiviral oseltamivir (214).34b 
111-4 Intramolecular Aziridine Opening Approach to the Amaryllidaceae 
Alkaloids 
111-4.1 Synthesis ofC-l Analogues of7-Deoxypancratistatin 
The efforts of the Hudlicky group to provide viable synthetic routes to 
Amaryllidaceae constituents and their unnatural analogues have spanned almost 
20 years. Our current work represents the 8th generation approach to the efficient 
synthesis of these congeners. In this case, the ready access to a specifically 
chosen class of derivatives was a driving force in the development of the current 
generation. It was envisioned that an aldehyde such as 166, which contains all of 
the structural elements needed for strong activity, would provide an ideal common 
intermediate for not only the total synthesis of several Amaryllidaceae 
constituents, but also a variety of C-I analogues (Figure 25). The oxidative 
cleavage and recyclization of a functionalized phenanthrene 215 suggested itself 
as an ideal transformed to attain the desired core configuration with the required 
C-I aldehyde. 
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Figure 25. Retrosynthetic analysis for the synthesis of Amaryllidaceae alkaloids 
and their C-l analogues. 
Phenanthrene 215 could, in turn, be attained from an intramolecular aziridine 
opening and cyclization of a tethered olefin such as 216. This transformation is 
second in importance only to the selective opening of the oxirane 217. The 
enzymatic dihydroxylation of bromobenzene would provide the diol 34 inclusive 
of all the functionality necessary for the synthesis of epoxy-aziridine 217. 
The synthesis of the key aldehyde intermediate 166 began with the 
enzymatic dihydroxylation of bromobenzene with E. coli JM109(pDTG601) to 
provide diol 34 (Scheme 26).128 The protection of the diol as its acetonide 218 
allowed for facial-selective aziridination via Yamada-Evans protocol to give 
219. 129 This N-tosyl aziridine was matched to that known previously in the 
synthesis of Amaryllidaceae constituents. The removal of the bromide proceeded 
under radical conditions to provide vinyl-N-tosylaziridine 70. 
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Reaction conditions: (a) E. coli JM109 (pDTG601A), 20 gIL; (b) 2,2-DMP, p-TsOH, 
acetone; (c) PhINTS, Cu(acach, acetonitrile, 0 DC - rt; (d) n-Bu3SnH, THF, AIBN, 
reflux, 76%; (e) m-CPBA, DCE, reflux, 96%; (f) 222, n-BuLi, Me2AICI, toluene, -50 to -
20 DC; (g) TBSOTf, Et3N, CH2CI2, -78 DC, 77% (2 steps) 
Scheme 26. Synthesis ofepoxyaziridine (217) and selective oxirane opening. 
Epoxidation of the olefin was accomplished by treatment with m-CPBA in 
refluxing DCE. The epoxides 217 and 220 were obtained in good yield (96%) but 
as a 3: 1 mixture of diastereomers. Improvement of this ratio under a variety of 
reaction conditions proved elusive but it was discovered that higher reaction 
temperatures and shorter reaction times provided optimal yields of the desired 
compounds. Successive recrystallizations from isopropyl alcohol allowed for 
enrichment of the ratio up to 10: 1 (217:220), but in general two recrystallizations 
provided a workable ratio of 7:1. These enriched mixtures of epoxyaziridines 
were added to the alane derived from acetylene 222. The synthesis of 222 from 
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piperonal (224) followed procedures established by Corey130 and Overman 
(Scheme 27). 131 Piperonal (224) was allowed to react with carbon tetrabromide in 
the presence of triphenylphosphine to give dibromide 225 which upon treatment 
with n-BuLi provided the desired alkyne 222 in good overall yield. 
Reaction conditions: (a) CBr4, Ph3P, CH2CI2; (b) n-BuLi, THF, -78°C, 75% (over 2 steps) 
Scheme 27. Synthesis of acetylene 222. 
The addition of epoxyazirdines 217 and 220 to the alane derivative of222 
produced intermediate alcohol 221 that was immediately protected as its silyl 
ether 223. The cumulative yield for this two-step sequence was eventually 
optimized to 77%, but initial attempts at the epoxide opening provided the desired 
product in poor yield (10-20%). This troubling bottleneck prompted further 
investigation which revealed a rather strict set of reaction conditions necessary for 
attainment of reproducible yields. Stringent control of temperature, both in the 
formation of the alane and in the addition of the epoxide, was found to be crucial. 
Deviation from this protocol led to decreased yields attributed to either the 
incomplete formation of the alane or various side reactions of the epoxyaziridine. 
Predominant side products included those derived from the nucleophilic opening 
of the aziridine and/or epoxide with chloride anion as well as opening of the 
aziridine with the alkyne (structures are not shown). It was also discovered that 
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for complete conversion of the epoxy aziridine two equivalents of the alane were 
required. Fewer equivalents of the alane resulted in incomplete conversion of 
starting material while more equivalents yielded increased production of the 
byproducts mentioned above. 
The reduction of alkyne 223 to its cis-alkene 216 was investigated using a 
variety of the catalytic hydrogenation and borane-based conditions (Table 2). The 
majority of hydrogenation conditions attempted proved ineffective for the 
selective reduction of the alkyne to the desired cis-alkene 216. Poisoning of 
Lindlar's catalyst with quinoline allowed for chemoselecive reduction of the 
alkyne in excellent yield. An alternate reduction protocol utilizing borane 
dimethyl sulfide complex also provided selective reduction of the alkyne, albeit in 
lower yields (76%). 
Table 2. Hydrogenation of alkyne 223. 
Conditions 
Lindlar's cat. 20 mol%, MeOH, 40 psi H2 
Lindlar's cat. 20 mol%, EtOAc, 40 psi H2 
Lindlar's cat. 20 mol%, EtOH, 40 psi H2 
Lindlar's cat. 40 mol%, MeOH, 1 atm H2 
Lindlar's cat. 40 mol%, MeOH, 1 atm H2 
quinoline (20 mol%) 
PdlC 40 mol%, MeOH, 1 atm H2 
BH3/SMe2, cyclohexene, 0 °C 
Time (b) 
24h 
24h 
24h 
3.5 h 
3h 
3h 
3.5 h 
Ratio of 223:226:216 
I : 3: 2 
1 : 4: 1 
1 : 2.5: 1 
0: 1 : 3 
0: 0: 1 
0:1:0 
0:0:1 
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The key precursor 216 for the intramolecular aziridine opening and cyc1ization 
was adsorbed onto rigorously dried silica and heated at 120°C for 24 hours to 
provide phenanthrene 215 (Scheme 28).132 This reaction is performed in the solid 
phase with an approximate mass ratio of 5: 1 (dry silica : substrate). Purification 
of the reaction products was conveniently accomplished by introduction of the dry 
silica mixture onto a prepared silica column followed by elution. 
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Reaction conditions: (a) silica gel, 120°C, 24 h, 74%; (b) OS04, NMO, CH2CI2/H20, rt, 
89% (228); (c) NaBH4' dioxane/EtOH, 0 °C; (d) Nal04, dioxane/H20, rt; (e) THF/H20, 
TsOH, rt, 2 h (f) IBX, DMF, rt, 61% (over 3 steps) 
Scheme 28. Intramolecular aziridine opening and synthesis of C-l aldehyde by 
oxidative phenanthrene cleavage. 
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In order to attain the proper phenanthridone core an oxidative cleavage of 
olefin 215 was required. Several methods for the efficient cleavage of the 
phenanthrene were examined in an attempt to efficiently generate aldehyde 166 or 
similar phenanthridone species. 
Innitial osmylation of 215 produced cis-diol 227 as a mixture with over-
oxidized ketoalcohol228. The crude mixture was reduced completely to cis-diol 
227 before the oxidative cleavage with periodate to provide dialdehyde 229 in 
83% over the 3 steps. The use of excess equivalents of co-oxidant (NMO) in the 
osmylation step allowed for isolation of hydroxyketone 228 as the sole product in 
89% yield. The complete assignment of stereochemistry in 228 was determined 
by extensive NMR analysis of its acetate 232 by Dr. Ion Ghiviriga at the 
University of Florida (Figure 26). The hydroxyketone 228 was likewise 
converted to dialdehyde 229 following a similar reduction and oxidative cleavage 
procedure. Dialdehyde 229 was observed in crude form as a complex mixture of 
alcohol 231 and atropisomers. It is interesting to note that first attempts at the 
oxidative cleavage of diol 227, which incorporated ethanol as a cosolvent, 
resulted in formation of ether 230. This material was converted quantitatively to 
alcohol 231 under acidic, aqueous conditions. Oxidation of 231 provided the 
desired phenanthridone 166, a fully protected C-I aldehyde analogue of 7-
deoxypancratistatin, in 69 % overall yield from ketone 228. 
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Figure 26. Full assignment ofNMR chemical shifts for the acetate of keto alcohol 
232. 
In addition to the protocols described above, a more direct route to 
dialdehyde 229 and phenanthridone 166 was investigated using direct ozonolysis 
of olefin 215 (Scheme 29). Treatment of the alkene with ozone followed by 
reductive workup allowed isolation of products similar to those obtained 
previously in the cleavage of diol 227. Treatment of this mixture with IBX 
provided the desired C-l aldehyde 166 in 76% over the two steps. This procedure 
was a considerable improvement over the previous oxidative cleavage protocol 
resulting in an increase in yield of 15% and elimination of two operations. In 
addition, the oxidative cleavage of hydroxyl ketone 228 was investigated using 
sodium periodate under a variety of acidic and basic conditions. Unfortunately, 
all reactions failed to provide the desired acid 233 or methyl ester 234. In the end, 
the ideal procedure for the oxidative cleavage for olefin 215 was found to be 
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direct ozonolysis to alcohol 231 and oxidation to C-l aldehyde 166. This protocol 
provides the desired phenanthridone in the most efficient and fewest steps. 
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Reaction conditions: (a) i) °3, CH2CI2, Sudan Red, -78°C, ii) Me2S, -78°C - rt; (b) IBX, 
DMF, rt, 76% (over 2 steps); (c) OS04, NMO, CH2CliH20, rt, 89% 
Scheme 29. Ozonolysis route to aldehyde 166 and proposed oxidative cleavage of 
hydroxyketone 228. 
The synthesis of C-l analogues of 7 -deoxypancratistatin proceeded from 
aldehyde intermediate 166 (Scheme 30). Oxidation of aldehyde 166 with m-
CPBA cleanly provided the acid at the C-l positions. The acid 235 was converted 
to its methyl ester 236. This transformation provided both access to a second C-l 
ester derivative and easier handling of the otherwise polar acid. Reductive 
cleavage of the N-tosyl protecting group gave phenanthridone 237, deprotection 
of which under acidic conditions provided the fully hydroxylated C-l ester 169. 
Saponification with lithium hydroxide gave the corresponding C-l carboxylic 
acid derivative of 7 -deoxypancratistatin 168. 
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Reaction conditions: (a) m-CPBA, Na2HP04, CH2CI2, 40 DC, 85%; (b) CH2N2, Et20, 0 
DC; (c) Na/naphthalene, DME, -50 DC, 58%; (d) 3% HCI in MeOH, rt, 69%; (e) LiOH, 
MeOH, rt, 95% 
Scheme 30. Conversion ofC-l aldehyde 166 to C-l ester 169 and acid 178. 
An alternative procedure for the synthesis of methyl ester 236 through 
ozonolysis was also envisioned (Scheme 31). A procedure for the cleavage of 
oletins to diesters reported by Marshall appeared particularly attractive for this 
transformation. 133 The direct cleavage of alkene 215 by treatment with ozone in 
the presence of methoxide provided an intermediate containing a monoester and 
an aldehyde after only ten minutes. This material was exposed to the same 
reaction conditions under prolonged reaction time (1.25 hours) to give ester 236 
in 6% yield. It is likely that oxidative cleavage occurs quickly resulting in the 
observed monoester but that prolonged reaction time is required to form and 
subsequently oxidize the hemiacetal from the aldehyde. The low yield of this 
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transfonnation was attributed to the instability of other functionality under 
prolonged treatment with ozone. 
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Reaction conditions: (a) 0 3, NaOH, MeOH, CH2CI2, -78°C, 6% 
Scheme 31. Alternative oxidative cleavage of olefin 215. 
The C-I hydroxymethyl and acetoxymethyl analogues were synthesized 
using a similarly straightforward protocol. The aldehyde 166 was reduced with 
sodium borohydride to give alcohol 238 in good yield (Scheme 32). Control of 
temperature was important for selective reduction of the aldehyde in the presence 
of the activated phenanthridone. Reactions perfonned above 0 °C resulted in 
reduction of the benzamide moiety. The alcohol 238 was converted to its acetate 
prior to reductive detosylation. Intennediate phenanthridone 240 was not isolated 
but instead converted directly to alcohol 241 via cleavage of the silyl ether by 
treatment with TBAF. 
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Reaction conditions: (a) NaBH4 , dioxane, EtOH, 0 GC, 85%; (b) A~O, pyridine, DMAP, 
CH2CI2, 81%, (e) Na/naphthalene, DME, -78 GC; (d) TBAF, THF, 0 GC, 74% (2 steps); (e) (i) K2C03, MeOH, H20, (ii) HCI, H20, 75%; (f) 3% HCI in MeOH, rt, 45% 
Scheme 32. Conversion ofC-l aldehyde 166 to alcohol 167 and acetoxymethyl 
derivative 170. 
Hydrolysis of the C-l acetoxymethyl derivative 241 with K2C03 was followed by 
acidification and cleavage of the acetonide to furnish the fully hydroxylated 
derivative 167. The C-l acetate analogue 170 was provided by controlled 
hydrolysis of the acetonide with 3% HCI in methanol. 
Alternative routes to alcohol 238 were investigated. Since the alkane 226 
could be readily formed from hydrogenation of alkyne 223, it was reasoned that 
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selective oxidation at the benzylic position following ring closure would give 
ketone 243 (Scheme 33). Formation of lactone 245 through oxidative ring 
expansion would be followed by cleavage and rearrangement to provide efficient 
synthesis of alcohol 238. 
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Reaction conditions: (a) silica gel, 120 DC, 24 h, 69%; (b) PCC, CH2CI2, rt, 11 h, 
243:244 (46%:23%); (c) m-CPBA, Na2HP04, CH2CI2, 40 DC, 22% 
Scheme 33. Alternative approaches to alcohol 238. 
Intramolecular ring closure and aziridine opening of 226 was achieved under 
solvent free conditions as described previously128 to give 242. The resulting 
cyclic alkane was treated with PCC in dry methylene chloride producing ketone 
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243 along with fully aromatic compound 244 as a minor product. Ketone 243 
was subjected to Baeyer-Villiger oxidation conditions in the hopes of generating 
lactone 245, but instead ester 246 was isolated in only moderate yield. The 
id~ntity of 246 was confirmed by tranesterification in basic methanol followed by 
a positive test for phenol by ferric chloride. 
In addition to the C-l oxygenated derivatives mentioned above, we also 
desired to generate a series of analogues bearing an amine at the C-l position. In 
theory, this would allow for further conversion to various amine salts that would 
confer greater water solubility. Our intention was to use the C-l aldehyde 
functional handle for this transformation (Scheme 34). 
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Reaction conditions: (a) Nalnaphthalene, DME, -78 ac, 78% 
Scheme 34. Attempted synthesis of C-I amines. 
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Table 3. Attempted reductive amination reactions. 
Amine 
MeNHiHCI 
Conditions 
NaBRt, AcOH, 
MeOH,rt 
NaBH3CN, AcOH, 
MeOH, rt - 50°C 
NaBH3CN, MeOH, rt -
50°C 
NaBH3CN, AcOH, 
MeOH,rt 
NaBH3CN, MeOH, rt 
Result 
reduction of amide and aldehyde 
no reaction at rt, reduction of aldehyde 
and cleavage of acetonide at 50°C 
no reaction, decomposition at 50°C 
reduction of aldehyde, slow cleavage of 
acetonide (15 h) 
no reaction 
reduction of amide and aldehyde (249, 
52%) 
Reductive amination was seen as the most straightforward route to the 
desired amines and so was pursued first. A number of protocols were examined 
for the reductive amination of aldehyde 166 in the hopes of installing the desired 
amine unit (Table 3). In early attempts the use of excess sodium borohydride 
resulted in reduction of both the phenanthridone and aldehyde moieties with no 
incorporation of amine (249). Attempts to cleave the N-tosyl group with 
Na/naphthaline resulted in epimerization at the C-I position (248). Use of 
sodium cyanoborohydride resulted in improved stability of the phenanthridone 
but failed to provide the desired reductive amination using a variety of amines. 
Reactions at elevated temperature with NaBH3CN and acetic acid led to reduction 
of the aldehyde and/or cleavage of the acetonide protecting group. Treatment of 
aldehyde 166 with methyl amine in the presence of TiCl4 followed by sodium 
cyanoborohydride likewise failed to produce the methylamine. The fully reduced 
product 249 was isolated, albeit in moderate yield. It is thought that steric factors 
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play a defming role in the stability of the C-I aldehyde under the conditions that 
were employed. 
In addition to attempts at reductive amination, installation of C-I amine 
functionality was pursued through direct displacement of C-I mesylate 250. 
Alcohol 238, derived from selective reduction of aldehyde 166, was converted to 
the corresponding mesylate in good yield (Scheme 35). Treatment of mesylate 
250 with an excess of methylamine at 55°C allowed for smooth displacement of 
the mesylate, but also transamidation to amine 251. As observed previously, the 
activated phenanthridone generates problems in further functionalization of these 
C-I analogues. Future work will focus on either transformations on the free 
phenanthridone or functionalization of the C-I position prior to closure of the B 
ring. 
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Reaction conditions: (a) MsCI, Et3N, CH2CI2 , 0 °C, 88%; (b) MeNH2 , THF, 55°C (sealed 
tube),41%. 
Scheme 35. Displacement of C-I mesylate and synthesis of amide 251. 
llI-4.2 Total Synthesis of trans-Dihydrolycoricidine 
In the course of exploring routes toward the total synthesis of 7-
deoxypancratistatin, it was recognized that the Amaryllidaceae constituent trans-
dihydrolycoricidine (3) could readily be acces,sed from our common aldehyde 
84 
intermediate 166. Formation of decarbonylated species 252 was attained by 
treatment of 166 with Wilkinson's reagent at 130°C (Scheme 36). Subsequent 
detosylation gave phenanthridone 253 in good yield (74%) over the two steps. 
Acid catalyzed hydrolysis of the acetonide and silyl ether yielded natural 
congener trans-dihydrolycoricidine (3) in 71 % yield from 253. 
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!c 
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trans-dihydrolycoricidine (3) 
Reaction conditions: (a) RhCI(Ph3Ph, toluene, 130°C; (b) Na/naphthalene, DME, -78 
°C, 74% (2 steps); (c) 3% HCI in MeOH, rt, 71% 
Scheme 36. Synthesis of trans-dihydrolycoricidine (3). 
111-4.3 Formal Total Synthesis of 7-Deoxypancratistatin 
Initial design for a general synthetic approach to the Amaryllidaceae 
constitutents included completion of the total synthesis of 7 -deoxypancratisatin by 
a Baeyer-Villiger type transformation to give formate 254, a protected form of the 
natural product (Figure 27). 
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Figure 27. Baeyer-Villiger reaction in the synthesis of 7 -deoxypancratistatin (2). 
The proposed transformation was based on a small number of reports which 
describe Baeyer-Villiger oxidation of cyclohexane carboxyaldehydes to their 
corresponding formates. 134 In general, aliphatic aldehydes give acids when 
treated under Baeyer-Villiger conditions.135 In our hands, treatment of aldehyde 
166 under a series of conditions known to promote the desired transformation 
either failed to promote reaction or cleanly provided C-1 carboxylic acid 
derivative 235, an intermediate described above in the synthesis of ester 236. The 
alternative Baeyer-Villiger substrate such as methyl ketone 257 was thought to 
provide a greater electronic differentiation between the two possible alkyl 
migrations (Scheme 37). It was expected that the more electron rich secondary 
center would migrate to produce a C-1 acetate protected version of 7-
deoxypancratistatin. The synthesis of the required methyl ketone 257 began with 
addition of methyl Grignard to aldehyde 166. It is interesting to note that other 
nucleophilic sources of a methyl moiety, such as MeLi, failed to provide the 
desired alcohol. Up to 12 equivalents of MeMgI were required for total 
conversion of starting material. The crude alcohol 256 was then directly oxidized 
with Collins reagent to provide methyl ketone 257 in excellent yield. 
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Reaction conditions: (a) m-CPBA, Na2HP04, CH2CI2, 40 DC, 85%; (b) MeMgI, Et20, rt,; (e) 
Collins reagent, CH2CI2, rt, 44% (over 2 steps); (d) m-CPBA, p-TsOH, CH2CI2, rt; (e) 
HF/pyridine, THF, 0 DC; (f) AeOH, THF/H20, 50 DC; (g) A~O, pyridine, rt, 38% (over 3 steps) 
Scheme 37. Investigation of Baeyer Villiger oxidation for C-l functionalization. 
Methyl ketone 257 proved unreative to basic or buffered reactions with 
peracids but upon treatment with m-CPBA, under acid catalysis, clean conversion 
to lacone 261 and free diol 260 was observed. In the case of product 261, 
definitive assignment of the structure was only realized after IR spectroscopy 
showed a very characteristic C=O lactone stretch at 1788 cm-I . Formation of this 
product results from trans esterification of the C-l methyl ester formed in the 
Baeyer-Villiger oxidation by C-3 hydroxyl. It was unclear whether the cleavage 
of the acetonide precedes the formation of the C-l methyl ester but treatment of 
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diol 260 under identical reaction conditions provided clean conversion to lactone 
261. It was thought that the steric bulk of the functionality present in the C ring 
of 257 was inhibiting migration of the electronically preferred secondary center. 
It was thought that replacement of the bulky sily ether and acetonide in 257 with 
acetates might lessen steric congestion around the C-l position. Triacetate 258 
was generated from ketone 257. However, Baeyer-Villiger oxidation of this 
triacetate provided methyl ester 259 as the sole product in 85% yield. At this 
point approaches toward 7-deoxypancratistatin via Baeyer-Vi1liger oxidation were 
discontinued in favor of other plans for a formal synthesis. 
In 1942, Hunsdiecker reported the conversion of the silver salts of 
carboxylic acids to the corresponding alkyl bromides of one less carbon.136 It was 
thought that if alkyl bromide 262 could be formed from the readily available acid 
255, cleavage of the silyl ether at the C-2 position would allow for formation of 
epoxide 263 (Scheme 38). Similar epoxides have been shown to undergo trans-
diaxial opening with oxygen nucleophiles to yield properly configured diols at the 
C-l/C-2 position. Initially we attempted Hunsdiecker transformation using the 
Cristol-Firth modification in which the, often difficult to prepare, silver salt is 
avoided. I37 Acid 255 was treated with excess red HgO and one equivalent of 
bromine in refluxing carbon tetrachloride to provide compound 262 in poor yield 
and as a 3: I mixture of isomers. Repetition of this reaction proved problematic 
and continued to give yields in the range of 5-15%. In an effort to provide 
synthetically useful quantities of bromide 262, more traditional Hunsdiecker 
conditions were investigated. The formation of the required silver salt from the 
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carboxylic acid is often the most difficult step in these reactions, a generalization 
that proved true in this case. A variety of conditions were attempted to form 
silver salt 264 (Table 4). Use of sodium ethoxide as base proved to be most 
effective in promoting silver-salt formation. Unfortunately, treatment of the silver 
salt 264 with bromine in CCl4 failed to provide bromide 262 and resulted in 
recovery of2: 80% of the acid 255 (based on silver salt) in each case. 
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Scheme 38. Hunsdiecker conditions employed toward the synthesis of 263. 
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Table 4. Conditions attempted for formation of silver salt 264. 
Conditions for salt 
formation 
Notes about salt Result of Hunsdiecker 
EtOH,AgN03 Fine white solid, 25 % 
yield 
Recovery of starting 
material 
EtOH, i) NaOH, ii) 
AgN03 
EtOH, i) NaOEt, ii) 
AgN03 
Black solid, 42 % 
Black solid, 68% 
No reaction, recovery of 
starting material 
No reaction, recovery of 
starting material 
Given the success of the facile C-l decarbonylation protocol used in the 
total synthesis of trans-dihydrolycoricidine (3), we thought to employ a similar 
transformation toward the total synthesis of 7 -deoxypancratistatin. Our goal was 
to generate an a,/3-unsaturated aldehyde such as 266 that upon decarbonylation 
and epoxidation would provide epoxide 267 and subsequently 7-
deoxypancratistatin (Scheme 39). 
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Reaction conditions: (a) TBAF, THF, rt, 22%; (b) (i) TsCI, pyridine, DMAP, CH2CI2, rt. (ii) various bases 
Scheme 39. Attempted synthesis of epoxide 267 through C-2 hydroxyl 
elimination. 
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Cleavage of the silyl ether in 166 generated hydroxyl-aldehyde 265, albeit 
in modest yield. The alcohol was converted to its tosylate, but treatment with a 
variety of bases (pyridine, DBU, n-BuLi, LDA) at a variety of temperatures (-78 
°C - 100°C) failed to provide the desired transformation. In most cases the 
starting O-tosylate was recovered but in the case of treatment with neat DBU at 
80°C, total decomposition was observed. 
Inspired by reports of Nicolaou's taxol synthesis 138 and/or Grieco's 
synthesis of compactin,139 we sought to generate olefin 270 by either thermal 
elimination of formaldehyde from oxetane 269 or Grob fragmentation of mesylate 
268, (Scheme 40). In each case, mesylate 268 served as a common intermediate 
for both syntheses. Its preparation began with alcohol 238, which was protected 
as its acetate 239 (Scheme 41). 
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Scheme 40. Attempted olefm formation by Grob fragmentation or through 
elimination oxetane 269. 
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Reaction conditions: (a) A~O, DMAP, pyridine, CH2CI2, rt, 81%; (b) TBAF, THF, O°C, 
84%; (e) MsCI, Et3N, CH2CI2, 0 °C, 96%; (d) K2C03, MeOH/H20, 0 °C - rt, 85% 
Scheme 41. Synthesis ofmesylate 268. 
Cleavage of the C-2 silyl ether was followed by mesylation of the resulting 
alcohol to give 272. When mesylate 272 was treated with basic methanol at 0 °C 
clean conversion to hemiacetal 273 was observed in less than ten minutes. 
Careful work-up allowed for isolation of this material. Resubmission of this 
intermediate to the same reaction conditions provided alcohol 268 in good yield. 
As mentioned previously, it was envisioned that olefm 270 could be 
generated from mesylate 268 by both formation and thermal elimination of 
oxetane 269 or by Grob fragmentation of alcohol 268. A variety of conditions 
were investigated to effect the desired transformation and are summarized in 
Table 5. Mesylate 268 proved unreactive to treatment with stoichiometric 
amounts of base at various temperatures. Even treatment with large excesses of 
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base and at elevated temperatures proved unfruitful. Last, the upper limits of the 
reaction were probed by treatment of alcohol 268 with excess KH at 180°C 
providing considerable decomposition along with recovery of a minor portion of 
starting material. 
Table 5. Attempted Grob fragmentations and oxetane formation. 
Base Solvent Temperature Result 
KH (1.5 eq) Toluene/THF o °C - rt - 120°C Recovery of starting 
material 83% 
KH (12 eq) Toluene/THF 150°C (sealed tube) Recovery of starting 
material 74% 
KH (10 eq) DMEwith Rt - 120°C (sealed Starting material 58% 
18-crown-6 tube) 
KH (10 eq) o-xylene 180°C (sealed tube) Starting material 34% 
Another possibility considered for the formation of olefm 270 was the 
decarboxylation and elimination of a tosylate such as 275 (Scheme 42). The C-2 
silyl ether in 236 was cleaved to give alcohol 274. Upon treatment with TsCl in 
CH2Cb the unexpected formation of a,J3-unsaturated ester 276 was observed. 
This product results from abstraction of the alpha proton of the ester and 
elimination of the intermediate tosylate. This elimination, under such mild 
conditions, came as a surprise given the difficulty in elimination of the C-2 
hydroxyl of aldehyde 265 (previously mentioned). 
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Reaction conditions: (a) TBAF, THF, rt, 82%; (b) TsCl, pyridine, DMAP, CH2CI2, rt, 
28% with 41 % recovery of starting material. 
Scheme 42. Approaches toward olefin 270 by decarboxylation. 
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An improved synthesis of tosylate 275 was devised in order to avoid ester 
274 and formation of elimination product 276. Cleavage of the silyl ether 235 
proceeded in modest yield to provide hydroxyl acid 277. Despite little precedent 
for the transformation, alcohol 277 was converted to tosylate 278 by treatment 
with two equivalence of methyl lithium followed by TsCl.Decarboxylation by 
treatment with base under elevated temperature failed to generate olefin 270. 
An alternative to the elimination of tosylate 275 is decarbonylation and 
dehydration of hydroxy acid 277 using DMF dimethyl acetal. This transformation, 
developed by Hara,14O was successfully employed by Wender in his synthesis of (-
)-retigeranic acid. 141 The substrate for Wender's transformation was acyclic, 
nevertheless we endeavored to produce olefin 270 by this method. Acid 277 was 
treated with DMF dimethyl acetal in refluxing chloroform but instead of olefin 
270, mixed acetal 279 was formed. The methyl ester in this product is the results 
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of liberation of methanol during formation of the mixed anhydride followed by 
esterifcation of the acid. 
0 OTBS 0 o OTs 
~><~ ~><~ 0 o (0 ~ o ~ 0 
0 235 0 277 o 275 
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Reaction conditions: (a) TBAF, THF, 50°C, 44%; (b) MeLi, TsCl, THF, 35%; (c) KHMDS, 
toluene, 120°C; (d) DMF dimethyl acetal, CHCI3, reflux; 58% 
Scheme 43. Additional approaches to olefm 270 through acid 277. 
Given previous difficulties in the generation of C-l/C-2 olefin 270 we 
chose to pursue generation of this material using a simplified precursor. 
Phenanthridone 253 was converted to its free alcohol 280. Three routes for 
conversion of this alcohol to olefin 282 were pursued. The first entailed 
conversion of the alcohol to its mesyl derivative 281. Unfortunately, all attempts 
at an E2 type elimination failed to give the desired olefm. Treatment of alcohol 
280 with nuc1eophile-free Mitsunobu conditions also failed to elicit the needed 
dehydration. Finally, given the Hudlicky group's recent work with the Burgess 
reagent and its derivatives142 we attempted this dehydration using freshly prepared 
Burgess reagent. Treatment of alcohol 280 with Burgess salt provided 
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sulfamidate 283 as the only isolated product. It was thought that refonnation of 
the sulfamidate anion by treatment with base would allow for completion of the 
dehydration reaction. To our dismay treatment of this intennediate with 
potassium hydride in refluxing dimethoxy ethane did not result in the fonnation of 
the desired alkene 282. 
OH QMs 
253 a :>< 
b ~>< • • ~ 0 ~ 0 NH 
0 280 0 281 
~e ~ H 0 0yN,S' II '0 o 0 = /' -
:>< :>< 
f + 0 ;: 0 ~ ~ 
0 282 
Reaction conditions: (a) TBAF, THF, 0 °C; (b) MsCl, pyridine, CH2CI2, rt, 84% (2 steps); (c) pyridine, 100°C; (d) PPh3, DIAD, dioxane, rt - reflux; (e) Burgess reagent, THF, rt-
reflux, 42%; (f) KH, DME, reflux 
Scheme 44. Further attempts at C-2 hydroxyl elimination and fonnation of olefin 
282. 
It was recognized that the much sought-after ole fins 270 and 282 were 
strikingly similar to an intennediate (285, Scheme 45.) prepared in Padwa's 
synthesis of 7 -deoxypancratistatin. 49k This intennediate became our new target 
and was prepared starting fonn silyl ether 253 (Scheme 45). N-Protection of the 
phenanthridone with p-methoxybenzyl bromide was followed by cleavage of the 
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silyl ether to yield alcohol 284. Chugaev elimination of the C-2 alcohol provided 
olefm 285, a formal intermediate in the synthesis of 7 -deoxypancratistatin. 
OTBS 
O\/~ 
01\ 0 
~H \, 
o 253 
OH 
0\/ b 
ol\~o ~ 
~PMB \, ~ I 
o 284 mp 172-174 °C 0 285 
lit. 171-173 °C ! 
reference 48k 
OH 
OH 
o 
7 -deoxypancratistatin (2) 
Reaction conditions: (a) (i) NaH, PMBBr, DMF, 0 °C - rt, (ii) TBAF, THF, 0 DC, 64% (2 
steps); (b) NaH, CS2, Mel, xylenes, 165°C, 35% 
Scheme 45. Formal synthesis of7-deoxypancratistatin. 
111-4.4 Biological Evaluation of Intermediates 
In addition to the formal synthesis of 7 -deoxypancratistatin (2) and total 
synthesis of trans-dihydrolycoricidine (3), our synthetic strategy has provided 
access to four new C-I analogues of 7 -deoxypancratistatin. These new 
Amaryllidaceae constituents were screened in vitro for their antitumor activities 
through collaboration with the Pandey group at the University of Windsor, ON 
and the Kornienko group at the Newmexico Institute of Mining and Technology. 
In the course of preliminary screening, it was discovered that C-l acid 168 and C-
1 methyl ester 169 were inactive. In contrast, the one carbon homologated C-l 
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alcohol 167 and its acetate 170 displayed significant activities and were promptly 
tested for anticancer activity against a panel of human cancer cells. These two 
analogues were also evaluated for their ability to selectively induce apoptosis in 
human leukemkia and neuroblastoma cells compared to normal human blood 
cells. 
The antiproliferative activities of alcohol 167 and acetate 170 are 
displayed in Table 6 along with the activities of several related natural and 
unnatural Amaryllidaceae constituents. Compounds 167 and 170 are compared 
directly to their related parent compound while the potencies of C-I benzoyl 
analogues 286 and 287, prepared by Pettit, are provided to highlight further 
viability of derivitization at the C-l position. These two analogues in particular 
are among the most active derivatives ever tested. The two novel analogues 167 
and 170 display anticancer activity that is lower than the naturally occurring 
pancratistatin and narcic1asine by an order of magnitude or more. When 
compared to their direct parent compound, 7-deoxypancratistatin (2), the 
analogues are shown to possess potency equal to or greater than the natural 
constituent. This result stands as further vindication of the idea of C-I 
derivatization since previous modification of any other portions of these 
compounds has universally failed to produce potencies comparable to the natural 
products. The failure of compounds 167 and 170 to match the activity of the 
more potent congeners pancratistatin (1) and narcic1asine (46) is consistent with 
the drop in potency associated with the absence of the 7 -hydroxyl moiety in the 
natural series. 
98 
Except for our work and the initial investigations of Pettit, C-l analogues 
have not been explored to detennine factors contributing to the increased activity 
of these derivatives. From these preliminary investigations it appears that the 
trend is for relatively lipophilic C-l substitutions to display greater potency. This 
is demonstrated by the increased activity of the 167 and 170 compared with the 
more polar acid 168. The C-l methyl ester 169 most likely displays poor activity 
because of its facile conversion to acid 168 under physiological conditions. These 
results match nicely with the increased potencies associated with the more 
lipophilic C-I benzoyl analogue 286. The precise mode by which the benzoyl and 
acetyl substitutions are affecting the pharmacophore is not known. A more 
detailed examination of C-I substitution is required to detennine if these moieties 
are actually participating in binding or are behaving as prodrugs and promoting 
greater cell penetration before being cleaved. 
Table 6. Human Cancer Cell Line and Murine P-388 Lyphocytic Inhibitory 
Activities. 
P388 Murine Lympboceutic Leukemia and 
Human Cancer Cell Results blg1mL] (ED 50) 
Compound leukemia pancreas breast CNS lung- colon prostate leukemia neuroblastoma 
P388 BxPC-3 MCF-7 SF-268 NSC KMIOL2 DV-145 Jurkat Shsy5y 
NCI-
H460 
1 0.039 0.028 0.032 0.017 0.048 0.062 0.016 0.163 0.163 
1 0.44 0.29 0.22 
46 0.001 0.026 0.019 0.021 0.032 0.021 0.011 
3 0.029 0.046 0.034 0.059 0.043 0.051 0.040 
286 0.0016 0.0019 0.00031 0.00055 0.0001 0.00037 0.00021 
287 0.061 0.25 0.041 0.17 0.029 0.13 0.13 
167 0.19 0.65 0.09 0.26 1.615 1.615 
170 0.11 0.29 0.11 0.37 0.183 0.183 
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The C-l hydroxymethyl analogue 167 and acetoxymethyl analogue 170 
were also evaluated for their ability to induce apoptosis in Jurkat and SH-SY5Y 
cells. The cells were treated for periods up to 72 hours with compound 167 and 
170. The apoptotic effect was observed through Hoechst staining (Figure 28). 
The results from Hoechst staining were confirmed by Annexin-V binding by 
treatment of the cell lines with 167 and 170 with 0.5 J.1M samples for 48 hours 
(Figure 29). In these experiments, cells with brightly stained and condensed 
nuclei are considered apoptotic. 
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DMSO 167 170 
Figure 28. Evaluation ofapoptosis induced by 167 and 170 after 72 hours with 
Hoechst staining. 
DMSO 167 170 
Figure 29. Evaluation of apotosis induced by 167 and 170 after 48 hours and 
Annexin-V binding. 
The ED50 (50% of cells were apoptotic) for alcohol 167 was determined 
to be 1 11M in lurkat cells (Figure 30). This same compound was found to be 
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effective at a concentration of 10 /lM against the SH-SY5Y cell line. As in the 
case of the previously mentioned cell line screen, the acetate 170 displayed 
stronger activity in these experiments. The ED50 for 170 was 0.5 /lM for both the 
Jurkat and SH-SY5Y cell lines (Figure 31). 
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Figure 30. Apoptosis induced by 167 after 72 hours and determination of ED 50. 
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Figure 31. Apoptosis induced by 170 after 72 hours and determination of ED 50. 
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Both alcohol 167 and acetate 170 were found to be effective against these 
cell lines but 170 in particular displayed potency remarkably similar to the natural 
congener pancratistatin (1). This result warrants attention because, as described 
previously, pancratistatin (containing 7 -hydroxyl) is traditionally more potent 
than 7-deoxypancratistatin (2) by an order of magnitude or more. Derivative 170 
appears to circumvent this deficiency of 7 -deoxypancratistatin by matching the 
activity of the more potent pancratistatin. Given that C-l substitution is the only 
modification present, it can be additionally inferred that the acetate moiety is 
responsible for the positive addition to the potency over the parent 7-
deoxypancratistatin. 
Selective induction of apoptosis is a trait recently associated with 
pancratistatin. In order to examine the potential of acetate 170 as a selective 
apoptosis inducer it was screened against normal human fibroblast (NHFs) and 
peripheral mono-nucleated blood cells (PMBC). The results of these screens are 
shown in Figure 33. Evaluation of these experiments revealed no visible 
apoptotic morphology in either the NHFs or PMBC non-cancerous cell lines. The 
lack of apoptosis induction in healthy cells indicates that acetate 170 possesses the 
ability to selectively kill cancerous cells that had previously only been observed in 
pancratistatin (1). 
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Figure 32. Screening of 170 against non-cancerous human cells with Hoechst 
staining. 
ID-5 Latent Symmetry, Diels-Alder Approach to Thebaine 
The use of heteroaromatic cycloadditions has enjoyed widespread 
application in synthesis. 143 One class of heteroaromatics which has found 
particular use in recent years is disubstituted pyridazines.2,3,144 In many cases 
these heterocycles, while aromatic, can behave as dienes. They have the added 
advantage of allowing for extrusion of nitrogen following initial [4 + 2] 
cycloaddition via a retro Diels-Alder process. This provides interesting synthetic 
options given the ability to essentially regenerate the diene after a Diels-Alder 
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reaction. These reports and others have inspired us to develop new synthetic 
route to thebaine (4) that takes advantage of the pseudo-C2 symmetry present in 
the target opioid. The key step relies on the ability of these pyridazines' s 
behavior as dienes to allow for formation of the complete thebaine pentacyclic 
core in a cascade sequence involving two intramolecular Diels-Alder reactions 
(Figure 33). 
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Figure 33. Retrosynthetic analysis oflatent symmetry approach to thebaine (4). 
Important in this strategy is an intramolecular Diels-Alder (lMDA) 
reaction between two suitably substituted pyridazines and the appropriate furan-
based dieneophile. The proposed cyc1oaddition of a compound such as 5 would 
provide control in the formation of the key C-13 quaternary center in thebaine (4). 
Cyc1ization precursor 5 could theoretically be accessed from desymmetrization of 
bis(pyridazines) 6, which would be available in a short number of operations 
from commerciaI3,6-dichloropyridazine (8). 
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As the synthesis relied on the ftrst IMDA reaction occurring between our 
proposed furan derivative and a tethered pyridazines, we elected to investigate 
this reaction using a model system. Since it was uncertain that a fully aromatic 
furanyl system would behave as a dieneophile, two models were envisioned. The 
ftrst would consist of a furan moiety 290 linked to a simplifted pyridazine through 
an amine or amide linker. Model system 293 could be constructed from furan 290, 
derived from furanal (288) (Figure 34). The second model would consist of a 
tethered dihydrofuran 294, accessible from ester 292. In both cases, the proposed 
dieneophiles would be linked to pyridazine 291 either by reductive amination of 
their amine derivatives or by amide formation with an amino-pyridazine unit 
derived from 291. 
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Figure 34. Proposed model systems for the synthesis of thebaine (4). 
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The synthesis of ketopyridazines began with 3,6-dicholorpyridazine (8) 
which was converted to its diiodo derivative 295 (Scheme 46). Displacement of 
iodide with methoxide yielded 3-iodo-6-methoxypyridazine (7). To our delight, 
iodide 7 smoothly coupled with TMS acetylene under Sonogashira conditions 
giving alkyne 296. The synthesis of this intermediate was important as it could 
also serve as an intermediate in the planned total synthesis. Generation of the 
desired ketone from this intermediate was achieved by an oxymercuration of the 
alkyne under strongly acidic conditions. In our hands, direct formation of ketone 
291 was found to be problematic because of the persistence of mercuric adduct 
297. Conditions suitable to provide the free ketone under acid hydrolysis were 
su1;>sequently strong enough to provide hydroxypyridazine 299. We elected to 
fIrst remove mercury with standard reductive conditions. These conditions also 
reduced the ketone but oxidation of the alcohol 298 with Collins reagent gave 
ketopyridazine 294 in modest yield over the three steps (61 %). 
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Reaction conditions: (a) KI, HI, acetone, reflux, 75%; (b) K2C03, MaOH, reflux, 52%; (c) 
TMS acetylene, Cui, PdCI2(PPh3n, Et3N, THF, rt. 84%; (d) HgS04, H2S04, THF/H20, 58%; (e) 20% H2S04 in H20/acetone, reflux; (f) NaBH4' EtOH, rt; (g) Collins' reagent, CH2CI2 , 
61 % (2 steps) 
Scheme 46. Synthesis of pyridazine 291. 
With pyridazines in hand, we began generation of the furanyl tethers 
(Scheme 47). Furanal 288 was oxidized to a mixture of furanones 300 and 301 in 
a 1:2 ratio. 145 Quantitative conversion of this mixture to single furanone 301 was 
achieved by treatment with triethylamine at room temperature. Reaction of 
furanone 301 with ethyl diazoacetate furnished pyrazole 302 in moderate yield. 
Elimination of nitrogen under thermal conditions led to ester 303. Synthesis of 
furan 290 with the appropriate ether moiety at the I-position was investigated 
(Table 7). The conversion of furanone such as 303 to the corresponding· 5-
methoxy furans has been reported (entry 1),146 but in our hands only exhaustive 
alkylation at the 4-position was observed. Formation of the silyl ether was 
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thought to be more facile, but TBSCI proved to be poorly reactive in this case. 
The more activated triflate did provide the desire furan 305 in good yield (67%). 
rrY0 ° 
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288 300 1:2 301 I t 
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~N-...;; 0 d HN . ) ~ o 0 302 ~:Et o 0 303 
~ Table 7 
o ~Et 
RO 0 
290 
Reaction conditions: (a) 2-(dimethylamino)ethanol, formic acid, H20 2, Na2S04, 
CH2CI2; (b) Et3N, 78% (2 steps); (c) ethyldiazoacetate, dioxane, 95 °C, 48%; (d) 
dioxane, 150 °C (sealed tube), 89%. 
Scheme 47. Synthesis offuran tether 290. 
Table 7 Formation offuran tether. 
Entry Conditions 
1 Dimethylsulfate, Et3N, 
CH2Ch, rt 
2 
3 
TBSCI, Et3N, CH2Ch, 0 
DC - rt 
Result 
No reaction 
o ~Et 
TBSO 0 67%, 305 
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The synthesis of the dihydrofuran tether proceeded through first 
cyclopropanation of dihydrofuran 289 with ethyl diazoacetate to give ester 306 
(Scheme 48). Cleavage of the cyclopropane moiety with copper bronze in 
refluxing acetonitrile provided the desired dihydrofuran 292. 
a 
289 
° ° 
(:t>----<OEt 
306 
b /0\\ ~ ~OEt 
292 
Reaction conditions: (a) ethyldiazoacetate, (Rh(OAc)2)2, rt, 85%; (b) Cu bronze, 
CH3CN, reflux, 54% 
Scheme 48. Synthesis of dihydrofuran 292. 
In addition to our investigations of the model systems described above, we 
elected to pursue synthesis of the bis(pyridazines) 6 required for the total 
synthesis. 3-Iodo-6-methoxypyridazine (7) was converted to acetylene 307 by 
first Sonogashira coupling with TMS-acetylene followed by treatment with TBAF 
(Scheme 49). This material was then converted to bis(pyridazines) 6 by a second 
Sonogashira coupling with another equivalent of pyridzine 7. Since the desired 
acetylene 6 is symmetrical, an obvious improvement of this three step procedure 
would be to perform the two coupling reactions in a single pot using acetylene 
gas. Such reactions are not known for pyridazines, but are well known for other 
aromatic systems. Using the conditions reported by Li and coworkers,147 we were 
able to generate acetylene 6 in a single step from iodopyridazine 7. 
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Reaction conditions: (a) (i) TMS acetylene, Cui, PdC12(Ph3h, Et3N, THF, rt, (ii) TBAF, 
THF. rt, 69%; (b) 7, Cui, PdC12(Ph3h, Et3N, rt. 71%; (c) acetylene, Pd(OAch, PPh3• 
CH3CNlH20. Et3N, Cui, 78%; (d) MeNH2, Ind2TiMe2, toluene, 110°C; (e) NaBH3CN, 
MeOH, ZnCI2, 68%, (2 steps) 
Scheme 49. Hydroamination ofbis(pyridazines) 6. 
At this time it became apparent that the ease with which acetylene 6 could 
be synthesized obviated the need to deal with a separate model system. The most 
direct route for the introduction of methyl amine functionality would be a 
hydroamination reaction between methyl amine and acetylene 6. The Doye 
hydroamination catalyst 312148 was chosen for initial investigation of this reaction 
because it could be readily prepared and had recently been demonstrated to effect 
hydroaminations with small amines. 149 The required catalyst was synthesized by 
treatment of indene (311) with 4 equiv of methyllithium and titanium 
tetrachloride (Scheme 50). 
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Reaction conditions: (a) MeLi. TiCI4 
Scheme 50. Synthesis of hydroa min at ion catalyst 312. 
With both the catalyst 312 and acetylene 6 in hand, we pursued the direct 
hydroamination reaction. Fortunately, treatment of 6 with titanocene 312 in the 
presence of methyl amine provided evidence for the desired transformation. 
Initially the imine 308 was identified from a crude reaction mixture and 
subsequently reduced to provide amine 309. Later this two-step procedure was 
combined into a single pot to provide amine 309 in good yield. 
CI ¢N I I ..-::N 
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Reaction conditions: (a) K2C03• MeOH, reflux. 63%; (b) TMS 
acetylene, Cui. PdCI2(Ph3h. Et3N. THF. rt. 56% (c) 
acetylene, Pd(OAch. PPh3• CH3CN/H20, Et3N, Cui 
Scheme 51. Sonogashira coupling ofTMS acetylene with chloropyridazine 313. 
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The use of choloropyridazine 8 in various Sonagashira coupling reactions 
was also investigated as a means of reducing step count and improving synthetic 
efficiency. Chloropyridazine 8 was converted to methoxy derivative 313. 
Sonogashira coupling of 313 with TMS acetylene provided 296. Unfortunately 
attempts at a double Sonagashira coupling were unsuccessful and resulted in 
isolation of the starting pyridazine 313. 
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292 
a /°1 Cfl ~OH 
314 
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Reaction conditions: (a) LiOH, MeOH, 50°C; (b) oxalyl chloride, DMF; (c) DMAP, Et3N, 
309; (d) 309, toluene, 150°C; (e) COl, 309, CH2CI2, relux; (f) toluene, 150°C 
Scheme 52. Tethering of dihydrofuran 292 to amine 309. 
The coupling of amine 309 to dihydrofuran 292 was attempted in several 
stages and with several derivatives of the ester moiety of 292 (Scheme 52). At 
first, a simple displacement reaction was attempted with the hopes of forming the 
more stable amide. The two partners proved unreactive toward one another at 
lower temperatures, but heating to 150°C in toluene (sealed tube) provided 317. 
The formation of olefin 317 presumably occurs through Hofmann type 
elimination of the amine. Treatment of acid 314, derived from 292, with 
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carbonyldiimidazole (CDI) also gave the olefin 317 as the only isolated product. 
Eventually tethered product 316 was generated by coupling of amine 309 with 
acid chloride 315. The first attempted IMDA reaction was performed in a sealed 
tube in toluene at 150°C and provided only elimination of the amide tether to 
give olefin 309. 
While these initial investigations toward the total synthesis of thebaine by 
latent symmetry approach have proven unsuccessful, work to effect the first of the 
Diels-Alder reactions is ongoing. The information garnered through the synthesis 
of these models will prove invaluable in future attempts to refine the route and 
complete the total synthesis. 
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IV. Conclusions and Future Work 
The Amaryllidaceae constituents 7-deoxypancratistatin (2) and trans-
dihydrolycoricidine (3) are isocarbostyril natural products which possess strong 
anticancer activity. In the course of the presented study, their total syntheses were 
completed using chemoenzymatic methods. The synthesis of four new C-I 
analogs of 7 -deoxypancratistatin was accomplished with two of the new 
analogues (acetate 170 and alcohol 167) displaying significant activity against a 
panel of human cancer cell lines. Through this work the use of C-l derivatization 
as a means of augmenting the potency of these congeners has been established. 
Application of this concept to other members of the isocarbostyril family, 
especially C-l derivatives of pancratistatin, is ongoing. 
In addition to the abovementioned syntheses, chemoenzymatic methods 
have been explored at a more fundamental level in the course of this work. 
Various dibromobenzenes and benzoates were identified as new substrates for the 
TDO enzyme. The absolute stereochemistry of the new diols was matched by 
stereochemical proof and these metabolites were applied to the synthesis of (-)-
conduritol E, pseudo-sugars, aminocyc1itols, and complex bicyclic ring systems. 
A new approach toward the synthesis of morphine alkaloids was developed 
and several model systems for the total synthesis of thebaine (4) were completed. 
Future work toward the synthesis of thebaine includes establishment of intra- or 
intermolecular Diels-Alder cyc1oadditions involving any of the described 
bis(pyridazines). Study and possible modification of the existing bis(pyridazine) 
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framework is required to remedy the problematic Hofmann elimination observed in 
amine 309. 
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V. Experimental Section 
V-I General Experimental Details 
All non-hydrolytic reactions were carried · out under an argon atmosphere. 
Glassware used for moisture-sensitive reactions was flame-dried under vacuum 
and subsequently purged with argon. THF was distilled from 
potassium/benzophenone. Methylene chloride and acetonitrile were distilled from 
calcium hydride. Electrochemistry supplies and apparatus were purchased from 
EG&G Princeton Applied Research. Flash column chromatography was 
performed using Kieselgel 60 (230-400 mesh). Analytical thin-layer 
chromatography was performed using silica gel 60-F254 plates. Melting points 
were measured on a Thomas-Hoover melting point apparatus and are reported 
uncorrected. IR spectra were obtained on a Perkin-Elmer FT-IR 1600 Series 
Spectrum One instrument and were recorded as neat samples. IH and l3C NMR 
spectra were obtained on either a 300-MHz or 600 MHz Broker instrument. Data 
are reported as (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = 
broad); coupling constants(s) in Hz, integration. Specific rotation measurements 
are given in deg cm3 g-l dm-l and were recorded on a Perkin-Elmer 341 
Polarimeter. Ultraviolet spectroscopy was performed using a Perkin-Elmer 8452 
A diode array spectrophotometer. Large-scale fermentation was performed in a 
15-L B. Braun Biostat C-15 fermentor. All biological media was purchased 
through Sigma-Aldrich Canada. Combustion analyses were performed by Atlantic 
Microlabs, Norcross, Georgia, USA. 
117 
General Experimental Procedures for Biotransformations 
Small-scale fermentation with E. coli JM 109 (pDTG601) 
Growth of colonies. Agar plates consisted of bactotryptone (10 g L-1), yeast 
extract (5 g L-1), NaCI (5 g L-1), agar (30 g L-1) and ampicillin (100 mg L-1). E. 
coli JM 109 pDTG601 cells were streaked onto a plate and were incubated at 35 
°C for 12-24 h. A single bacterial colony was selected for the preculture 
preparations described in the following section. 
Preparation of preculture. Luria Bertani (LB) liquid medium consisted of 
bactotryptone (10 g L-1), yeast extract (5 g L-1), NaCI (5 g L-1) and ampicillin (100 
mg L-1). The pre culture medium (3 mL) was inoculated with a single colony of E. 
coli JM 109 (pDTG601) and the resulting inoculum was grown at 35°C on an 
orbital shaker (200 rpm) for 6 h. 
Fernbach flask preparation. LB liquid medium consisted ofbactotryptone (10 g 
L-1), yeast extract (5 g L-1), NaCI (5 g L-1), glucose (5 g L-1) and ampicillin (100 
mg L-1) . 500 mL of LB medium was inoculated with 1 mL of E. coli JM 109 
(pDTG601) pre culture medium. This inoculum was grown at 35°C on an orbital 
shaker (180 rpm) for 5 h. A chemical inducer, isopropyl-1-thio-P-D-
galactopyranoside (IPTG ) (10 mg L-1), was added via sterile filter and the cells 
were grown for additional 7 h at 35°C on an orbital shaker (200 rpm). 
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Substrate Addition. The cells were separated from the supernatant by 
centrifugation at 7000 rpm for 15 min and the supernatant was decanted. The cell 
pellet was re-suspended in 500 mL of 0.1 M phosphate buffer consisting of 
KH2P04 (6.8 g L-I), K2HP04 (8.7 gILl) and glucose (2 g L-I). The aromatic 
substrate (400 mg L-1) was added as a solution in isopropyl alcohol. Product 
formation was monitored by thin-layer chromatography (hexane-ethyl acetate, 
1:1). 
Product Isolation. After 5 h of incubation with substrate the pH of the culture 
medium was adjusted with 6 M NaOH to 8.5, and a cell pellet was obtained by 
centrifugation at 7000 rpm and 4 °C for 20 min. The supernatant liquid was 
extracted with acid-free ethyl acetate (prepared by stirring with a saturated 
solution of Na2C03) and separation of the organic from the aqueous layer. The 
extract was dried over anhydrous MgS04, filtered and the solvent was removed 
under reduced pressure. The crude material was purified by crystallization or flash 
column chromatography (silica gel deactivated with 10% distilled water) 
immediately after concentration of the solvent in order to minimize 
decomposition of the unstable dienediols. 
Large-scale fermentations were carried out in a 15-L (8-L working volume) B. 
Braun Fermentor according to a published procedure. I IS 
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Extraction of Products. Dienediols obtained from large-scale (8-L 
fermentation) were extracted from the aqueous fermentation broth into ethyl 
acetate either by standard manual extraction or by continuous extraction. The 
dienediols derived from small-scale fermentations «l'-L) were extracted 
manually. Progress of either manual or continuous extraction was monitored by 
thin layer chromatographic analysis ofthe aqueous layer. 
General Procedure for the Acitivation of Silica Gel. Silica gel {1.5 g, 230-400 
mesh) was poured onto a sintered glass Buchner funnel and washed with reagent 
grade THF (2 x 15 mL) and diethyl ether (2 x 15 mL). The silica gel was 
transferred to a round-bottomed flask and heated externally at 140 ·C under 
vacuum (1 mm Hg) for 24 h. 
General procedure for PAD reduction of diols. To a stirring solution of diene 
(2.5 mmol) and potassium azodicarboxylate (PAD) (7.5 to 15.0 mmol) in MeOH 
(4 mL), glacial acetic acid was added {17.5 to 37.5 eq.) dropwise at -15°C. The 
reaction was allowed to warm to room temperature slowly over 14 h, then 
quenched by the addition ofNa2C03 (7 to 15 mL) and concentrated under reduced 
pressure and extracted with ethyl acetate (5 x 5 mL). The combined organic layers 
were washed with brine {1 x 7 mL), dried over Na2S04 and concentrated under 
reduced pressure. The crude material was recrystalized from - ethyl 
acetatelhexanes. 
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General procedure for the transesterificatioli of PAD-reduced diols. A 
solution of PAD-reduced diol (0.79 mmol), conc. H2S04 (5 drops) in dry ethanol 
(10 mL) was refluxed for 4 days. The mixture was concentrated, diluted in 
saturated. NaHC03 (2 mL) and extracted with ethyl acetate (3 x 20 mL). The 
organic extracts were combined, dried over MgS04, filtered, concentrated, and 
purified by flash chromatography (eluant I: 1 ethyl acetatelhexanes) and 
recrystallized from ethyl acetatelhexanes. 
General procedure for formation of acetonide (ketalization) of diols with 2,2-
dimethoxypropane. To a stirring solution of diol (0.832 mmol) and 2,2-
dimethoxypropane (0.71 mL, 5.83 mmol) in acetone (1 mL) was added a catalytic 
amount of p-TsOH. The reaction was allowed to stir at room temperature for 2 h, 
then it was diluted with ethyl acetate (5 mL) and washed with saturated NaHC03 
(3 x 2 mL). The organic layer was washed with brine (1 x 3 mL) then dried with 
Na2S04. The crude material was purified via flash column chromatography with a 
solvent gradient of 2: 1 hexanes-ethyl acetate. 
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V -2 Detailed Experimental Procedures 
Br 
Br~OH 
U OH 
(IS,2S)-3,4-Dibromocyclohexa-3,5-diene-l,2-diol (161). 
The biooxidation of o-dibromobenzene was performed according to the general 
procedure for large-scale fermentation. o-Dibromobenzene (159) (60 g) was 
added dropwise over 45 min to a 15-L fermentor containing a growing culture of 
E. coli 1M 109 (pDTG601). After stirring the media for an additional 1 h, the cell 
broth was separated from the cells by centrifugation. The broth was extracted 
with 3 L of ethyl acetate using a rotary evaporator-driven continuous extractor 
over a three-day period. The combined organic layers were washed twice with 
approximately 10% by volume saturated sodium carbonate solution to remove any 
phenolic residue. The organic extracts of the fermentation broth were 
concentrated in vacuo and the dienediol precipitated by addition of pentane. 
Recrystallization from ethyl acetate/pentane provided the title compound as a 
white solid (32.8 g, 4.1 gIL): mp 144-146 ·C (from ethyl acetate-pentane); [aD 22] 
+104, (c 0.15, diethyl ether); Rf 0.36 (hexanes/ethyl acetate, 1:1); IR (film) v 
3175, 1621 em-I; IH NMR (300 MHz, acetone-d6) ~: 6.03 (dd, J = 9.9, 2.1 Hz, 
IH), 6.00 (dd, J = 6.6, 2.4 Hz, IH), 4.62 (d, J = 6.9 Hz, IH), 4.55 (m, IH), 4.28 
(m,2H); l3C NMR (75 MHz, acetone d6) ~: 133.4, 126.5, 126.2, 120.6, 74.2, 69.0; 
HRMS-EI calcd for C6H6Br02 (M+): 267.8731, found: 267.8733; Anal. calcd for 
C6H6Br02; C, 26.70; H, 2.24; Found C, 27.04; H, 2.32. 
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Br 
B''6::>< 
(3 as, 7 as)-2,2-Dimethyl-4,5-dibromo-4,6-benzo [1,3] dioxole (177). 
Dienediol 161 (3.0 g, 1lmmol, 1 equiv) was transferred to a 100 mL round-
bottomed flask and suspended in 5 mL acetone and 15 mL of 2,2,...DMP. A few 
crystals of pTsOH were added and the reaction mixture was stirred at rt for 3 h. 
The reaction was quenched with 12 mL of 10% aq sodium hydroxide solution, 
and the acetone was removed under reduced pressure. The residue was diluted 
with ethyl acetate, and the layers were separated. The aqueous layer was then 
extracted with several portions of ethyl acetate. The combined organic layers 
were washed with brine and dried over anhydrous MgS04. The solvent was 
removed under vacuum to provide a light oil (3.21 g, 95%), which was essentially 
pure. An analytical sample was obtained after chromatography over 10% 
deactivated silica gel (hexanes:ethyl acetate, 8:1), affording the title compound as 
a clear and colorless oil. [a]o22 +101 (c 0.75, CHCh); Rf 0.50 (50% ethyl acetate 
in hexanes); IR (film) v 2988, 2933, 2896, 1634 em-I; IH NMR (300 MHz, 
CDCh) () 6.14 (d, J= 9.9 Hz, IH), 5.93 (dd, J = 9.9, 3.6 Hz, IH), 4.82-4.72 (m, 
2H), 1.45 (s, 6H); 13C NMR (75 MHz, CDCh) () 128.7, 125.6, 123.8. 120.3, 
106.9, 77.3, 71.3, 26.6, 25.0; HRMS-EI Calcd for C9HlOBr202, 307.9047; Found, 
307.9037. 
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Br 
Br~~>< HO"'~O 
OH 
(3aS,4R,5S, 7 as)-2,2-Dimethyl-6, 7-dibromo-4,5-dihydroxybenzo [1,3] dioxole 
(178). 
The protected dienediol177 (3.1 g, 10 mmol, 1 equiv) was suspended in 60 mL of 
an 8:1 (by volume) mixture of acetone/ water. N-Methylmorpholine-N-oxide 
(2.34 g, 20 mmol, 2 equiv) was added followed by 4 crystals of osmium 
tetraoxide. The reaction mixture darkened slightly and was stirred for 18 h until 
consumption of starting material was complete as evidenced by TLC analysis. 
The reaction mixture was quenched by addition of 5 mL saturated aq. sodium 
bisulfite, followed by a further addtition of 2 g solid sodium bisulfite, and the pH 
of the mixture was adjusted to approximately 2 by addition of conc HCI. The 
mixture was stirred for 15 min and the acetone was removed under reduced 
pressure. The remaining aqueous portion was extracted repeatedly with ethyl 
acetate (3 x 60 mL), the combined organic extracts were washed sequentially with 
1 N HCl, 20% aq solution of KOH, and brine before being dried over anhydrous 
MgS04. The organic solution was filtered through a short column of silica gel 
and the solvent evaporated to furnish 2.4 g of a white crystalline solid (71%) 
which required no further purification for the subsequent reaction. An analytical 
sample was obtained from a portion of the solid, recrystallized from ethyl 
acetate/pentane. mp 155-156 ·C; [a]D22 +5.47 (c 0.75, MeOH); Rf 0.3 (50% ethyl 
acetate in hexanes); IR (KBr) v 3435,3360,2994,2905, 1606 cm-\ IH NMR (300 
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MHz, CDCh) 84.77 (dd, J= 504, 1.2 Hz, IH), 4.50-4.45 (m, 2H), 4.34 (m, IH), 
2.68 (bs, 2H), 1.43 (s, 6H); BC NMR (75 MHz, CDCh) 8 127.6, 125.6, 77.6, 
75.3, 70.9, 69.1, 27.6, 26.1; HRMS-EI calcd for CSH90 4Br, 326.8867; found, 
326.8863; Anal Calcd for C9H12Br204: C, 31.42; H, 3.52, Found: C, 31.55; H, 
3.78. 
(X0H 
HO"·: OH 
OH 
(-)-Conduritol E (162). 
Dibromide 178 (0.50 g, 104 mmol, 1 equiv) was dissolved in 50 mL distilled THF 
and transferred to a flame-dried 100 mL round-bottomed flask equipped with a 
reflux condenser. The solution was degassed in an ultrasound bath and under 
positive argon pressure for 10 min. Azo(bisisobutyronitrile) (23 mg, 0.14 mmol, 
0.1 equiv) was added, and the solution heated to steady reflux (83 ·C external 
temp). At this time, tributyltin hydride (1.0 mL, 3.36 mmol, 2 equiv) was added 
in a single portion. Reflux was maintained for 1.5 h until complete consumption 
of starting material was evidenced by TLC analysis. The reaction mixture was 
cooled and potassium fluoride (2 g) was added. The resulting preciptitate was 
filtered and the filtrate concentrated under reduced pressure. The residue was 
. purified by flash column chromatography, eluting with 4: 1 hexanes/ethyl acetate 
to 100% ethyl acetate to provide 170 mg (64%) of the de-brominated material. 
The solid was dissolved in 5 mL of methanol and to this solution was added 2 mL 
of a 3% (by volume) solution of cone HCl in methanol and the resulting solution 
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stirred for 40 h after which time the solvent was removed under reduced pressure 
to provide a white solid. The solid was purified by flash column chromatography 
I 
(4:1 chloroform/methanol) to give (-)-conduritol E as a white crystalline solid (78 
mg, 81 %). mp 194-195 °C (EtOH) (litl20b mp 193°C); [a]D20 -285 (c 1.0, H20), 
litl20b [a]D20 -294 (c 1.0, H20) ; Rf 0.18 (chloroform-methanol, 4:1); IR (film) v 
3434, 1634 cm-I ; IH NMR (300 MHz, MeOD) ~ 5.79 (m, 2H), 4.27 (s, 2H), 3.93 
(m, 2H); 13C NMR (75 MHz, MeOD) ~ 130.7, 70.9, 67.6; HRMS-EI Calcd for 
CJIlO04, 146.0579; Found, 146.0577. 
Br 
Br~OH 
U OH 
(IS,2S)-3,4-Dibromo-cyclohexa-3-ene-l,2-diol (180). 
Diol 161 (0.384g, 1.47 mmol, 1 equiv) was dissolved in 6 mL MeOH, and the 
round-bottomed flask containing the solution was subsequently placed into an 
icelNaCI bath. Potasium azodicarboxylate (0.93g, 4.3 mmol, 3 equiv) was added 
in two portions to the methanolic solution. Acetic acid (0.85 mL, 13 mmol, 9 
equiv) in 2 mL MeOH was added dropwise over 40 min. The reaction flask was 
allowed to warm to room temperature overnight (15 h). The reaction was 
quenched by adding 2 mL saturated Na2C03 solution and stirring for 20 min. 
Methanol was removed under reduced pressure and the residue diluted with 10 
mL EtOAc. The layers were separated and the aqueous phase was extracted with 
EtOAc (3 x 10 mL). The .combined organic layers were washed with brine, dried 
over MgS04, and treated with activated charcoal. Filtration and subsequent 
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concentration of the filtrate under reduced pressure afforded 180 as a white 
crystalline solid (0.367g, 95%). mp 175-176 °c (ethyl acetateihexane); [a]D21 -
50.4 (c 0.75, MeOH); RfO.23 (Hex: EtOAc, 1:1); IR (KBr pellet) v 3246, 1626 
cm-1; IH NMR (300 MHz, acetone d6) 04.61 (d, J = 6 Hz, IH), 4.26 (s, IH), 3.96-
3.84 (m, 2H), 2.79-2.51 (m, 2H), 2.05-1.92 (m, IH), 1.85-1.73 (m, IH); l3C NMR 
(75 MHz, acetone d6) 0 127.1, 124.9, 73.5, 68.25, 35.2, 26.9; HRMS-EI Calcd for 
2.97; Found C, 27.34; H, 3.16 
Br 
Br~OH 
U OTHS 
(lS,6S)-2,3-dibromo-6-«2,3-dimethylbutan-2-yl)dimethylsilyloxy)cyclohex-2-
enol (181). 
A 5 mL round-bottomed flask was charged with diol180 (200 mg, 0.74 mmol, 1 
equiv), imidazole (65 mg, 0.96 mmol, 1.3 equiv) and 1 mL anhydrous DMF. The 
flask was cooled externally to -30°C then thexyldimethylsilyl chloride (0.15 mL, 
0.78 mmol, 1.1 equiv) was added. The mixture was stirred at -30°C for 1 h then 
placed in a freezer (-18°C) for 21 h. The mixture was allowed to warm to room 
temperature and diluted with 50 mL ether, washed with distilled H20 (10 mL), 
brine, and then dried over MgS04. After filtration, the filtrate was concentrated 
under reduced pressure. The crude silyl ether was purified by flash column 
chromatography (pentane: Et20, 10:1) to give 181 as a clear and colorless oil 
(0.26 g, 86%). [a]D21 -41.1 (c 0.75, MeOH); Rf 0.23 (pentane: Et20, 10:1); IR 
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(film) v 3547, 2958, 2868, 1628 em-I; IH NMR (300 MHz, CDCh) b 4.26-4.17 
(m, 1H), 4.03-3.93 (m, 1H), 2.84 (d, J = 4.0, 1H), 2.77-2.64 (m, 1H), 2.63-2.48 
(m, 1H), 2.10-1.90 (m, 1H), 1.77-1.57 (m, 2H), 0.95-0.84 (m, 13H), 0.17 (s, 6H); 
BC NMR (75 MHz, CDCh) b 130.8, 127.8, 122.9, 74.1, 73.6, 69.6, 35.1, 34.1, 
27.2,24.8,20.2,20.0, 18.5, 18.4; HRMS-EI Calcd for C14H26Br202Si, 328.9032; 
Found,328.9026; Anal calcd for CI4H2~r202Si; C, 40.59; H, 6.33; Found C, 
40.96; H, 6.36. 
(X0H 
OTHS 
(IR, 2S)-2-[(thexyJdimethyJsilyJ)oxy] cyciohexan-I-ol (182). 
A flask containing a magnetic stirring bar was charged with dibromide 181 (0.219 
g, 0.53 mmol, 1 equiv), triethylamine (0.5 mL, 3.5 mmol, 7 equiv), platinum 
oxide (Adams catalyst, 24 mg, 0.11 mmol, 0.2 equiv) and 0.5 mL MeOH. The 
reaction flask was evacuated, flushed with hydrogen via a filled balloon (1 atm), 
and stirred until total consumption of starting material was observed by TLC (6 
h). The crude mixture was filtered through a short plug of Celite and the solvent 
was removed under reduced pressure. The crude residue was purified by flash 
column chromatography (pentane: diethyl ether, 10: 1) to give the title compound 
as a clear and colorless oil (71 mg, 52%) having spectral data matching that of 
previously reported. [a]D23 + 3.4 (c 1.0, CHCh); lit:12la [a]D23 + 3.3 (c 1.0, 
CHCh). 
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o 
O~Ph (X MeO 'CF3 
OTHS 
Mosher ester derivative 183. 
Alcohol 182 (20 mg, 0.076 mmol, 1 equiv) was transferred to a flame-dried 
round-bottomed flask containing a magnetic stirring bar under an argon 
atmosphere. Anhydrous triethylamine (17 ilL) was added followed by DMAP 
(4.8 mg, O.038mmol, 0.5 equiv). (R)-( -)-a-:Methoxy-a-
(trifluoromethylphenylacetic acid chloride (23 ilL, 0.11 mmol, 1.5 equiv) was 
added dropwise. Within minutes, a white precipitate was observed. The reaction 
was stirred overnight. The reaction mixture was then diluted with 5 mL methylene 
chloride, transferred to a separatory funnel and washed with 5 mL of a saturated 
solution of sodium bicarbonate. The layers were separated and the organic layer 
dried (MgS04) and the solvent evaporated to provide the ester as a crude oil. The 
ester was purified by flash column chromatography (pentane: diethyl ether, 10: I) 
to afford the ester as a clear and colorless oil (20 mg, 57%). Rf 0.46 (pentane: 
Et20, 10:1); IR (film) 2948, 2867, 1745, 1463, 1450, 1379, 1263, 1169 em-I; IH 
NMR (300 MHz, CDCh): 6: 7.60 (m, 2 H), 7.40 (m, 3 H), 5.12 (m, IH) 3.80 (m, 
IH), 3.55 (m, 3H), 1.75-1.55 (m, 7H), 1.5-1.2 (m, 2H) 0.88 (dd, J= 6.8,5.2 Hz, 
6H), 0.81 (d, J = 4.1 Hz, 6H), 0 (s, 3H), -0.10 (s, 3H) 19p NMR (188 MHz, 
CDCh) 6: -72.4 ppm. Litl21a 19p NMR (188 MHz, CDCh) 6: -72.8 ppm. 
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C02Me h OH 
U OH 
6-Carboxymethyl-(IS,2S)-1,2-dihydroxycycIohexa-3,S-diene (163). 
See General Experimental Procedures for Biotransformations: Large-scale 
fermentations. (12.92 g, 19.2%, 75.8% based on recovered starting material) pale 
yellow oil; RI0.33 (1:2 hexanes/ethyl acetate); [a]D23 +71.3 (c l.6, CHCh); IR 
(film) v 3412, 2098, 1690, 1639, 1291, 820, 772 em-I; IH NMR (300 MHz, 
CDCh) 8 7.05 (d, J= 5.3 Hz, IH), 6.17 (dd, J= 10.3,0.6 Hz, IH), 6.05 (qd, J= 
5.1, 2.2Hz, IH), 4.50-4.56 (m, lH), 4.41-4.50 (m, IH), 3.77 (s, 3H), 3.52-3.67 (m, 
2H) ppm; BC NMR (75 MHz, CDCh) 8 167.5, 138.6, 134.3, 128.4, 122.6, 69.5, 
64.8, 52.1 ppm; MS (EI) mlz (%): 170(M+, 33), 152(61), 139(22), 138(96), 
136(71), 121(100), 110(95), 109(66), 105(23), 93(42), 92(22) 82(57), 81(56), 
65(59),53(49),51(22); HRMS calcd for CSHlO04 170.0579, found 170.0580. 
C02Et h OH 
U OH 
6-Carboxymethyl-(IS,2S)-1,2-dibydroxycyclobexa-3,S-diene (191). 
See General Experimental Procedures for Biotransformations: Large-scale 
fermentations. (8.06 g, 43.4%, 45.6% based on recovered starting material) 
Colorless crystals, mp 48°C (ethyl acetatelhexanes); RI0.31 (1:2 hexanes/ethyl 
acetate); [a]D23 +54.7 (c 3.8, CHCh); IR (film) v 3385, 2981, 2934, 1700, 1280, 
1243, 1104, 1068, 825, 771 em-I; IH NMR (300 MHz, CDCh) 8 7.04 (d, J = 5.3 
Hz, IH), 6.15 (dt, J = 1.1, 9.4 Hz, IH), 6.03 (dq, J = 2.3, 9.2 Hz, lH), 4.49-4.55 
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(m, IH), 4.40-4.48 (m, IH), 4.22 (q, J = 7.0 Hz, 2H), 3.65-3.78 (m, 2H), 1.28 (t, J 
= 7.2 Hz, 3H) ppm; l3C NMR (75 MHz, CDCh) () 167.1, 138.7, 134.1, 128.7, 
122.5,69.8,64.5,60.9, 14.2 ppm; MS (EI) mlz (%): 184(M+, 9), 166(20), 138(26), 
122(33), 121(52), 105(100), 77(39), 51(21), 45(20); HRMS calcd for C9H1204 
184.0736, found 184.0731; AnaL calcd: C 58.69, H 6.57, found C 58.77, H 6.60. 
C02n-Pr ~OH 
U OH 
6-Carboxypropyl-(IS,2S)-1,2-dihydroxycyclohexa-3,S-diene (192). 
See General Experimental Procedures for Biotransformations: Large-scale 
fermentations. (711 mg, 5.8%, 65.0% based on recovered starting material) waxy 
solid; RIO.15 (1:1 ethyl acetate/hexanes); [a]D22 +58.8 (c 1.1, CHCh); IR (film) v 
3398, 2968, 1700, 1280, 1240 em-I; IH NMR (300 MHz, CDCh) () 7.08 (d, J = 
5.4 Hz, IH), 6.20 (dd, J = 9.5,2.5 Hz, IH), 6.09 (ddd, J = 9.5, 5.4,2.2 Hz, IH), 
4.58 (d, J = 6.3 Hz, IH), 4.48 (ddd, J = 6.3, 2.5, 2.2 Hz, IH), 4.16 (t, J= 6.7 Hz, 
2H), 3.40 (bs, 2H), 1.72 (qt, J= 7.4, 6.7 Hz, 2H), 0.98 (t, J= 7.4 Hz, 3H) ppm; l3C 
NMR (75 MHz, CDCh) () 167.1, 138.4, 133.9, 128.7, 122.6, 69.4, 66.6, 64.8, 
22.0, 10.4 ppm; MS (EI) mlz (%): 198 (M+, 18), 180(22), 138(100), 121(81), 110 
(54), 105 (77); HRMS ca1cd for C9H1204 198.0892, found 198.0892. 
~~~ 
U OH 
6-Carboxyisopropyl-(IS,2S)-1,2-dihydroxycyclohexa-3,S-diene (193). 
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See General Experimental Procedures for Biotransformations: Large-scale 
fermentations. (488 mg, 4.1 %, 34.0% based on recovered starting material) 
colourless crystals; mp 83-85 °C (ethyl acetatelhexane); Rf = 0.31 (6:4 ethyl 
acetatelhexane); [a]D22 +64.70 (c 1.1, CHCI3); IR (KBr) v 3274, 2981, 1698, 1263, 
1241 em-I; IH NMR (300 MHz, CDCh) 8 7.05 (ddd, J = 5.5, 1.0, 0.5 Hz, IH), 
6.20 (ddt, J= 9.6, 2,7, 0.9 Hz, IH), 6.08 (ddd, J= 9.6, J= 5.5, 2.2 Hz, IH), 5.12 
(hept, J = 6.3 Hz, IH), 4.58 (dd, J = 604, 0.5 Hz, IH), 4048 (br m, IH), 3.60-3.25 
(hr s, 2H), 1.30 (d, J = 6.3 Hz, 6H) ppm; l3C NMR (75 MHz, CDCh) 8 166.5, 
138.2, 133.6, 128.9, 122.63, 9904 69.2, 68.5, 64.9, 21.8 ppm; MS (EI) mlz (%): 
198(~, 19), 180(16), 156(14), 138(100); HRMS (EI) calcd for ClOHI404: 
198.08921, found: 198.08896. Anal. Calcd. for ClOHI40 4: C, 60.59; H, 7.12. 
Found: C, 60.68; H, 7.19. 
)=o~ 
U OH 
6-Carboxyallyl-(1S,2S)-1,2-dihydroxycyclohexa-3,S-diene (196). 
See General Experimental Procedures for Biotransformations: Large-scale 
fermentations. (5.79 g, 52.0%, 73.6% based on recovered starting material) 
colourless crystals; mp 48-50 °C (ethyl acetatelhexane); Rf = 0.23 (1: 1 ethyl 
acetatelhexane); [a]D22 +72.54 (c 1.6, CHCh); IR (KBr) v 3394, 1704, 1273, 1238 
em-I; IH NMR (300 MHz, CDCh) 8 7.12 (d, J= 5.5 Hz, IH), 6.23 (ddt, J= 9.6, 
2,7, 1.0 Hz, IH), 6.11 (ddd, J = 9.5,5.5,2.2 Hz, IH), 5.98 (ddt, J = 17.2, 1004,5.7 
Hz, IH), 5.37 (dt, J = 17.2, 1.5 Hz, IH), 5.28 (dt, lOA, 1.3 Hz, IH), 4.72 (ddd, J = 
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5.7, 1.5, 1.3 Hz, IH), 4.61 (br s, IH), 4.50 (br s, IH), 3.25 (d, J = 3.8 Hz, IH), 
3.18 (brd, J = 7.3 Hz, IH) ppm; BC NMR (75 MHz, CDCh) () 166.6, 138.8, 
134.4, 131.9, 128.4, 122.4, 118.3, 69.6, 65.5, 64.5 ppm; MS (EI) mlz (%): 
196(~, 20), 178(18), 138(80), 121(95),41(100). HRMS (EI) ca1cd for ClOH120 4: 
mlz 196.07356, found: 196.07364. Anal. Ca1cd. for ClOHI204 + 118 H20: C, 
60.52; H, 6.22. Found: C, 60.52; H, 6.26. 
02XO/ ~ OH 
~ OH 
6-Carboxyisopropyl-(IS,2S)-1,2-dihydroxycyclobex-3-ene (197). 
See General Experimental Procedures for Biotransformations: Large-scale 
fermentations. (9.20g, 69.1%, 75.8% based on recovered starting material) 
colourless crystals; mp 70-72 °c (ethyl acetatelhexane); Rf = 0.31 (6:4 ethyl 
acetatelhexane); [a]n22 +88.20 (c 1.6, CHCh); IR (KBr) v 3385, 3291, 1707, 1270, 
1234 em-I; IH NMR (300 MHz, acetone-d6) () 7.01 (dd, J= 5.3, J= 1.1 Hz, IH), 
6.16 (dq, J= 9.5, J= 1.4 Hz, IH), 6.09 (ddd, J= 9.5, J= 5.3, J= 2.2 Hz, IH), 
4.86 (dd, J = 15.8, J = 2.5 Hz, 1H), 4.80 (dd, J = 15.8, J = 2.5 Hz, IH), 4.50-4.23 
(m, 2H), 4.10 (d, J = 7.4 Hz, IH), 3.96 (d, J = 5.0 Hz, 1H), 3.06 (t, J = 2.5 Hz, 
IH) ppm; BC NMR (75 MHz, acetone-~) () 167.2, 142.5, 136.3, 131.1, 123.5, 
80.0, 77.3, 72.5, 65.5, 53.4 ppm; MS (EI) mlz (%): 194~, 7%), 176(28), 
138(47), 121(100); HRMS (EI) ca1cd for ClOHlO04: mlz 194.0579, found: 
194.0581; Anal. Calcd. for ClOHlO0 4: C, 61.85; H, 5.19. Found: C, 62.08; H, 5.18. 
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t(H 
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6-Carboxymethyl-(IS,2S)-1,2-dihydroxycyclohex-3-ene (198). 
See General procedure for PAD reduction of diols. (848 mg, 84%,) colorless oil; 
RfO.29 (1:1 ethyl acetatelhexanes); [a]D23 -52.9 (c 2.9, CHCh); IR (film) v 3411, 
2998, 2951, 2668, 1703, 1648, 1437, 1370, 1254, 1210, 1160, 1108, 1073, 1041, 
995,963,920,878,852, 757670 cm-I; IH NMR (300 MHz, CDCh) 8 7.02 (dd, J 
= 4.4, J= 3.3 Hz, IH), 4.46 (d, J= 3.1 Hz, IH), 4.05 (s, IH), 3.70 (m, 4H), 3.52 
(s, OH), 2.42-2.30 (m, IH), 2.21-2.09 (m, IH), 1.18-1.61 (m, lH) ppm; 13C NMR 
(75 MHz, CDCh) 8 161.2, 143.3, 130.4,68.5,64.8,51.8,24.7,24.4 ppm; MS (EI) 
mlz (%): 172(M+, 3), 129(11), 128(100), 97(70), 68(30); HRMS calcd for 
CSHI204 172.0731, found 172.0730. 
C02Et h OH 
U OH 
6-Carboxyethyl-(lS,2S)-1,2-dihydroxycyclohex-3-ene (199). 
See General procedure for PAD reduction of diols. (378 mg, 84%,) colorless 
crystals; mp 91-92 °C (ethyl acetatelhexanes); RfO.29 (1:1 ethyl acetatelhexanes); 
[a]D23 -53.3 (c 1.6, CHCh); IR (film) v 3400, 2981, 2937, 2909, 1731, 1647, 
1372, 1251, 1105, 1073, 993, 921, 878, 761, 670 cm-I; IH NMR (300 MHz, 
CDCh) 8 7.09 (t, J= 4.1 Hz, IH), 4.50 (d, J= 3.8 Hz, IH), 4.22 (q, J= 7.2 Hz, 
2H), 3.81-3.93 (m, IH), 3.51 (s, IH), 2.69 (s, IH), 2.37-2.50 (m, IH), 1.79-1.94 
(m, IH), 1.66-1.75 (m, IH), 1.29 (t, J = 7.2 Hz, 3H) ppm; 13C NMR (75 MHz, 
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CDCh) ~ 167.1, 143.1, 130.1,67.7,65.7,60.9,25.0,23.9, 14.2 ppm; MS (El) mlz 
(%): 186(M\ 1), 143(12), 142(90), 105(12), 97(16), 96(100), 68(38), 67(10), 
41(12); HRMS calcd for C9H1404 186.0892, found 186.0892; Anal. calcd: C 
58.05; H 7.58. found C 57.97; H 7.51. 
~~~ 
U OH 
6-Carboxypropyl-(IS,2S)-1,2-dihydroxycyclohex-3-ene (200). 
See General procedure for PAD reduction of diols. (276 mg, 91%) colourless 
crystals; mp 73-75 DC; RfO.15 (1:1 ethyl acetate/hexanes); [a]D20 -50.85 (c 1.5, 
CHCh); lR (film) v 3406, 2966, 2934, 2876, 1707, 1648, 1247 cm-I; IH NMR 
(300 MHz, CDCh) ~ 7.14 (t, J= 3.4 Hz, IH), 4.55 (d, J= 3.4 Hz, IH), 4.16 (t, J= 
6.6 Hz, 2H), 3.92 (br s, IH), 3.93 (m, IH), 3.28 (br s, IH), 3.56-2.54 (m, IH), 
2.31-216 (m, IH), 1.98-1.85 (m, IH), 1.81-1.69 (m, IH), 1.73 (qt, J= 7.4, J= 6.6 
Hz, 2H), 1.00 (t, J = 7.4 Hz, IH) ppm; l3C NMR (75 MHz, CDCh) ~ 167.0, 
143.0, 130.5, 68.3, 66.4, 65.1, 24.53, 24.49, 21.9, 10.4 ppm; MS (El) mlz (%): 
200(M\ 3), 156(M+-C2H40, 68), 141(17), 114(80),96(100); HRMS (El) calcd for 
ClOHI604: mlz 200.1048; found: 200.1052. Anal. Calcd. for ClOHI604: C, 59.98; 
H, 8.05. Found: C, 59.87; H, 8.04. 
6-Carboxyisopropyl-(IS,2S)-1,2-dibydroxycyclohex-3-ene (201). 
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See General procedure for PAD reduction of diols. (203 mg, 56%) pale yellow 
oil; Rf= 0.31 (6:4 ethyl acetatelhexane); [a]D20 -44.74 (c 1.3, CHCh); IH NMR 
(300 MHz, CDCh) 8 7.08 (t, J= 3.9 Hz, IH), 5.11 (hept, J= 6.3 Hz, IH), 4.51 (br 
s, IH), 4048 (br m, IH), 3.94-3.84 (m, IH), 3.59 (d, J = 2.6 Hz, IH), 2.7 (d, J = 
5.7 Hz, IH), 2.52-2.38 (m, IH), 2.67-2.12 (m, IH), 1.95-1.81 (m, IH), 1.77-1.66 
(m, IH), 1.29 (d, J = 6.3 Hz, 3H), 1.28 (d, J = 6.3 Hz, 3H) ppm; l3C NMR (75 
MHz, CDCh) 8 166.6, 142.7, 13004,6804,67.7, 65.7, 25.1, 23.8, 21.9, 21.8 ppm; 
IR (film) v 3403, 2980, 1706, 1260 em-I; MS (EI) mlz (%): 156(~-C2~0, 50), 
141(18), 114(100),96(94); HRMS (EI) calcd for ClOHI604: mlz 200.1049; found: 
200.1054. 
-
OAe 
(3aR,4R,SR, 7aR)-7-(methoxycarbonyl)-2,2-dimethyl-3a,4,S, 7a-
tetrahydrobenzo[d] [1,3]dioxole-4,S-diyl diacetate (203). 
To a solution of diol163 (300 mg, 1.76 mmol) in 2,2-dimethoxypropane (2 mL) 
and acetone (1 mL) was added p-toluenesulfonic acid (catalytic amount) at room 
temperature. After complete consumption of starting material (TLC analysis), the 
solution was diluted with ethyl acetate (60 mL), washed with saturated NaHC03 
(3 x 5 mL), dried over Na2S04, filtered, and concentrated. The crude acetonide 
was dissolved in a mixture of acetoneIH20 (5: 1, 12 mL) and N-
methylmorpholine-N-oxide (309 mg, 2.64 mmol) was added, followed by a single 
crystal of OS04. The solution was stirred until total consumption of starting 
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material (15 h) as monitored by TLC analysis. The reaction mixture was 
concentrated to dryness under reduced pressure, suspended in DCM (10 mL), and 
cooled in an ice bath. To the stirring suspension was added triethylamine (1.1 
mL, 8 mmol), Ac20 (0.60 mL, 6.2 mmol), and DMAP (43 mg, 0.35 mmol). The 
reaction was stirred overnight (12 h) before being quenched with NaHC03 (5 
mL). The layers were separated and the aqueous phase was extracted with DCM 
(3 x 20 mL). The organic layers were combined and dried over Na2S04, filtered, 
and concentrated. The crude material was purified via flash column 
chromatography with a solvent gradient of 5: 1 - 3: 1 hexanes-ethyl acetate. Yield: 
401 mg, 69%, colourless oil; RfO.65 (1:1 hexanes/ethyl acetate); [a]D20 -67.54 (c 
2.5, EtOH); IR (film): v 2989, 2954, 2938,1754,1726,1661,1437,1372,1303, 
1234, 1219 cm-l ; IH NMR (300 MHz, CDCb) 8 6.83 (dd, J = 3.0, 1.1 Hz, IH), 
5.72 (t, J= 3.7 Hz, IH), 5.53 (ddd, J= 5.3, 3.8, 1.1 Hz, IH), 5.07 (dd, J= 5.8, 0.8 
Hz, IH), 4.43 (dd, J = 5.6, 5.3 Hz, IH), 3.84 (s, IH), 2.08 (s, 3H), 2.07 (s, 3H), 
1.41 (s, 6H), ppm; BC NMR (75 MHz, CDCb) 8 169.9, 169.7, 165.4, 136.7, 
131.4, 110.2, 72.9, 70.3, 69.6, 66.3, 52.3,27.4,25.7,20.8,20.7 ppm; MS (EI) mlz 
(%): 313(M+-CH3, 52), 211(19), 169(36), 168(12), 137(11), 85(43), 83(58), 
47(12),43(100); HRMS (~-CH3) calcd for CI~1708 313.0923, found 313.0919. 
OAe 
(3aR,4R,5R, 7R, 7aR)-7-(methoxycarbonyl)-2,2-
dimethylhexahydrobenzo [d) [1,3] dioxole-4,5-diyl diacetate (204). 
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To a solution of ester 203 (40 mg, 0.122 mmol) in ethanol (3 mL) was added 5% 
RhlAlz03 (40 mg). The reaction was stirred under an atmosphere of H2 (60 psi, 
24 h). The reaction was filtered through Celite by elution with EtOH and 
concentrated. The crude material was purified via flash column chromatography 
with a solvent gradient of 5: 1 hexanes-ethyl acetate. Yield: 28 mg, 70%, colorless 
oil; RjO.60 (1:1 hexanes/ethyl acetate); [a]D20 -71.56 (c 0.93, CHCh); IR (film): v 
2976, 2954, 2938, 1750, 1734, 1732, 14337, 1372, 11240, 1221, 1195 em-I; IH 
NMR (600 MHz, CDCh) b 5.40 (m, IH), 4.93 (dd, J= 7.9, 2.6 Hz, IH), 4.69 (t, J 
= 4.9 Hz, IH), 4.23 (dd, J= 8.0, 5.0 Hz, IH), 3.78 (s, 3H), 3.13 (dt, J= 12.8,4.5 
Hz, IH), 2.21 (dt, J= 14.9, 12.9 Hz, IH), 2.12-2.06 (m, 4H), 1.52 (s, 3H), 1.38 (s, 
3H) ppm; 13C NMR (150 MHz, CDCh) b 171.4, 170.3, 169.7, 109.9, 75.5, 73.9, 
7.1,68.7,52.2,38.11,27.9,26.2,24.9,20.9 ppm; MS (EI) mlz (%): 313 (~-CH3, 
13), 241(15), 171(23), 153(47), 43(100); HRMS ~-CH3) calcd for CI4H1908 
315.1080, found 315.1082. 
HO 
HO".2x:>< 
OH 
(3aS,4R,5R, 7S, 7aR)-7-(hydroxymethyl)-2,2-
dimethylhexahydrobenzo [d] [1,3] dioxole-4,5-diol (206) 
LAH (26 mg, 0.73 mmol) was added to a solution of ester 204 (40 mg, 0.121 
mmol) in dry THF (2 mL). The reaction mixture was brought to reflux and stirred 
for 4 hours, allowed to cool to room temperature, and quenched with a mixture of 
THFIH20. The reaction was filtered, dried over Na2S04, filtered again, and 
138 
concentrated. The crude material was purified via flash column chromatography 
with a solvent gradient of 5: 1 hexanes-ethyl acetate. Yield: 23 mg, 86%, colorless 
oil; RfO.14 (9:1 chloroform/methanol); [a]D20 -57.08 (c 0.70, MeOH); IH NMR 
(600 MHz, acetone-d6) 84.30 (t, J= 4.4, 1H), 4.01 (dd, J= 6.9, 5.5 Hz, 1H), 4.00-
3.94 (m, 2H), 3.70-3.60 (m, 2H), 3.58-3.48 (m, 3H), 2.44-2.37 (m, 1H), 1.75 (dt, J 
= 13.0,4.6 Hz, 1H), 1.48 (dt, J= 6.6, 2.8 Hz, 1H), 1.40 (s, 3H), 1.28 (s, 3H) ppm; 
BC NMR (150 MHz, CDCh) 8 107.8, 79.4, 74.6, 73.7, 68.9, 63.58, 34.2, 28.3, 
27.7,25.7 ppm; MS (EI) mlz (%) 203 (~-CH3, 100),204(10),203(100), 125(19), 
107(11), 100(13), 97(13), 95(21), 83(32), 79(33), 73(14), 71(11), 70(14), 69(20), 
67(16), 60(17), 59(55), 57(18), 55(18), 43(53), 41(22); HRMS ~-CH3) calcd 
for C9HISOS 203.0933, found 203.0926. 
(3aR, 7 as)-Ethyl-3a, 7 a-dihydro-2,2-dimethylbenzo [d] [1,3] dioxole-4-
carboxylate (207). 
(173 mg, 92%) colorless oil; RfO.56 (1:1 hexanes/ethyl acetate); [a]D23 +74.6 (c 
4.02, CHCh); IR (film): v 3018,2987,2936, 1712, 1651, 1425, 1380, 1259, 1155, 
1031,917,856,697,667,512 cm-I; IH NMR (300 MHz, CDCh) 8 7.06 (dd, J= 
5.3,3.1 Hz, 1H), 4.84 (d, J= 5.7 Hz, 1H), 4.28-4.41 (m, 1H), 4.07-4.26 (m, 2H), 
2.21-2.45 (m, 1H), 1.99-2.16 (m, 1H), 1.86-1.99 (m, 1H), 1.58-1.72 (m, 1H), 1.33 
(d, J= 10.2 Hz, 6H), 1.24 (t, J= 7.2 Hz, 3H) ppm; BC NMR (75 MHz, CDC h) 8 
166.2, 142.3, 130.0, 108.5, 72.6, 70.4, 60.5, 27.8, 26.2, 25.1, 20.9, 14.2 ppm; MS 
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(EI) mlz (%): 226 ~-CH3), 211(77), 181(15), 169(17), 123(100), 105(17), 
95(13), 83(11), 79(76), 67(14), 59(10), 55(11),43(82), 41(14); HRMS (~-CH3) 
calcd for C12HI60 4 211.0970, found 211.0969; Anal. calcd: C 64.27; H 7.19. 
Found C 64.52; H 7.08. 
°et°/ -7 0\/ 
~ 01\ 
(3aR,7 as)-Prop-2-ynyl-3a, 7a-dihydro-2,2-dimethylbenzo [d] [1,3]dioxole-4-
carboxylate (208). 
(764 mg, 63%) colorless oil; Rf= 0.54 (2:8 ethyl acetate/hexane); [a]n22 + 112.70 
(c 1.3, CHCh); IR (KBr) v 2987, 2935, 1718, 1030 cm-I; IH NMR (300 MHz, 
CDCh) 8 7.22 (dd, J= 5.3, 1.1 Hz, IH), 6.19-6.09 (series ofm, 2H), 4.95 (d, J= 
8.4 Hz, IH), 4.89 (dd, J= 8.4, J= 2.4 Hz, IH), 4.84 (dd, J= 2.5, J= 1.0 Hz, 2H), 
2.50 (t, J = 2.5 Hz, IH), 1.47 (s, 3H), 1.41 (s, 3H) ppm; BC NMR (75 MHz, 
CDCh) 8 165.3, 134.8, 134.4, 125.5, 121.2, 105.7, 77.7, 74.9, 71.8, 68.0, 52.3, 
26.7, 25.0 ppm; MS (EI) mlz (%): 219(M+-Me, 42), 177(41), 163(17), 121(83), 
43(100). HRMS (EI) calcd for CI2Hl104: mlz 219.0657, found: 219.0659. Anal. 
Calcd. for CBH1404: C, 66.66; H, 6.02. Found: C, 66.68; H, 6.08. 
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(lS,2R,3S,4S,4aS,5S,6R,8aR)-1,2,3,4,4a,5,6,8a-octahydro-2,3,5,6-
tetrahydroxy-O,O-diisopropylyden-l,4-ethenonaphthalene-l, 7-
bis( ethyldicarboxylate) (209). 
Neat 207 (400 mg, 1.78 mmol) was maintained for 7 d at rt, purified by flash-
chromatography (eluant 3:7 ethyl acetatelhexane) to yield 209 (372 mg, 93%) as a 
clear and colorless oil; [a]o22 +62.90 (c 1.3, CHCh). IR (KBr) v 2984, 2938, 
1722, 1262, 1221, 1071 cm-I; IH NMR (600 MHz, CDCh) () 6.44 (d, J = 3.7 Hz, 
IH), 6.39 (d, J= 8.5 Hz, IH), 6.05 (dd, J= 8.5, 6.3 Hz, IH), 4.61 (dd, J= 7.2, 1.2 
Hz, IH), 4.59 (d, J = 4.9 Hz, IH), 4.43 (ddd, J = 7.2, J = 3.4, 0.5 Hz, IH), 4.36 
(qd, J= 7.1, 1.7 Hz, 2H), 4.28-4.18 (m, 2H), 4.17 (dd, J= 4.9, 2.5 Hz, IH), 3.02 
(1 H, m), 2.95 (ddd, J= 9.2,3.7, 1.3 Hz, lH), 2.34 (ddd, J= 9.2, 1.3, 1.2 Hz, IH), 
1.37 (s, 3H), 1.36 (t, J= 7.1 Hz, 3H), 1.31 (s,3H), 1.30 (s, 3H), 1.28 (t, J= 7.1 
Hz, 3H), 1.28 (s, 3H) ppm. 13C NMR (150 MHz, CDCh) () 171.5, 165.8, 136.4, 
131.4, 130.2, 128.8, 109.7, 108.2, 80.7, 78.3, 76.9, 69.2, 61.4, 60.7, 53.9, 40.4, 
38.6, 34.9,28.1, 26.5, 25.3, 25.1, 14.20, 14.15 ppm;; MS (EI) mlz (%): 433(~-
Me, 6), 390(8), 375(7), 345(4), 100(17), 61(21), 43(100). HRMS (EI) calcd for 
C24H3208: mlz 448.20972, found: 448.20863. 
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(IS,2R,3S,4S,4aS,5S,6R,8aR)-1,2,3,4,4a,5,6,8a-octahydro-2,3,5,6-
tetrahydroxy-O,O-diisopropylyden-l,4-ethenonaphthalene-l, 7-
dipropargyldicarboxylate (21 0). 
A solution of 208 (390 mg, 1.66 mmol) in toluene (1 mL) was maintained at 110 
°C for 6 hours, purified by flash-chromatography (eluant 3:7 ethyl acetatelhexane) 
to afford 210 as a foamy solid (321 mg, 82%); mp 43-45 °C (ethyl 
acetatelhexanes). Rf = 0.32 (3:7 ethyl acetatelhexane); [0.]D22 +53.03 (c 1.2, 
CHCh). IH NMR (600 MHz, CDCh) B 6.58 (d, J= 3.8 Hz, lH), 6.40 (d, J= 8.4 
Hz, lH), 6.08 (dd, J= 8.4, 6.4 Hz, IH), 4.96 (dd, J= 15.5,2.4 Hz, IH), 4.83 (dd, 
J= 15.5,2.4 Hz, IH), 4.82 (dd, J= 15.6,2.4 Hz, IH), 4.72 (dd, J= 15.6,2.4 Hz, 
IH), 4.64 (d, J= 7.2 Hz, IH), 4.59 (d, J= 4.9 Hz, IH), 4.45 (dd, J= 7.2,3.5 Hz, 
IH), 4.61 (dd, J = 4.9, 2.2 Hz, IH), 3.04 (m, IH), 3.03 (dd, J = 9.1, 3.5 Hz, IH), 
2.64 (t, J= 2.4 Hz, 3H), 2.48 (t, J= 2.4 Hz, 3H), 2.7 (d, J= 9.1 Hz, IH), 1.37 (s, 
3H), 1.309 (s, 3H), 1.303 (s, 3H), 1.29 (s, 3H) ppm; BC NMR (150 MHz, CDCh) 
B 170.7, 164.9, 137.3, 131.0, 129.6, 129.1, 109.9, 108.3, 80.5, 78.2, 77.6, 77.1, 
76.8, 75.7, 75.0, 69.0, 53.8, 52.9, 52.3, 40.4, 38.8, 34.6, 28.1, 26.5, 25.3, 25.1 
ppm; IR (KBr) v 2987, 2938, 1728, 1243, 1217, 1071 cm-I; MS (EI) mlz (%): 
453(~-Me, 26), 395(32), 297(15), 121(31), 100(60), 85(22), 43(100). HRMS 
(EI) calcd for C24H320 S: mlz 453.15494, found: 453.15470. Anal. Calcd. for 
C26H2S0S: C, 66.66; H, 6.02. Found: C, 66.61; H, 6.16. 
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C02Et MeO,C*~>< Me02C~O 
(lS,4S,SS,6R)-1-Etbyl-2,3-dimetbyl-S,6-dibydroxy-O,O-
ispropylydenhicyclo [2.2.2] octa-2,7-diene-1,2,3-tricarhoxylate (211). 
A solution of 207 (400 mg, 1.78 mmol), dimethylacetylenedicarboxylate 
(DMAD) (380 mg, 2.68 mmol) in toluene (1.0 mL) was stirred at rt for 72 hours. 
The resulting mixture was purified by flash-chromatography (eluant ethyl 
acetatelhexane in gradient from 2:8 to 3:7) to afford an oil that was purified by 
crystallization from ethyl acetatelhexane to provide 211 as colorless crystals (210 
mg, 57%); mp 70-71 °C (ethyl acetate hexanes). Rf = 0.35 (3:7 ethyl 
acetatelhexane); [a]n22 +21.75 (c 2.0, CHCb). IH NMR (300 MHz, CDCb) 0 6.76 
(ddd, J = 7.3, J = 1.3, J = 0.9 Hz, IH), 6.44 (dq, J = 7.3, 6.0, 0.7 Hz, IH), 4.71 
(dd, J = 6.9, 0.9 Hz, IH), 4.49 (ddd, J = 6.9, 3.6, 0.7 Hz, IH), 4.37 (ddd, J = 6.0, 
3.6, J = 1.3 Hz, IH), 4.33 (qd, J = 7.2, 1.7 Hz, 2H), 3.77 (s, 6H), 1.34 (t, J = 7.2 
Hz, 3H), 1.34 (s, 3H), 1.28 (s, 3H) ppm; l3C NMR (75 MHz, CDCh) 0 169.5, 
165.5, 164.1, 144.8, 137.8, 131.4, 130.4, 114.3, 81.8, 78.3, 62.0, 60.0, 52.48, 
52.39, 43.7, 25.70, 25.67, 14.0 ppm; IR (KBr) v 2989, 2953, 1748, 1724, 1261 
em-I; MS (EI) mlz (%): 351(M+-Me, 6), 207(21), 221(62), 175(88), 100(100). 
HRMS (EI) calcd for C17HI90S: mlz 351.10799, found: 351.10811. Anal. Calcd. 
for CIsH220S: C, 59.01; H, 6.05. Found: C, 59.16; H, 6.08. 
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(IR,2S,6S, 7 S)-9-Acetyl-4,4-dimethyl-3,5,8-trioxa-9-aza-
tricyclo[5.2.2.02,6]undec-l0-ene-7-carboxylic acid ethyl ester (212). 
To a stirring solution of diol191 (5.0 g, 27 mmol) in 2,2-dimethoxypropane (80 
mL) was added p-toluenesulfonic acid (catalytic amount) at room temperature. 
After complete consumption of starting material (TLC analysis), the solution was 
cooled 0 'c before the addition of H20 (10 mL). On a preparative scale the 
intermediate acetonide 207 was not isolated. 
NaI04 (5.80 g, 27.1 mmol) was added to the reaction flask prior to the addition of 
a solution of acetohydroxamic acid (2.03 g, 27.1 mmol) in MeOH (25 mL) 
dropwise over 5 minutes. The resulting solution was stirred at room temperature 
for 16 h, quenched by the slow addition of sat. NaHS03 (10 mL) and extracted 
into Et20 (3 x 100 mL). The combined organic layers were washed with brine (2 
x 30 mL) and dried over Na2S04. The crude material was purified via flash 
column chromatography with a solvent system of 1:4 (hexanes/ethyl acetate) to 
yield 212 as a white solid (5.65 g, 70% over 2 steps); RI0.33 (3:7 hexanes/ethyl 
acetate); mp 89-90 °C (hexanes/ethyl acetate); [a]D23 -18.0 (c 0.54, CHCh); IR 
(film) v 3466, 2938, 2987, 1747, 1684, 1620, 1372, 1275, 1086 em-I; IH NMR 
(600 MHz, CDCh) 0 6.57-6.65 (m, 2H), 5.47-5.52 (m, IH), 4.71 (d, J = 6.8 Hz, 
lH), 4.56 (dd, J= 4.7, 6.6 Hz, IH), 4.38 (q, J= 7.2 Hz, 2H), 2.01 (s, 3H), 1.38 (t, 
J = 7.2 Hz, 3H), 1.32 (s, 3H), 1.30 (s, 3H) ppm; l3C NMR (150 MHz, CDCh) 0 
173.9, 166.6, 132.4, 128.4, 111.7, 79.2, 76.1, 72.8, 62.7, 50.0, 25.6, 25.4, 21.7, 
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14.1 ppm; MS (EI) mlz (%): 297(Ml, 124(52), 105(35), 100(32), 96(30), 
43(100),; HRMS calcd for CI4HI9N06 297.1212, found 297.1215. 
-
NHAc 
7-Acetylamino-4-hydroxy-2,2-dimethyl-3a,4, 7,7 a-tetrahydro-
benzo[I,3]dioxole-4-carboxylic acid ethyl ester (213) 
To a stirred solution of 212 (955 mg, 3.21 mmol) in 15:1 CH3CN:H20 (10 mL) 
was added molybdenum hexacarbonyl (848 mg, 3.21 mmol) at room temperature. 
The reaction was brought to reflux for 3 h before being allowed to cool to room 
temperature. The reaction was concentrated and filtered through a plug of celite. 
The crude material was purified via flash column chromatography with a solvent 
system of 1:9 (hexanes/ethyl acetate) to yield 213 (720 mg, 75%) as a white solid; 
Rj0.20 (ethyl acetate); mp 97-99 °C (hexanes-ethyl acetate); [a]D23 -94.3 (cO.79, 
CHCh); IR (film) v 3433, 2094, 1644, 1271, 1217, 1060 em-I; IH NMR (600 
MHz, CDCh) 06.25 (d, J = 8.7 Hz, INH), 5.98 (dd, J = 3.8, 9.8 Hz, IH), 5.94 
(dd, J = 0.9, 9.9 Hz, IH), 4.77-4.81 (m, IH), 4.37 (t, J = 8.3 Hz, IH), 4.34 (dd, J = 
4.3, 7.7 Hz, IH), 4.22-4.29 (m, 2H), 4.12 (s, 10H), 1.99 (s, 3H), 1.35 (s, 3H), 
1.32 (t, J = 7.4 Hz, 3H), 1.28 (s, 3H) ppm; I3C NMR (150 MHz, CDCh) 0 172.7, 
170.0, 132.9, 129.6, 109.3, 81.0, 76.3, 74.5, 62.8, 48.8, 26.2, 24.2, 23.5, 14.0 
ppm; MS (EI) mlz (%): 284 (M+-CH3), 199(99), 153(38), 125(36),96(37),86(61), 
84(100),83(47),43(90),; HRMS calcd for CI3HlsN06284.1130, found 284.1137. 
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217 
(3aS,4R,SS,SaS,6aS,6bS)-2,2-dimethyl-7-[( 4-
methylphenyl)suHonyl] hexahydro-4,S-epiminooxireno [e] [1,3]benzodioxole 
(217), 
(3aS,4R,SS,SaR,6aR,6bS)-2,2-dimethyl-7-[ (4-
methylphenyl)suHonyl] hexahydro-4,S-epiminooxireno [e] [1,3] benzodioxole 
(220). 
A solution of m-CPBA (10.5 g, 46.7 mmol) in 1,2-dichloroethane (150 mL) was 
dried over Na2S04 and filtered into a flask containing aziridine 7064 (5.0 g, 16 
mmol). The resulting solution was heated to reflux until total consumption of 
starting material (6 hours). The reaction was allowed to cool to room temperature 
at which time m-chlorobenzoic acid crystallized out as a white solid. The reaction 
was filtered and concentrated. The residue was taken up EtOAc (350 mL) and 
washed sequentially with NaHS03 (2 x 100 mL), carbonate (2 x 100 mL), and 
brine (35 mL). The organic phase was dried over Na2S04, filtered, and 
concentrated to yield a 2.89: 1 mixture of epoxides 217 and 220 (5.04 g, 96 %) as 
a slightly yellow solid. The epoxide could be used without further purification or 
enriched in favor of the major isomer by successive recrystalizations from 
isopropanol. A small sample of the mixture taken and the two epoxides were 
separated by flash column chromatography (10% deactivated silica gel, 
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hexanes/ethyl acetate 7:1 - 4:1) to provide analytical samples of epoxides 217 and 
220 
Epoxide 217 
Rj0.43 (hexanes/ethyl acetate, 2:1); mp 115-116 °c (isopropanol); [a]o2I - 79.36 
(c 1.0, CHCh); IR (film) v2988, 2936, 1597, 1383, 1373, 1329, 1251, 1218, 
1158, 1091, 1055 em-I; IH NMR (300 MHz, CDCh) <i: 7.90 (d, J = 8.3 Hz, 2H), 
7.36 (d, J= 8.3 Hz, 2H), 4.4 (d, J= 6.2 Hz, IH), 4.26 (d, J= 6.0 Hz, 1H), 3.53 (d, 
J= 3.7 Hz, 1H), 3.38 (dd, J = 6.8 Hz, 3.8 Hz, 1H), 3.13 (dd, J= 3.5 Hz, 0.9 Hz, 
IH), 3.04 (dd, J = 6.8 Hz, 1.1 Hz, IH), 2.46 (s, 3H), 1.46 (s, 3H), 1.36 (s, 3H); 
BC NMR (75 MHz, CDCh) <i: 144.9, 134.5, 129.9, 128.0, 110.2, 70.8, 69.8, 50.1, 
46.7, 37.3, 35.7, 27.4, 25.2, 21.7; HRMS-EI Calcd for CI~I9NOsS (M+-15): 
322.0749, Found: 322.0744; Anal. calcd for CI6HI9NOSS C, 56.96; H, 5.68; found 
C, 56.23; H, 5.61. 
Epoxide 220 
Rj0.40 (hexanes/ethyl acetate, 2:1); mp 179-180 °c (isopropanol); [a]o2I - 62.82 
(c 1.0, CHCh); IR (film) v2985, 2929, 1602, 1384, 1366, 1324, 1245, 1222, 
1163, 1153, 1041,1001 cm-I; IH NMR (600 MHz, CDCh) <i: 7.83 (d, J= 8.1 Hz, 
2H), 7.39 (d, J= 8.1 Hz, 2H), 4.40 (d, J= 6.3 Hz, IH), 4.31 (dd, J = 6.2 Hz, 2.3 
Hz, IH), 3.58 (dd, J = 3.9 Hz, 2.4 Hz, IH), 3.44 (dd, J = 6.7 Hz, 2.0 Hz, IH), 
3.27 (d, J = 3.5 Hz, IH), 3.18 (t, J = 6.8 Hz, IH), 2.48 (s, 3H), 1.54 (s, 3H), 1.35 
(s,3H); BC NMR (150 MHz, CDCh) <i:145.3, 133.7, 130.0, 128.1, 111.1, 71.9, 
69.9, 52.4, 25.0, 39.3, 38.6, 26.6, 25.9, 21.7; HRMS-EI Calcd for CI~I9NOsS 
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~-15): 322.0749, Found: 322.0753; Anal. calcd for C16H19N05S C, 56.96; H, 
5.68; found C, 56.23; H, 5.61. 
(3aS,4R,5R,6R, 7 S, 7aS)-6-(1,3-benzodioxol-5-ylethynyl)-7-{ [tert-
butyl( dimethyl)silyl]oxy}-2,2-dimethyl-8-[ (4-
methylphenyl)sulfonyl] hexahydro-4,5-epimino-l,3-benzodioxole 
(223). 
To a solution of acetylene 222 (0.43 g, 2.96 mmol) in 8 mL dry toluene at -50°C 
was added 1.46 mL of a solution of nBuLi in hexanes (2.01 M, 2.96 mmol) over 5 
min. The solution was stirred for 15 minutes before 2.97 mL of a solution of 
Me2AICI (1.0M in CH2Ch, 2.96 mmol) was added dropwise over 10 min. The 
reaction flask was kept at -50°C for 0.5 h and then moved to an ice bath and 
stirred an additional 0.5 h before being allowed to warm to room temperature and 
stir for 0.5 h. The reaction flask was then cooled to -20°C and 8 mL of a solution 
of epoxide 217:220 (7:1 mixture of isomers, 0.5 g, 1.48 mmol) in toluene was 
added dropwise over 20 min before being allowed to slowly warm to room 
temperature over 5 h. The reaction was cooled in an ice bath and quenched with 1 
M HCl (1 ml). Ethyl acetate (50 mL) was added and the layers where separated. 
The aqueous phase was extracted with EtOAc (3 x 50 mL) and the combined 
organic layers dried over Na2S04. Concentration under reduced pressure gave 
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0.883 g of crude alcohol intermediate which was immediately subjected to 
protection protocol. A small sample for characterization was purified by flash 
column chromatography (hexanes/ethyl acetate, 7:1 to 4:1) afforded alcohol 
(3aS,4R,5R,6R, 7 S, 7 aR)-6-(I,3-benzodioxol-5-ylethynyl)-2,2-dimethyl-B-[ (4-
methylphenyl)suHonylJ hexahydro-4,5-epimino-l,3-benzodioxol-7 -01 
(221) as a clear and colorless oil; [a]22D -113.05 (c 0.5, CHCh); Rf 0.30 
(hexanes:ethyl acetate, 2:1); IR (film) v 3491, 2988, 1163 cm-I; IH NMR (300 
MHz, CDCh) B: 7.78 (d, J= 8.1 Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 6.91 (dd, J = 
8.2 Hz, 1.8 Hz 1H), 6.83 (d, J = 1.5 Hz, 1H), 6.73 (d, J = 7.9 Hz, 1H), 5.97 (s, 
2H), 4.47 (d, J = 6.4 Hz, 1H), 4.22 (dd, J = 6.1, 4.4 Hz, 1H), 3.98 (m, 1H), 3.40 
(d, J = 6.4 Hz, 1H), 3.24 (m, 2H), 3.06 (d, J = 9.6 Hz, 1H), 2.47 (s, 3H), 1.49 (s, 
3H), 1.32 (s, 3H) ppm; l3C NMR (75 MHz, CDCh) B: 148.1, 147.5, 145.7, 134.2, 
130.4,128.1,126.4,116.2,111.8,110.3, 108.6, 101.5,84.2,83.8,75.4,70.1,68.7, 
42.3, 40.5, 31.1, 27.4, 25.2, 21.9 ppm; HRMS (FAB M~ calcd for C25H25N07S 
484.1430, found 484.1428. 
The free alcohol intermediate 221 (0.8 g, crude) was dissolved in 20 mL of 
CH2Ch and triethylamine (0.484 mL, 3.48 mmol) was added. The reaction flask 
was cooled to _78°C and t-butyldimethylsilytriflate (0.457 mL, 0.1.99 mmol) was 
added dropwise to the stirring solution. After stirring for 30 minutes at -78°C the 
reaction was quenched with water (20 ml) and the two phases separated. The 
aqueous phase was extracted with CH2Ch (3 x 50 mL) and the combined organic 
solution was washed sequentially with 5% citric acid (2 mL) and brine (2 mL) 
before drying over sodium sulfate. The solvent was removed under reduced 
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pressure and the residue was purified by flash column chromatography 
(hexane/ethyl acetate, 9:1-2:1) affording 223 (0.677 g, 77% over 2 steps) as a 
colorless oil; [af4n +57.7 (c 0.5, CHCh); Rj0.49 (hexanes:ethyl acetate, 2:1); IR 
(film) v 2953,2929,2892,2856, 1599, 1490 em-I; IH NMR (300 MHz, CDCh) 0: 
7.83 (d, J = 8.1 Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 6.94 (d, J = 8.1 Hz, 1H), 6.84 
(s, 1H), 6.77 (d, J = 8.1 Hz, 1H), 5.99 (s, 2H), 4.45 (d, J = 5.1 Hz, 1H), 3.83 (m, 
2H), 3.26 (m, 2H), 2.84 (d, J = 7.5 Hz), 2.47 (s, 3H), 1.52 (s, 3H), 1.35 (s, 3H), 
0.87 (s, 9R), 0.11 (s, 6H) ppm; I3C NMR (75 MHz, CDCh) 0: 147.8, 147.3, 
134.7, 129.8, 127.9, 126.1, 111.6, 109.7, 108.4, 101.3, 86.3, 83.5, 71.7, 43.2, 
39.53,34.58,27.9,25.8,25.79,25.7,21.7, 18.12, -4.4, -4.7 ppm; HRMS-EI Calcd 
62.28; H, 6.58; found C, 62.22; H, 6.73. 
OTBDMS 
(3aS,4R,5R,6R, 7S, 7aS)-6-[ (Z)-2-(1,3-benzodioxol-5-yl)vinyl]-7-{ [tert-
butyl( dimethyl)silyl] oxy}-2,2-dimethyl-H-[ (4-
methylphenyl)sulfonyl] hexahydro-4,5-epimino-l,3-benzodioxole 
(216). 
A) Alkyne 223 (500 mg, 0.837 mmol) was taken up in 45 mL MeOH and 
quinoline (34 mg, 0.168 mmol) was added. Lindlar's catalyst (35 mg, 0.335 
mmol) added. The reaction mixture was purged with aspirator vacuum and 
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flushed with H2 before being placed under H2 using a balloon, and stirred for 3 h. 
The reaction mixture was filtered through a short plug a Celite and the solvent 
was removed under reduced pressure. The crude residue was purified by flash 
column chromatography (hexanes/ethyl acetate, 4:1) to give the title compound as 
a clear and colorless oil (480 mg, 95%) 
B) To a 1.0 M solution of BH3.THF complex (2.5 mL, 2.5 mmol) was added 
cyclohexene (0.484 mL, 4.77 mmol) at 0 °C. After 10m a heavy precipitate was 
formed. The reaction mixture was kept at 0 °C for 1 h before acetylene derivative 
223 (0.356 mg, 0.596 mmol) in 4.5 mL of THF was added. The reaction mixture 
was stirred at 0 °C until total consumption of starting material (2 h, TLC) before 
being quenched with 1 mL HOAc. EtOAc (60 mL) was added and the reaction 
mixture was washed with saturated aq. NaHC03 (2 x 15 mL), H20 (2 x 15 mL), 
and brine (10 mL) before drying over sodium sulfate. The solvent was removed 
under reduced pressure and the residue was purified by flash column 
chromatography (hexanes/ethyl acetate, 8:1) affording 0.271 g of 216 (76%).; 
[a]23D -26.14 (c 1.0, CHCh; Rj0.35 (hexanes:ethyl acetate, 4:1); IR (film) v 2986, 
2930,2894, 2856, 1598,1489 cm- l ; IH NMR (300 MHz, CDCh) 8: 7.78 (d, J = 
8.1 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 6.65 (m, 3H), 6.51 (d, J = 11.7 Hz, 1H), 
5.97 (s, 2H), 5.54 (t, J = 11.3 Hz, 1H), 4.43 (d, J = 6, 1H), 3.85 (t, J = 6.3, 1H), 
3.61 (t, J = 7.2 Hz), 3.18 (d, J= 6.6, lH), 2.91 (m, 2H), 2.44 (s, 3H), 1.52 (s, 3H), 
1.33 (s, 3H), 0.79 (s, 9H), 0.02 (s, 3H), -0.04 (s, 3H) ppm; \3C NMR (150 MHz, 
CDCh) 8: 147.5, 146.6, 144.6, 134.7, 132.0, 129.8, 129.7, 128.5, 122.5, 109.35, 
109.0, 108.1, 100.9, 83.2, 78.0, 72.6, 71.8, 43.7, 39.9, 30.1, 27.8, 25.8, 25.79, 
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25.51,21.7, 18.1, -4.3, -4.7 ppm; HRMS-EI Calcd for C31I4IN07SSi: 599.2373; 
Found, 599.2376; Anal. calcd for C31I4IN07SSi C, 62.28; H, 6.58; found C, 
61.30; H, 6.63 
OTBDMS 
~x o 
(3aS,4R,5R,6R, 7 S, 7 as)-6-[2-(1,3-benzodioxol-5-yl)ethyl]-7-{ [tert-
butyl( dimethyl)silyl] oxy}-2,2-dimethyl-8-[ (4-
methylphenyl)sulfonyl]bexahydro-4,5-epimino-l,3-benzodioxole 
(226). 
Alkyne 223 (100 mg, 0.168 mmol) was taken up in 10 mL MeOH and Lindlar's 
catalyst (35 mg, 0.335 mmol) added. The reaction mixture was purged with 
aspirator vacuum and flushed with H2 before being placed under H2 using a 
balloon, and stirred for 24 hours. The reaction mixture was filtered through a 
short plug a celite and the solvent was removed under reduced pressure. The 
crude residue was purified by flash column chromatography (hexanes:ethyl 
acetate, 4:1) to give the title compound as a clear and colorless oil (95 mg, 94%).; 
[a230] -47.2 (c 1.8, CHCh) Rf0.35 (hexanes/ethyl acetate, 2:1); IR (film) v 2986, 
2954,2929,2891,2857,1598,1504,1489 em-I; IH NMR (500 MHz, CDCh) 0: 
7.87 (d, J = 7 Hz, 2H), 7.37 (d, J = 7 Hz, 2H), 6.70 (d, J = 6.5 Hz, IH), 6.55 (s, 
IH), 6.51 (d, J = 7 Hz, IH), 5.93 (s, 2H), 4.41 (d, J = 5 Hz, IH), 3.79 (t, J = 5 Hz, 
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1H), 3.43 (m, 1H), 3.18 (d, J= 6 Hz, 1H), 2.84 (m, 1H), 2.60 (m, 1H), 2.45 (s, 
3H), 2.40 (m, 1H), 2.05 (m, 1H), 1.68 (s, 3H), 1.34 (s, 3H), 0.83 (s, 9H), 0.06 (s, 
3H), 0.03 (s, 3H); BC NMR (250 MHz, CDCh) 8: 146.6, 145.7, 144.8, 135.1, 
134.9, 129.8, 128.0, 127.9, 121.2, 109.2, 108.9, 108.1, 100.8, 78.6, 72.5, 71.9, 
43.2,39.9,39.5,32.9,32.7,27.8,25.9,25.8,25.5, 21.7, 18.2, -4.0, -4.8; HRMS-
EI Calcd for C31~3N07SSi: 601.2530; Found, 601.2534. 
OTBS 
-
NHTs 
N-[(1R,2aS,4aS,5S,5aR,12bR)-5-(tert-Butyldimethylsiianyloxy)-3,3-dimethyl-
1,2a,4a,5,5a,12b-hexahydrophenanthro [2,3-d] [1,3] dioxol-1-yl]4-
methylbenzenesulfonamide (215). 
A flame-dried 25-mL flask was charged with olefm 216 (336 mg, 0.561 mmol) 
and silica gel (1.5 g) which has been activated by heating under vacuum at 120°C 
overnight. The starting materials were suspended in 10 mL freshly distilled 
methylene chloride and the solvent removed under reduced pressure. The silica 
gel supporting the adsorbed reactants was heated externally at 120°C under 
nitrogen atmosphere for 24 h, after which time the silica gel was loaded onto flash 
silica gel column and eluted with hexanes/ethyl acetate (8:1 - 5:1) to give olefin 
215 as a clear and colorless oil. Yield 249 mg, 74%; [aJ D 23 -123.7 (c 1.0, CHCh); 
Rf 0.35 (hexanes/ethyl acetate, 2:1); IR (film) v 3268, 2929, 2887, 2857, 
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1598,1503, 1485 cm-I; IH NMR (600 MHz, CDCh) 8: 7.43 (d, J = 7.0 Hz, 2H), 
7.13 (d, J= 7.2 Hz, 2H), 6.49 (s, 2H), 6.34 (d, J= 8.1 Hz, IH), 5.95 (s, IH), 5.86 
(s, IH), 5.76 (d, J= 8.0 Hz, IH), 4.51 (d, J= 7.2 Hz, IH), 4.28 (m, IH), 4.11 (m, 
IH), 3.99 (m, IH), 3.79 (m, IH), 2.82 (m, IH), 2.62 (dd, J = 11.1 Hz, 5.4 Hz, 
IH), 2.40 (s, 3H), 1.43 (s, 3H), 1.33 (s, 3H), 0.89 (s, 9H), 0.11 (s, 3H), 0.07 (s, 
3H) ppm; l3C NMR (150 MHz, CDCh) 8: 146.7, 145.9, 142.1, 138.9, 128.9, 
128.6, 127.7, 126.8, 126.3, 126.2, 110.4, 109.2, 107.0, 79.0, 78.3, 70.3, 54.1,42.5, 
41.5, 38.9, 27.8, 26.3, 25.7, 25.3, 22.7, 21.5, 18.0, -5.0, -5.0 ppm; HRMS-EI 
Calcd for C31H41N07SSi: 599.2373; Found, 599.2370; Anal. calcd for 
C3IH41N07SSi C, 62.07; H, 6.89; found C, 62.16; H, 6.94. 
H9 H 9TBS 
o - - -
7 ~>< 
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NHTs 
N-[(IR,2aS,4aS,5S,5aS,12bR)-5-(tert-Butyl-dimethyl-silanyloxy)-6-hydroxy-
3,3-dimethyl-7 -oxo-l,2a,4a,5,5a,6, 7,12b-octahydro-phenanthro [2,3-
d] [1,3]dioxol-l-yI]4-methyI-benzenesulfonamide (228). 
To a solution of olefin 215 (0.240 mg, 0.4 mmol) in methylene chloride (10 mL) 
was added 4-methylmorpholine-N-oxide (58 mg, 0.48 mmol). The reaction 
mixture was allowed to stir for 10 minutes before the introduction of a single 
crystal of osmium tetroxide and two drops of water. The reaction was stirred until 
total consumption of starting material (10 h) before being quenched with a 
154 
saturated solution of saturated sodium bisulfite (6 mL). The two layers were 
separated and the aqueous phase was extracted with ethyl acetate (3 x 30 mL). 
The organic phase was dried over sodium sulfate, filtered, and concentrated to 
provide hydroxyketone 228 as a white crystalline solid (0.227 g, 89%) that was 
used without further purification; Rj0.42 (hexanes:ethyl acetate, 1:1); mp >200 
DC (hexane/ethyl acetate); IR (film) v 3478, 3263,2929,2857, 1670, 1614, 1504, 
1482, 1444, 1386, 1330, 1252, 1218, 1156, 1075, 1039 em-I; IH NMR (600 MHz, 
CDCb) 0: 7.54 (d, J = 7.8 Hz, 2H), 7.49, (s, 1H), 7.18 (d, J = 7.8 Hz, 2H), 6.70 (s, 
1H), 6.07 (s, 1H), 6.00 (s, 1H), 4.79 (d, J = 8.7 Hz, 1H), 4.71 (m, 2H), 4.19 (m, 
1H), 4.08 (m, IH), 3.74 (m, 2H), 3.08 (dd, J = 10.2 Hz, 1.8 Hz, 1H), 2.45 (m, 
1H), 2.41 (s, 3H), 1.36 (s, 3H), 1.31 (s, 3H), 0.87 (s, 9H), 0.12 (s, 3H), 0.07 (s, 
3H) ppm; 13C NMR (150 MHz, CDCb) 0: 196.6, 152.5, 147.9, 142.6, 140.5, 
138.9, 129.1, 126.9, 124.7, 111.2, 109.6, 106.9, 102.1, 78.9, 78.7, 70.3, 65.9, 57.9, 
49.4, 39.7, 27.9, 25.7, 21.5, 17.95, -5.1 ppm; HRMS-EI Calcd for C27H32N09SSi 
(~-57): 574.1567, Found: 574.1572 
(3aS,3bR,10bR,IIR,12S,12aS)-12-(tert-Butyl-dimethyl-silanyloxy)-2,2-
dimethyl-5-oxo-4-( toluene-4-sulfonyl)-3a,3b,4,5,1 Ob,II,12,12a-octahydro-
1,3,7 ,9-tetraoxa-4-aza-dicyclopenta[a,h ]phenanthrene-ll-carbaldehyde (166). 
To a 10 mL round-bottomed flask was added hydroxyl ketone 228 (0.4 g, 0.6 
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mmol) and 6 mL of a I: I mixture of ethanol/dioxane. The reaction flask was 
cooled externally in an ice bath and NaBH4 (24 mg, 0.63 mmol) was added in one 
portion. The reaction was removed from the bath and allowed to warm to room 
temperature over I h. The reaction was quenched with 1 N HCI (4 mL) and 
separated. The aqueous phase was extracted with CH2Ch (3 x 20 mL) and the 
organic phase combined before drying over sodium sulfate. The crude mixture 
was concentrated in a 25 mL round bottomed flash and taken up in dioxane (8 
mL). A stirring bar was added and the reaction was stirred while sodium 
periodate (0.332, 1.5 mmol) was added. The flask was covered to exclude light 
and H20 (15 drops) added. The reaction was stirred until total consumption of 
starting material (23h) as monitored by TLC. The reaction was quenched with 
H20 (10 mL) and separated. The aqueous phase was extracted with CH2Ch (3 x 
50 mL) and the combined organic phases dried over sodium sulfate. 
Concentration provided hemi-aminal 231. 
To a solution of herni-aminal 231 (394 mg, 0.620 mmol) in N,N-
Dimethylformarnide (3 mL) was added 2-Iodoxybenzoic acid (520 mg, 1.86 
mmol). After total consumption of starting material (by TLC), the reaction 
mixture was diluted with diethyl ether (200 mL) and washed sequentially with 
saturated aqueous sodium bisulfite (10 mL), sodium bicarbonate (3 x 10 mL), 
H20 (10 x 1mL), and brine (10 mL). The organic phase was dried over 
magnesium sulfate, filtered and concentrated. The final product 166 was isolated 
by column chromatography (hexanes/ethyl acetate, 4:1). Yield: 225 mg, 61%, 
over 3 steps, white solid; Rf 0.31 (hexanes:ethyl acetate, 4:1); mp >200 cC, 
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recrystallized from hexanes/etbyl acetate 4:1; [a]D21 + 31.67 (c 0.5, CHCh); IR 
(film) v 2929, 2857, 1725, 1689, 1619, 1505, 1484, 1386, 1361, 1287, 1255, 
1220, 1172, 1077, 1036 cm-1; IH NMR (600 MHz, CDCh) 3: 9.49 (s, IH), 8.3 (d, 
J = 8.2 Hz, 2H), 7.58 (s, IH), 7.33 (d, J = 8.2 Hz, 2H), 7.28 (s, IH), 6.55 (s, IH), 
6.04 (d,J= 5 Hz, 2H), 5.81 (dd,J= 8.4 Hz, 5.2 Hz, IH), 4.79 (m, IH), 4.50 (dd, J 
= 12.7 Hz, 8.4 Hz, IH), 4.27 (dd, J= 5.2 Hz, 2.7 Hz, IH), 3.83 (dd, J= 12.6,4.0 
Hz, IH), 3.31 (m, IH), 2.45 (s, 3H), 1.42 (s, 3H), 1.32 (s, IH), 0.99 (s, 9H), 0.26 
(s, 3H), 0.25 (s, 3H) ppm; BC NMR (150 MHz, CDCh) 3: 196.2, 166.0, 153.0, 
147.1, 143.9, 138.8, 137.0, 128.9, 128.8, 110.1, 109.4, 104.2, 102.2, 72.4, 66.6, 
65.5, 55.6, 35.4, 31.0, 27.9, 26.9, 25.7, 22.7, 21.7, 18.1, 14.2, -4.7, -4.9 ppm; 
HRMS-EI Calcd for C30H36N09SSi ~-15): 614.1879, Found: 614.1870; Anal. 
calcd for C31H39N09SSi C, 59.12; H, 6.24; found C, 59.31; H, 6.29. 
o QTBS 
o 
(3aS,3bR,1 ObR,IIR,12S,12aS)-12-(tert-Butyl-dimethyl-silanyloxy)-2,2-
dimethyl-5-oxo-4-(toluene-4-sulfonyl)-3a,3b,4,5,1 Ob,11,12,12a-octahydro-
1,3, 7,9-tetraoxa-4-aza-dicyclopenta[a,h ]phenanthrene-ll-carboxylic acid 
(235). 
To a solution of aldehyde 166 (144 mg, 0.229 mmol) in dry methylene chloride (5 
mL) was added sodium phosphate dibasic (81 mg, 0.57 mmol). The suspension 
was stirred while 3-chloroperbenzoic acid (130 mg, 0.57 mmol) was added. The 
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reaction flask was sealed and heated at 40°C overnight. The reaction mixture 
was diluted with methylene chloride (80 mL) and washed sequentially with 
saturated aqueous sodium bisulfite (10 mL), sodium bicarbonate (10 mL), and 
dried over sodium sulfate. The organic phase was filtered and concentrated in 
vacuo to provide carboxylic acid 235 as a white crystalline solid (0.125 g, 85%) 
that was used without further purification. RIO.I (hexanes/ethyl acetate, 1:1); mp 
>200 °c (chloroform/ether); [a]n22 - 35.09 (c 1.25, CHCh); IR (KBr) v 3246, 
2930,2891,2857, 1710, 168~ 1619, 1505, 1484, 1361, 1240, 1220, 1172, 1078, 
1033 cm-l; IH NMR (300 MHz, CDCh) 0: 8.29 (d, J = 8.3 Hz, 2H), 7.53 (s, IH), 
7.32 (d, J= 8.3 Hz, 2H), 7.28 (s, IH), 6.56 (s, IH), 6.02 (d, J= 3 Hz, 2H), 5.77 
(dd, J= 8.30 Hz, J= 5.3 Hz, IH), 4.85 (dd, J= 12.5 Hz, 8.4 Hz, IH), 4.84 (t, J= 
4.7 Hz, IH), 4.22 (dd J = 5.22, 2.8 Hz, IH), 3.76 (dd, J = 12.4 Hz, 4.1 Hz, IH), 
3.38 (t, J = 3.5 Hz, IH), 2.45 (s, 3H), 1.40 (s, 3H), 1.27 (s, IH), 0.96 (s, 9H), 0.21 
(s, 6H) ppm; 13C NMR (150 MHz, CDCh) 0: 174.3, 166.2, 152.8, 146.9, 143.8, 
138.9, 137.7, 129.0, 128.8, 122.4, 109.8, 109.2, 103.4, 102.1, 72.8, 68.2, 64.9, 
48.0, 35.5, 27.4, 26.9, 25.7, 21.7, 18.0, -4.9, -5.0 ppm; HRMS-EI Calcd for 
C27H30NOlOSSi (~-57): 588.1359, Found: 588.1354; Anal. calcd for 
C3lH39NOlOSSi C, 57.65; H, 6.09; found C, 58.01; H, 6.37 
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(3aS,3bR,10bR,IIR,12S,12aS)-12-(tert-Butyl-dimethyl""silanyloxy)-2,2-
dimethyl-5-oxo-4-(toluene-4-sulfonyl)-3a,3b,4,5,10b,ll,12,12a-octahydro-
1,3,7 ,9-tetraoxa-4-aza-dicyclopenta[a,h ]phenanthrene-ll-carboxylic acid 
methyl ester (236). 
To a solution of carboxylic acid 235 (45 mg, 0.069 mmol) in diethyl ether (3 mL) 
was added freshly prepared diazomethane solution in diethyl ether until the 
persistence of yellow color and total consumption of starting material (by TLC). 
The reaction was quenched with one drop of acetic acid followed by saturated 
sodium bicarbonate solution (1 mL), diluted with diethyl ether (30mL) and 
washed with saturated sodium bicarbonate solution (2 x 1 mL), dried over 
magnesium sulfate, filtered and concentrated. The crude reaction mixture was 
passed through short silica plug using hexane/ethyl acetate 1: 1 as eluent and 
concentrated to provide methyl ester 236 that was used without further 
purification. Yield: 38 mg, 83%, white crystalline solid; RI0.45 (hexanes/ethyl 
acetate, 1:1); mp >200 °C (hexane/ethyl acetate); [a]o22 - 25.6809 (c 0.75, 
CHCh); IR (KBr) v 2986, 2953, 2931, 2896, 2858, 1739, 1692, 1620, 1598, 
1505, 1485, 1361, 1289, 1264, 1173 cm-I; IH NMR (300 MHz, CDCh) 8: 8.30 (d, 
J = 8.4 Hz, 2H), 7.55 (s, IH), 7.32 (d, J = 8.3 Hz, 2H), 6.58 (s, IH), 6.02 (s, 2H), 
5.78 (dd, J= 8.30 Hz, 5.4 Hz, IH), 4.9 (dd, J= 12.5 Hz, 8.3 Hz, IH), 4.78 (t, J= 
3.0 Hz, IH), 4.24 (dd J = 5.36 Hz, 2.9 Hz, IH), 3.79 (dd, J = 12.4, 4.2 Hz, IH), 
3.56 (s, 3H), 3.40 (t, J = 3.7 Hz, IH), 2.45 (s, 3H), 1.41 (s, 3H), 1.35 (s, IH), 0.98 
(s, 9H), 0.24 (s, 3H), 0.23 (s, 3H) ppm; l3C NMR (75 MHz, CDCh) 8:169.4, 
166.3, 152.8, 146.8, 143.7, 139.0, 138.2, 128.9, 128.8, 122.4, 109.8, 109.2, 103.5, 
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102.0, 72.9, 68.2, 65.2, 51.9, 48.1, 35.9, 27.5, 26.8, 25.7, 21.6, 18.0, -4.8, -4.9 
ppm; HRMS-EI Calcd for C28H32NOlOSSi(~-57): 602.1516, Found: 602.1516 
o OTBS 
:>< 
o 
(3aS,3bR,1 ObR,11R,12S,12aS)-12-(/erl-Butyl-dimethyl-silanyloxy)-2,2-
dimethyl-5-oxo-3a,3b,4,5,1 Ob,11,12,12a-octahydro-l,3, 7 ,9-tetraoxa-4-aza 
dicyclopenta[a,h]phenanthrene-ll-carboxylic acid methyl ester (237). 
To a solution of 236 (52 mg, 0.079 mmol) in dry THF (1 mL) at -50°C was 
added a 0.5 M solution of Nalnaphthalene in DME until a green color persisted 
and total consumption of starting material was observed (by TLC). The solution 
was stirred for 10 minutes before the reaction was quenched with saturated 
aqueous ammonium chloride solution (1 mL). The reaction was warmed to room 
temperature and extracted with CH2Ch (6 x 15 mL). The combined organic phase 
was dried over sodium sulfate, filtered, and concentrated. The final product was 
isolated by column chromatography (hexanes/ethyl acetate, 5:1-2:1). Yield: 23 
mg, 58%, clear and colorless oil; Rf 0.28 (hexanes:ethyl acetate, 1:1); [a]n22 -
14.51 (c 0.50, CHCh); IR (film) v3320, 2952, 2930, 2895, 2857, 1743, 1669, 
1619, 1504, 1484, 1460, 1385, 1369, 1321, 1288, 1260, 1222 cm-I; IH NMR (600 
MHz, CDCh) B: 7.62 (s, IH), 6.56 (s, IH), 6.02 (s, 2H), 5.96 (s, IH), 4.86 (t, J= 
2.6, IH), 4.41 (dd, J = 13.6 Hz, 8.2 Hz, IH), 4.18 (dd, J = 8.25 Hz, 4.8 Hz, IH), 
4.11 (m, IH), 3.66 (s, 3H), 3.40 (dd, J= 13.6 Hz, 3.7 Hz, IH), 3.33 (m, IH), 2.06 
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(s, 1H), 1.40 (s, 3H), 1.37 (s, 3H), 0.92 (s, 9H), 0.21 (s, 3H), 0.20 (s, 3H) ppm; 
BC NMR (150 MHz, CDCl3) 0:169.6, 165.4, 151.4, 146.6, 135.4, 122.6, 110.5, 
108.6, 103.3, 101.7, 69.2, 53.1, 51.9,45.9, 33.4, 27.6,26.5,25.7, 17.9, -4.9, -5.0 
ppm; HRMS-EI Calcd for C2sH3sNOsSi (M+): 505.2132, Found: 505.2131 
o 
OH 
o 
(IR,2S,3R,4S,4aR,11 bR)-2,3,4-Trihydroxy-6-oxo-l,2,3,4,4a,5,6,11 b-
octahydro-[1,3]dioxolo [4,5:11phenanthridine-l-carboxylic acid methyl ester 
(169). 
To a solution of the detosylated methyl ester 237 (23 mg, 0.046 mmol) in 
methanol (2 mL) was added 3% HCl in methanol (0.5 mL). The reaction mixture 
was stirred until total consumption of starting material (3 days). The solvent was 
removed under reduced pressure and the residue was purified by flash column 
chromatography using a 30:1 to 20:1 gradient of methylene chloride/methanol as 
eluent to provide methyl ester 169 (11 mg, 69%) as a white crystalline solid. Rf 
0.06 (methylene chloride/methanol, 20:1); mp >200 °c (methylene chloride/ 
methanol); [a]D22 + 24.53 (c 0.25,MeOH); IR (KBr) v3311, 2913, 1732, 1648, 
1609, 1497, 1462, 1349, 1259, 1037cm-1; IH NMR (300 MHz, MeOD) 0: 7.33 (s, 
1H), 6.59 (s, 1H), 5.93 (d, J = 3.7, 2H), 4.50 (t, J = 3.12, 1H), 4.21 (dd, J = 13.1 
Hz, J= 10.1 Hz, 1H), 3.86 (m, 1H), 3.79, (dd, J= 10.1, J= 3.0, 1H), 3.51 (s,3H), 
3.39 (m, 1H), 3.29 (dd, J= 13.1, J= 4.1, 1H) ppm; BC NMR (75 MHz, MeOD) 
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B: 170.8, 166.4, 151.7, 146.4, 137.3, 121.7, 106.9, 103.7, 101.8, 72.2, 71.9, 70.9, 
51.4, 50.6,44.8,35.4 ppm; HRMS-FAB: (mlz) (M + Ht: Calcd for CI6H17NOg: 
352.1032, Found: 352.0941 
o 
OH 
o 
(1R,2S,3R,4S,4aR,11 bR)-2,3,4-Trlhydroxy-6-oxo-l,2,3,4,4a,S,6,11 b-
octahydro-[1,3] dioxolo [4,S"11phenanthridine-l-carboxylic acid (168). 
To a solution of 169 (6 mg, 0.017 mmol) in methanol (0.5 mL) was added LiOH 
(1 mg, 1.5 mmol). The reaction mixture was heated at 45°C and stirred until total 
consumption of starting material (2 days) as monitored by TLC. The reaction was 
made slightly acidic with the addition of HC1 (5 drops, 1M) and concentrated to 
provide acid 168 (5 mg, 95%) as a white crystalline solid. mp >200 °c 
(methanol); RjO.06 (methylene chloride/methanol, 4:1); IR (KBr) v 3412, 2920, 
2115, 1641, 1505, 1471, 1409, 1462, 1363, 1267 cm-I; IH NMR (300 MHz, 
MeOD) B: 7.41 (s, 1H), 6.72 (s, 1H), 6.02 (d, J= 3.7, 2H), 4.64 (t, J = 3.12, 1H), 
4.35 (dd, J = 13.1 Hz, 10.1 Hz, 1H), 3.99 (m, 1H), 3.89, (dd, J = 10.1, 3.0, 1H), 
3.45 (m, 1H), 3.38 (m, 1H) ppm; 13C NMR (75 MHz, MeOD) B: 172.1, 166.4, 
151.7, 146.4, 137.6, 121.7, 106.8, 103.8, 101.8, 72.4, 71.9, 71.1, 51.34, 45.03, 
35.4 ppm. 
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OH OTBS 
0 ::>< \, 
0 
(3aS,3bR,1 ObR,IIS,12S,12aS)-12-(tert-Butyl-dimethyl-silanyloxy)-II-
hydroxymethyl-2,2-dimethyl-4-(toluene-4-sulfonyl)-3b,4,10b,II,12,12a-
hexahydro-3aH-l,3,7 ,9-tetraoxa-4-aza-dicyclopenta[ a,h ]phenanthren-5-one 
(238). 
To a solution of aldehyde 166 (175 mg, 0.278 mmol) in EtOHIdioxane (1:1, 5 
mL) at O°C was added NaBH4 (3 mg, 0.08 mmol). The reaction was allowed to 
warm to room temperature over 1.5 hours before being quenched with a solution 
of saturated N~Cl (1 mL). The EtOHIdioxane mixture was removed under 
reduced pressure and the aqueous residue was extracted with CH2Ch (3 x 25 mL). 
The organic phases were combined, dried over sodium sulfate, filtered, and 
concentrated to provide alcohol 238 which was used without further purification. 
Yield: 150 mg, 85%, clear and colorless oil; ; Rj0.44 (hexanes/ethyl acetate, 1:1); 
[a]D22 - 47.72 (c 1.50, CHCb); IR (film) v 3547, 2986, 2932, 2586, 1692, 1616, 
1594, 1508, 1481, 1360 cm-I; IH NMR (300 MHz, CDCb) 0: 8.28 (d, J = 8.3 Hz, 
2H), 7.54 (s, 1H), 7.30 (d, J= 8.2 Hz, 2H), 6.77 (s, 1H), 6.04 (d, J= 1.6 Hz, 2H), 
5.65 (dd, J = 8.8 Hz, 5.6 Hz, 1H), 4.57 (d, J = 1.8 Hz, 1H), 4.32 (d, J = 4.6 Hz, 
1H), 4.16 (ddJ= 12.8,8.9 Hz, 1H), 3.78 (m 2H), 3.38 (dd, J= 11.3 Hz, 3.6 Hz, 
1H), 2.55 (bs, 1H), 2.43 (s, 3H), 1.96 (bs, 1H), 1.43 (s, 3H), 1.35 (s, 3H), 0.96 (s, 
9H), 0.20 (s, 6H) ppm; 13C NMR (75 MHz, CDCb) 0: 166.4, 153.1, 147.1, 143.7, 
138.9, 137.0, 129.0, 128.7, 123.2, 109.1, 108.7, 104.9, 102.1, 73.1, 67.3, 64.8, 
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60.0,46.9,37.4,28.1, 26.3, 25.8,21.6, 18.0, -4.8, -4.9 ppm; HRMS-EI Calcd for 
C31141N09SSi (M+-15): 616.2032, Found: 616.2032. 
o )lo OTBS 
{(3aS,3bR,1 ObR,11S,12S,12aS)-12-{ [tert-butyl( dimethyl)silyl]oxy}-2,2-
dimethyl-4-[( 4-methylphenyl)sulfonyl]-S-oxo-3a,3b,4,S,1 Ob,11,12,12a-
octahydrobis [1,3]dioxolo [4,S-c:4',S':llphenanthridin-ll -yl} methyl acetate 
(239). 
To a solution of 238 (150 mg, 0.237 mmol) in dry CH2Ch (10 mL) was added 
DMAP (1.5 mg, 0.012 mmol), followed by pyridine (0.1 mL, 1.187 mmol). Ac20 
(45 pL, 0.475 mmol) was added and the reaction was stirred for 1 h before being 
quenched with saturated sodium bicarbonate (5 mL). The reaction was diluted 
with Et20 (75 mL) and separated. The aqueous layer was extracted with Et20 (2 
x 75 mL) and the combined organic phases were washed with H20 (10 mL), brine 
(10 mL), dried over magnesium sulfate, filtered, and concentrated. The fmal 
product was isolated by column chromatography using 5:1 mixture of 
hexanes/ethyl acetate as eluent. Yield: 128 mg, 81 %, clear and colorless oil; Rf 
0.51 (hexanes/ethyl acetate, 1:1); [a]n22 - 41.081 (c 3.0, CHCh); IR (film) v 
2988,2952,2930,2858,1742,1694,1619,1598,1505, 1485, 1395, 1362, 1254; 
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IH NMR (600 MHz, CDCh) b: 8.29 (d, J= 8.3 Hz, 2H), 7.54 (s, IH), 7.31 (d, J= 
8.2 Hz, 2H), 6.84 (s, IH), 6.03 (d, J= 12.6 Hz, 2H), 5.62 (dd, J= 8.7 Hz, J= 5.6 
Hz, IH), 4.50 (s, IH), 4.31 (d, J= 5.3 Hz, IH), 4.18 (t, J= 11.1 Hz, IH), 3.97 
(dd, J = 13.0 Hz, J = 8.8 Hz, IH), 3.85 (dd, J = 11.0 Hz, J = 3.6 Hz, IH), 3.80 
(dd, J= 13.0, J= 4.2, IH), 2.7 (d, J= 5.2, IH), 2.44 (s, 3H), 2.03 (s, 3H), 1.42 (s, 
3H), 1.36 (s, 3H), 0.96 (s, 9H), 0.19 (s, IH); l3C NMR (150 MHz, CDC13) 
b:170.7, 166.2, 153.2, 147.3, 143.8, 138.8, 136.2, 129.1, 128.7, 123.2, 108.9, 
108.8, 105.0, 102.2, 78.4, 73.0, 66.3, 64.4, 60.8, 44.0, 37.0, 28.3,26.2, 25.8, 
25.78, 25.75, 25.6, 21.6, 20.8, 18.1, -4.8, -5.0; HRMS-EI Calcd for 
C32H40NOlOSSi (M+-15): 658.2142, Found: 658.2152. 
o )lo 
o 
«3aS,3bR,10bR,11S,12S,12aR)-12-hydroxy-2,2-dimethyl-5-oxo-
3a,3b,4,5,1 Ob,11,12,12a-octahydrobis [l,3]dioxolo[ 4,5-c:4' ,5' -j]phenanthridin-
ll-yl)methyl acetate (240). 
To a solution of 239 (137 mg, 0.203 mmol) in dry DME (5 mL) at -78°C was 
added a 0.5 M solution of Na/naphthalene in DME until a green color persisted 
and total consumption of starting material was observed (by TLC). The solution 
was stirred for 10 minutes before the reaction was quenched with saturated 
aqueous ammonium chloride solution (2 mL). The reaction was warmed to room 
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temperature, concentrated to remove DME, and extracted with CH2Ch (3 x 40 
mL). The combined organic phase was dried over sodium sulfate, filtered, and 
concentrated. The resulting crude acetate was taken up in THF (2.5 mL) and 
cooled to 0 °C. TBAF (0.1 mL, 1M in THF) was added dropwise over 2 min. 
The reaction was stirred until total consumption of starting material was observed 
(TLC) before the stirring bar was removed, silica (200 mg added), and the 
reaction concentrated to dryness. The [mal product was isolated by column 
chromatography using 1:1 mixture ofhexanes/ethyl acetate as eluent Yield: 61 
mg, 74%, white solid; mp >200 °C (ethyl acetatelhexanes); Rf 0.059 
(hexanes/ethyl acetate, 1:1); [a]D22 - 38.301 (c 1.35, DMSO); IR (film) v3303, 
2982,2922,2901,2853,1734,1655,1652,1612,1483, 1459, 1364, 1246, 1235, 
1215; IH NMR (300 MHz, DMSO) 0: 7.76 (s, IH), 7.35 (s, IH), 7.03 (s, IH) 6.09 
(d, J= 1.8, 2H), 5.48 (d, J= 4.2, IH), 4.35, (s, IH), 4.24 (d, J= 5.3, IH), 4.19-
4.10 (m, 3H), 3.46 (dd, J = 14.0 Hz, 8.2 Hz, IH), 3.21 (dd, J = 13.9 Hz, J = 3.8 
Hz, IH), 2.80 (bs, IH), 2.02 (s, IH), 1.39 (s, 3H), 1.31 (s, 3H); I3C NMR (75 
MHz, DMSO) 0:170.9, 163.9, 151.3, 146.7, 134.5, 124.2, 108.9, 107.6, 105.4, 
102.2, 77.9, 77.2, 65.3, 61.2, 53.5, 34.7, 28.3, 26.4, 21.2; HRMS-EI Calcd for 
C20H23NOS(Ml: 405.1424, Found: 405.1431. 
OAe QH 
OH 
~ OH 
0 
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«1 S,2S,3R,4S,4aR,11 bR)-2,3,4-tribydroxy-6-oxo-l,2,3,4,4a,5,6,11 b-
octabydro-[1,3]dioxolo[4,5-j]pbenantbridin-l-yl)metbyl acetate (170). 
To a solution of acetate 240 (21 mg, 0.052 mmol) in MeOH (1 mL) was added an 
HCl solution (3 % in MeOH, 3 mL). The reaction was stirred until total 
consumption of starting material as monitored by TLC (3 h) before being 
quenched to basic pH with saturated sodium bicarbonate solution. The crude 
reaction mixture was concentrated to dryness. The fmal product was isolated by 
column chromatography (methlene chloride/methanol, 5:1). Yield: 6 mg, 45%, 
white solid; mp >200 °C (methylene chloride/methanol; Rf 0.41 (methlene 
chloride: methanol, 5:1); [a]D22 97.32 (c 0.3, DMSO); IH NMR (600 MHz, 
DMSO) B: 7.36 (s, IH), 7.01 (s, IH), 6.76, (s, IH), 6.10, (s, 2H), 5.14, (bs, 3H), 
4.38 (t, J= 10.7 Hz, IH), 4.15 - 4.10 (m, 2H), 3.84 (s, IH), 3.70 (dd J= 9.8 Hz, 
2.9 Hz, IH), 3.50 (ddJ= 13.2 Hz, 9.9 Hz, IH), 3.27 (ddJ= 13.3 Hz, J= 4.0 Hz, 
IH), 2.69 (bs, IH), 2.03 (8, 3H) ppm; 13C NMR (150 MHz, DMSO) B: 171.0, 
164.1; 151.3, 146.6, 135.3, 123.8, 107.5, 105.5, 102.2, 73.1, 71.3, 69.1, 61.9, 51.6, 
36.9, 21.3 ppm; HRMS-FAB Calcd for CI7H20NOS (M + 1): 366.0988, Found: 
366.1088. 
OH 
o 
OH 
OH 
(IS,2S,3R,4S,4aR,11 bR)-2,3,4-tribydroxy-l-(bydroxymethyl)-1,2,3,4,4a,5-
hexahydro-[1,3]dioxolo[4,5-j]phenanthridin-6(llbH)-one (167). 
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To a solution of acetate 240 (25 mg, 0.062 mmol) at 0 °C, in MeOH (5 mL) was 
added K2C03 (40 mg, 0.62 mmol) and H20 (1 mL). The suspension was stirred 
until total consumption of starting material (TLC) before being quenched with 
HCI (4 drops, 6N). The reaction was allowed to warm to room temperature and 
stir (4 h). The pH of the reaction was made basic with the addition of saturated 
sodium bicarbonate solution and the methanol removed under reduced pressure. 
The resulting aqueous phase was concentrated overnight on a freeze-dryer. The 
salts were triturated with MeOH (5 x 5 mL) and the MeOH washes collected and 
concentrated. The final product was isolated by column chromatography 
(methylene chloride/methanol, 5:1). Yield: 15 mg, 75%, white solid; mp >200 °C 
methylene chloride/methanol; Rf 0.20 (methlene chloride/methanol, 5:1); [a]n22 
90.91 (c 0.25, DMSO); IR (film) v3361, 2916, 1646, 1608, 1503, 1460, 1385, 
1361, 1252; IH NMR (600 MHz, DMSO) 0: 7.34 (s, IH), 6.97 (s, IH), 6.66, (s, 
IH), 6.09, (d, J = 0.78, 2H), 5.04 - 4.97, (m, 3H), 4.47 (dd J = 6.6 Hz, 3.8 Hz, 
IH), 4.19 (s, IH), 3.89 (q, J = 7.86 Hz, IH), 3.82 (s, IH), 3.69-3.64 (m, IH), 3.42 
(dd J = 13.2 Hz, 9.9 Hz, IH), 3.39 - 3.32 (m, IH), 3.15, (dd J = 13.3 Hz, 4.5 Hz, 
IH), 2.41 (s, IH) ppm; l3C NMR (150 MHz, DMSO) 0: 164.2, 151.2, 146.3, 
136.3, 123.7, 107.4, 105.6, 102.1, 73.3, 71.6, 69.7, 57.8, 51.8, 44.4, 37.3 ppm; 
HRMS-FAB Calcd for Cl5HISN07 (M + 1): 324.1085, Found: 324.1084. 
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N-[(lR,2aS,4aS,5S,5aR,12bR)-5-(tert-Butyl-dimethyl-silanyloxy)-3,3-
dimethyl-l,2a,4a,5,5a,12b-hexahydro-phenanthro [2,3-dJ [1,3]dioxol-5-
ylethanyl] 4-methyl-benzenesulfonamide (242). 
A flame-dried 10-mL flask was charged with alkane 226 (158 mg, 0.261 mmo1) 
and silica gel which has been activate by heating under vacuum at 120 °C 
overnight (1.3 g). The starting materials were suspended in 5 mL freshly distilled 
methylene chloride and the solvent removed under reduced pressure. The silica 
gel supporting the absorbed reactants was heated externally at 120°C under 
nitrogen atmosphere for 24 h, after which time the silica gel was loaded onto flash 
silica gel column and eluted with hexanes:ethy1 acetate, 8:1 - 5:1 to give 109 mg 
(69%) of alkane 242 as a clear and colorless oil. Rj0.35 (hexanes:ethy1 acetate, 
2:1); [a]23D -46.2 (c 2.8, CHCh); IR (film) v 3483,3273,2983,2954,2930,2891, 
2857, 1599, 1504, 1462, 1384, 1371, 1330 cm-I; IH NMR (300 MHz, CDCh) B: 
7.47 (d, J= 8.3 Hz, 2H), 7.12 (d, J= 8.1 Hz, 2H), 6.45 (s, 1H), 6.44 (s, IH), 5.90 
(d, J= 1.4 Hz, 1H), 5.82 (d, J= 1.4 Hz, 1H), 4.69 (d, J= 8.9 Hz, 1H), 4.08 (m, 
3H), 3.69 (q, J= 9.5 Hz, 1H), 2.86-2.61 (m, 3H), 2.40 (s, 3H), 2.22-2.01 (m,2H), 
1.73 (m, 1H), 1.44 (s, 3H), 1.31 (s, 3H), 0.87 (s, 9H), 0.10 (s, 3H), 0.04 (s, 3H) 
ppm; l3C NMR (75 MHz, CDCh) B: 146.4, 145.0, 142.2, 138.9, 129.6, 128.9, 
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128.8, 126.7, 110.6, 109.0, 108.6, 100.6, 79.5, 79.1, 71.1, 57.2, 41.3, 39.5,27.9, 
27.7, 25.9, 25.7, 21.6, 21.4, 18.0, -4.9, -5.0 ppm; HRMS-EI Calcd for 
61.87; H, 7.20; found C, 61.73; H, 7.29. 
N-«1R,2S,3S,4S,4aR,11bR)-4-(tert-butyldimethylsilyloxy)-3,3-dimethyl-6-
oxo-l,2,3,4,4a,5,6,11 b-octahydrophenanthro[3,2-d] [1,3]dioxol-l-yl)-4 
methylbenzenesulfonamide (243). 
Acetonide 242 (34 mg, 0.056 mmol) was taken up in dry CH2Ch (1.5 mL) and 
PCC (0.49 mg, 0.226 mmol) was added. The reaction was stirred until total 
consumption of starting material as monitored by TLC (14 h) before being diluted 
with diethyl ether and filtered through a short plug of celite and concentrated. 
The final product was isolated by flash column chromatography (hexanes/ethyl 
acetate, 4:1). Yield: 16 mg, 46 %, foamy solid; [a]23D -55.35 (c 0.06, CHCh); Rf 
0.29 (hexanes:ethyl acetate, 2:1); IR (film) v 3460,3266,2984,2953,29292897, 
2857, 1671, 1654, 1615, 1504, 1468, 1371, 1330, 1280 cm-\ IH NMR (600 
MHz, CDCh) 8: 7.43 (d, J= 8.1 Hz, 2H), 7.36 (s, 1H), 7.13 (d, J= 8.1 HZ,2H), 
6.60 (s, 1H), 6.01 (s, 1H), 5.94 (s, 1H), 5.22 (d, J = 9.2 Hz, 1H), 4.17-4.13 (m, 
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2H), 4.08 (s, IH), 3.68 (dd, J= 8.6,8.5 Hz, IH), 3.15 (dd, J= 18.3, 14.3 Hz, IH), 
3.0 (dd, J= 11.9,3.6 Hz, IH), 2.59 (dd, J= 18.4,4.5 Hz, IH), 2.54 (d, J= 14.8 
Hz, IH), 2.41 (s, 3H), 1.42(s, 3H), 1.33 (s, 3H), 0.86 (s, 9H), 0.09 (s, 3H),0.04 (s, 
3H) ppm; I3C NMR (150 MHz, CDCh) <5: 194.9, 151.6, 147.6, 142.3, 140.1, 
138.8, 129.1, 127.1, 126.7, 110.4, 109.3, 106.8, 101.7, 79.2, 79.1, 69.4,57.2,42.1, 
39.6, 36.8, 27.9, 25.9, 25.7, 25.6, 25.5, 21.5, 18.0, -5.0, -5.1 ppm; HRMS-EI 
Calcd C27H32NOgSSi: 558.1618; Found, 558.1617; AnaL calcd for C31H41NOgSSi: 
C, 60.46; H, 6.71; found C, 59.41; H, 60.63. 
N-( (lR,2S,3S,4S)-4-{ [tert-butyl( dimethyl)silyl]oxy}-3,3-dimethyl -1,2,3,4 
tetrahydrophenanthro [2,3-d] [1,3] dioxol-l-yl)-4-methylbenzenesulfonamide 
(244). 
Acetonide 242 (34 mg, 0.056 mmol) was taken up in dry CH2Ch (1.5 mL) and 
PCC (0.49 mg, 0.226 mmol) was added. The reaction was stirred until total 
consumption of starting material as monitored by TLC (14 h) before being diluted 
with diethyl ether and filtered through a short plug of celite and concentrated. 
The final product was isolated by flash column chromatography (hexanes/ethyl 
acetate, 4: 1). Yield: 7.7 mg, 23 %, slight yellow oil; [a]D 23 80.07 (c 1.25, CHCh); 
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Rf 0.44 (hexanes:ethy1 acetate, 2: 1); IR (film) v 3666, 3024, 2954, 2929, 2858, 
1621, 1598, 1503, 1470, 1411, 1381, 1372, 1334, 1214 em-I; IH NMR (300 MHz, 
CDCh) e>: 7.69 (d, J= 8.2 Hz, 2H), 7.59 (d, J= 8.2 Hz, 2H), 7.7.20-7.16 (m, 3H), 
7.05 (s, 1H), 6.88 (s,lH), 6.41 (d, J= 10.7 Hz, 1H), 6.01 (s, 1H), 5.20 (dd, J= 6.9, 
J = 2.0 Hz, 1H), 4.86 (d, J = 1.9 Hz, 1H), 4.68 (dd, J = 6.9, J = 2.0 Hz, 1H), 2.39 
(s, 3H), 1.26 (s, 3H), 0.92 (s, 6H), 0.77 (s, 3H), 0.28 (s, 3H),0.07 (s, 3H) ppm; 
l3C NMR (150 MHz, CDCh) e>: 148.5, 147.6, 143.2, 138.3, 132.3, 131.1, 130.5, 
129.4, 129.1, 127.5, 127.2, 125.9, 108.6, 104.0, 101.2, 100.1, 77.8, 77.7, 72.6, 
49.5, 25.9, 25.8, 24.6, 21.5, 18.0, -4.5, -4.8 ppm; HRMS-EI Calcd for 
62.28; H, 6.58; found C, 62.15; H, 6.64 
(3 'as,4 'R,5'R,6'S, 7'S, 7'aS)-7'-(tert-butyldimethylsilyloxy)-N,2' ,2'-trimethyl-
6' -( (methylamino )methyl)-4' -( 4-methylphenylsulfonamido )-3' a,4' ,5' ,6' ,7',7' a-
hexahydro-5,5'-bibenzo [d] [1,3]dioxole-6-carboxamide (251). 
Mesylate 250 (20 mg, 0.028 mmol) was taken up in THF (1.5 mL) and cooled 
externally to -78°C. MeNH2 was bubbled through until approximately 0.5 mL of 
methyl amine was condensed. The vessel was sealed and heated to 50°C until 
172 
total consumption of starting material as monitored by TLC. The reaction was 
cooled to 0 °C and the methylamine was allowed to slowly evaporate. The 
reaction was transferred to a separatory funnel and diluted with EtOAc (60 mL), 
washed with Na2C03 (2 x 2 mL), and brine (1 mL) before being dried over 
Na2S04, filtered, and concentrated. The final product was isolated by flash 
column chromatography (methylene chloride/methanol, 15:1). Yield: 7.5 mg, 41 
%, clear and colorless oil; [a]23D -63.42 (c 0.75, CHCh); Rf 0.17 (methylene 
chloride/methanol, 15:1); IR (film) v 3416, 2956, 2930, 2895, 2857, 1631, 1550, 
1506, 1487, 1384, 1327, 1250 em-I; IH NMR (600 MHz, CDCh) b: 7.59 (d, J = 
8.3 HZ,2H), 7.13 (d, J = 8.3 Hz, 2H), 6.98 (s, IH), 6.74 (s, IH), 6.70 (s, IH), 
6.03 (d, J= l.1 Hz, IH), 6.01 (d, J= l.2 Hz, IH), 4.20-4.10 (m, 3H), 3.66 (m, 
IH), 3.50 (dd, J = 1l.2, J = 8.0 Hz, IH), 2.95 (d, J = 4.8 Hz, 3H), 2.88 (dd, J = 
1l.2, 7.1 Hz, 2H), 2.82 (d, J = 4.9 Hz, IH), 2.38 (s, 3H), 2.33 (d, J = 10.8 Hz, 
IH), 2.29 (s, 3H), l.49 (s, 3H), l.27 (s, 3H), 0.91 (s, 9H), 0.16 (s, 3H),0.12 (s, 3H) 
ppm; i3C NMR (150 MHz, CDCh) b: 171.4, 149.0, 146.6, 142.1, 139.3, 132.1, 
128.8, 126.9, 109.5, 108.6, 107.3, 1Ol.7, 8l.2, 77.9, 7l.6, 59.2, 49.8, 4l.6, 35.3, 
27.4, 27.1, 26.5, 25.9, 25.9, 25.3, 23.2, 2l.4, 18.1, -4.3, -5.0 ppm; HRMS-EI 
Calcd C33~9N308SSi: 675.3010; Found, 675.2009. 
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(3aS,3bR,10bR,12S,12aS)-12-(tert-butyldimethylsilyloxy)-2,2-dimethyl-
3b,4,1 Ob,II,12,12a-hexahydrobis [1,3] dioxolo [4,S-c:4' ,5' -j]phenanthridin-
S(3aH)-one (253). 
To a solution of aldehyde 166 (192 mg, 0.305 mmol) in toluene (10 mL) was 
added RhCl(PPh3)3 (424 mg, 0.458 mmol). The reaction vessel was sealed, 
lowered into a pre-heated oil bath (130 °C), and stirred until total consumption of 
starting material as monitored by TLC (7.5 h). The crude reaction mixture was 
filtered through a silica plug using a mixture of 2: 1 hexanes/ethyl acetate as eluent 
and allowed to stand overnight. The resulting yellow crystals were removed by 
filtration and the crude reaction mixture was concentrated under reduced pressure 
and dried under vacuum. The crude was taken up in DME (8 mL) and cooled to-
60 °C. To the acetonide solution was added a 0.5 M solution ofNa/naphthalene in 
DME until a green color persisted and total consumption of starting material was 
observed (by TLC). The solution was stirred for 10 minutes before the reaction 
was quenched with saturated aqueous ammonium chloride solution (3 mL). The 
reaction was warmed to room temperature, concentrated to remove DME, and 
extracted with CH2Ch (3 x 50 mL). The combined organic phase was dried over 
sodium sulfate, filtered, and concentrated. The final product was isolated by 
column chromatography using 3:1 mixture of hexanes/ethyl acetate as eluent. 
Yield: 101 mg, 74%, clear and colorless oil; Rj0.49 (hexanes/ethyl acetate, 1:1); 
[a]D22 - 20.929 (c 1.5, CHCh); IR (film) v3360, 2952, 2929, 2894, 2857, 1670, 
1615, 1505, 1482, 1459, 1384, 1345, 1270, 1256, 1243, 1219; IH NMR (600 
MHz, CDCh) 0: 7.59 (s, IH), 6.77 (s, IH), 6.28 (s, IH) 6.03 (d, J = 5.28, 2H), 
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4.42 (d, J = 2.10, IH), 4.18, (dd, J = 8.3 Hz, 4.8 Hz, IH), 4.11 (m, IH), 3.43 (dd, 
J = 13.2 Hz, 8.6 Hz, IH), 3.12 (t, J = 13.5 Hz, IH), 2.26 (d, J = 13.6 Hz, IH), 
1.77 (t, J = 13.9 Hz, IH), 1.46 (s, 3H), 1.41 (s, 3H), 0.91 (s, 9H), 0.15 (s, 3H), 
0.14 (s, 3H); l3C NMR (150 MHz, CDCh) 8:165.7, 151.4, 146.7, 136.5, 122.9, 
109.9, 108.4, 104.3, 101.7, 77.7, 66.9, 57.9, 31.9, 31.6, 28.3, 26.5, 25.7, 25.6, 
21.1, 17.9, -4.8, -4.9 ppm; HRMS-EI Calcd for C23H33N06Si (M+): 447.2077, 
Found: 447.2083. 
9H 
OH 
OH 
o 
7-Deoxy-trans-dihydrolycoricidine (3). 
To a solution of acetonide 253 (13 mg, 0.29 mmol) in MeOH (1 mL) was added a 
10% solution of HCl in MeOH (10 mL). The reaction was stirred until total 
consumption of starting material as monitored by TLC (3 days). The final product 
was isolated by flash column chromatography (chlorofonnlmethanol, gradient 
7:1-5:1). Yield: 6.1 mg, 71%, white solid; mp > 200°C (MeOH); Rf 0.25 
(methylene chloride/methanol, 5:1); [a]D22 28.6 (c 0.25, DMSO), lit.150[a]D25 138 
(c 0.96, DMSO); IR (KBr) v 3559, 3488, 3450, 3429, 1671, 1471, 1263 cm-I; IH 
NMR (600 MHz, DMSO-d6) 8: 7.30 (s, IH), 6.95 (s, IH), 6.94 (s, IH), 6.08 (s, 
2H), 4.99 (d, J= 3.4 Hz, IH), 4.96 (d, J= 5.9 Hz, IH), 4.84 (d, J= 3.2 Hz, IH), 
3.89, (hr s, IH), 3.72 (br s, 2H), 3.30 (d, J = 12.3 Hz, IH), 2.89 (td, J = 12.4, 3.6 
Hz, IH), 2.15 (dt, J= 13.0,3.0 Hz, IH), 1.65 (td, J= 12.9,2.2 Hz, IH) ppm; BC 
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NMR (150 MHz, DMSO-d6) b: 164.7, 151.1, 146.4, 138.5, 123.7, 107.4, 104.8, 
102.0, 72.1, 70.1, 69.1, 55.6, 34.7, 28.8 ppm; HRMS-EI Calcd for C14H16N06 
(M++1): 294.0978, Found: 294.1011. 
o 
o 
(3aS,3bR,1 ObR,IIR,12S,12aS)-II-Acetyl-12-(tert-butyl-dimethyl-silanyloxy)-
2,2-dimethyl-4-(toluene-4-sulfonyl)-3b,4,10b,II,12,12a-hexahydro-3aH-
1,3,7 ,9-tetraoxa-4-aza-dicyclopenta[a,h ]phenanthren-5-one (257) 
To a solution of aldehyde 166 (200 mg, 0.318 mmol) in Et20 (3 mL) at O°C was 
added MeMgI (423 mg, 0.382 mmol) dropwise. The reaction stirred until total 
consumption of starting material (2 h) as monitored by TLC. The reaction mixture 
was quenched with NH4CI (3 mL). The solvent was removed under reduced 
pressure and the aqueous phase was extracted with EtOAc (3 x 20 mL). The 
organic phase was combined, dried over sodium sulfate, filtered, and 
concentrated. The crude mixture was concentrated and taken up in dry CH2Ch (5 
mL). A stirring bar was added and the reaction was stirred while Collins reagent 
(416 mg, 1.616 mmol) was added. The reaction was stirred until total 
consumption of starting material (15 minutes) as monitored by TLC. The reaction 
mixture was diluted with hexanes/ethyl acetate 2:1 (15 mL) and filtered through a 
silica plug. The combined organic layer was washed with 0.25 M HCI (3 mL), 
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NaHC03 (3 mL), dried over sodium sulfate, filtered and concentrated. The final 
product was isolated by column chromatography (hexane/ethyl acetate, 4:1). 
Yield: 76 mg, 44%, clear and colorless oil; Rf 0.26 (hexanes:ethyl acetate, 2:1); 
[a]D22 - 56.87 (c 4.0, CHCh); IR (film) v 3002, 2975, 2861, 2373, 1718, 1700, 
1652, 1506, 1486, 1361, 1263, 1222, 1171, 1097, 1036 cm- l ; IH NMR (300 MHz, 
CDCh) b: 8.24 (d, J= 7.2 Hz, 2H), 7.58 (s, IH), 7.35 (d, J= 8.4 Hz, 2H), 6.50 (s, 
IH), 6.02 (d, J = 3.3 Hz, 2H), 5.82 (dd, J = 8.1 Hz, J = 5.4 Hz, IH), 4.91 (m 2H), 
4.29 (d, J = 2.7 Hz, IH), 3.80 (dd J = 12.3, J = 3.9 Hz, IH), 3.47 (m IH), 2.48 (s, 
3H), 2.22 (s, 3H), 1.44 (s, 3H), 1.34 (s, 3H), 1.01 (s, 9H), 0.31 (s, 6H) ppm; l3e 
NMR (150 MHz, CDCh) b: 202.5 166.4, 152.7, 146.6, 143.6, 139.0, 138.5, 128.9, 
128.7, 123.2, 110.1, 109.2, 103.3, 101.9, 73.0, 67.2, 65.2, 56.8, 36.1,29.3, 27.3, 
26.9, 25.7, 21.6, 18.0, -4.6, -4.9 ppm; HRMS-EI Calcd for C32lLnN09SSi (M+-
15): 628.2036, Found: 628.2036. 
OH 
o 
(lR,4S,5S,5aR,12bR,13S)-13-{ [tert-butyl( dimetbyl)silyl]oxy}-5-bydroxy-6-[ (4-
metbylpbenyl)sulfonyl]-1,4,5,5a,6,12b-bexabydro-l,4-
metbano [1,3] dioxolo [4,5-g]oxepino[4,5-c]isoquinoline-2, 7 -dione (261). 
To a solution of ketone 257 (13 mg, 0.021mmol) in CH2Ch (0.5 mL) in a conical 
vial was added a single crystal of p-toluenesulfonic acid monohydrate followed 
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by m-CPBA (7 mg, 0.31 mmol). The vial was sealed and stirred overnight (10 h). 
The reaction was diluted with CH2Cb (20 mL), washed with saturated NaHS03 (2 
mL), and NaHC03 (2 x 1.5 mL). The organic phase was dried over sodium 
sulfate, filtered, and concentrated. The final product was isolated by column 
chromatography using a gradient of3:1 to 1:1 mixture ofhexanes: ethyl acetate as 
eluent. Yield: 4 mg, 33%, clear oil; Rf 0.16 (hexanes/ethyl acetate, 2:1); IR 
(film) v3507, 2935, 2929, 1788, 1685, 1617, 1505, 1485, 1360, 1275; IH NMR 
(600 MHz, CDCh) b: 7.99 (d, J =7.7 Hz, 2H), 7.42 (s, 1H), 7.33 (d, J =7.8 Hz, 
2H), 6.96 (s, 1H), 6.06 (s, 2H), 5.45 (m, 1H), 4.81 (d, J = 5.4, 1H), 4.74 (t, J = 
5.1 Hz, 1H), 4.12 (t, J= 10.2 Hz, 1H), 3.83 (d, J=11.7 Hz, 1H), 3.2 (d, J=6.7 Hz, 
1H), 3.27 (s, 1H), 2.45 (s, 3H), 1.02 (s, 9H), 0.27 (s, 3H), 0.23 (s, 3H); l3C NMR 
(150 MHz, CDCl3) b:171.2, 164.7, 152.7, 147.7, 144.4, 138.5, 135.0, 129.5, 
127.7, 122.2, 109.6, 104.9, 102.3, 96.1, 82.8, 69.3, 69.1, 64.0, 42.9, 36.4, 25.7, 
21.7, 17.9, 1.0, -0.8; HRMS-EI Calcd for C27H30N09Si (~-15): 572.1368, 
Found: 572.1389. 
OAe OMs 
0 ~>< 
\, 0 
0 
[(3aS,3bR,1 ObR,11S,12S,12aS)-2,2-dimethyl-4-[ (4-methylphenyl)sulfonyl]-5-
oxo-12-(sulfooxy)-3a,3b,4,S,lOb,11,12,12a-octahydrobis[1,3] dioxolo [4,S-
c:4' ,S' "11phenanthridin-ll-yl] methyl acetate (272). 
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To a stirring solution of 271 (73 mg, 0.131 mmol) in dry CH2Ch (4 mL) at 0 °c 
was added triethylamine (0.55 pL, 0.394 mmol) followed by methanesulfonyl 
chloride (0.02 mL, 0.263 mmol). The reaction was stirred at 0 °c until total 
consumption of starting material as indicated by TLC (20 minutes). The reaction 
was diluted with EtzO (100 mL), washed sequentially with H20 (10 mL), 
saturated sodium bicarbonate (5 mL), H20 (3 x 1 mL), and brine (5 mL). The 
ether layer was dried over magnesium sulfate, filter, and concentrated to provide 
mesylate 277 which was used without further purification. Yield: 80 mg, 96%, 
clear oil; Rf 0.27 (hexanes/ethyl acetate, 1:1); [a]o22 5.42 (c 0.75, CHCh); IR 
(film) v3025, 2988, 2929, 1741, 1691, 1618, 1597, 1505, 1485, 1435, 1358, 1255; 
IH NMR (600 MHz, CDCh) 8: 8.22 (d,J= 8.3 Hz, 2H), 7.50 (s, 1H), 7.33 (d,J= 
8.2 Hz, 2H), 6.89 (s, IH), 6.08 (dd, J= 5.1 Hz, J= 1.1 Hz, 2H), 5.58 (dd, J= 7.7 
Hz, J= 5.9 Hz, 1H), 5.36 (d, J= 3.5, 1H), 4.52 (t, J= 4.9 Hz, 1H), 4.15 (dd, J= 
10.9 Hz, J= 10.9 Hz, 1H), 4.12 (dd, J= 13.0 Hz, J= 7.9 Hz, 1H), 4.00 (dd, J= 
11.3 Hz, 3.8 Hz, 1H), 3.70 (dd, J= 12.9,4.8, 1H), 3.21 (s, 3H), 3.11 (dd, J= 3.7, 
3.7, 1H), 2.45 (s, 3H), 2.08 (s, 3H), 1.46 (s, 3H), 1.42 (s, 3H); BC NMR (150 
MHz, CDC13) 8:170.78, 165.38, 153.36, 147.69, 144.23, 138.20, 133.86, 128.93, 
128.91, 122.92, 110.06, 108.88, 105.20, 102.38, 75.85, 75.69, 73.89, 62.32, 60.30, 
40.93, 37.08, 31.55, 27.96, 25.89, 21.66, 20.78 ; HRMS-EI Calcd for 
C27H28N012S2 (~-15): 622.1053, Found: 622.1057 
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OH 
o 
(3aS,3bR,lObR,12S,12aR)-12-Hydroxy-4-(4-methoxy-benzyl)-2,2-dimethyl-
3b,4,1 Ob,11,12,12a-hexahydro-3aH-l,3, 7,9-tetraoxa-4-aza-
dicyclopenta [a,h ]phenanthren-5-one (284). 
To a solution of acetonide 253 (21 mg, 0.047 mmol) in DMF (0.24 mL) at 0 °C 
was added NaH (spatula tip, 60 % dispersion in mineral oil). The reaction was 
stirred at 0 °C for 10 min and then at rt for 20 min. The reaction was cooled in ice 
again before p-methoxy benzylbromide (11 JlL, 0.07 mmol) was added and the 
reaction was allowed to warm to rt over 2 h. The reaction was taken up in EtzO (5 
mL) and quenched with H20 (2 mL), transferred to a separatory funnel and 
diluted further with Et20 (50 mL). The ether layer was wased with H20 (6 x 0.5 
mL), brine (1 x 1 mL), dried over magnesium sulfate, flitered, and concentrated 
under reduced pressure. The crude residue was taken up in THF (1 mL) and 
cooled to O°C. TBAF (56 JlL, 0.056 mmol, 1 M in THF) was added and the 
reaction stirred for 20 minutes. Silica (0.2 g) was added and the reaction 
concentrated to dryness. The fmal product was isolated by flash column 
chromatography (hexanes : ethyl acetate, gradient 2:1-1:1). Yield: 13.6 mg, 64%, 
slight yellow oil; Rf 0.41 (hexanes:ethyl acetate, 2:1); [a]D22 + 40.90 (c 0.50, 
CHCb); IR (film) v IR (film) v 3550, 2920, 1642, 1516, 1453 cml ; IH NMR (600 
MHz, CDCb) 8: 7.63 (s, IH), 7.24 (d, J= 8.6 Hz, 2H), 6.82 (d, J= 8.6 Hz, 2H), 
6.75 (s, IH), 6.03, (s, 2H), 5.21 (d, J= 15.8 Hz, IH), 4.90 (d, J= 15.5 Hz, IH), 
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4.39 (dd, J = 7.6, 6.2 Hz, 1H), 4.23 (m, 1H), 4.12 (t, J = 5.61 Hz, 1H), 3.78 (s, 
3H), 3.71 (dd, J= 13.4, 7.9 Hz, 1H), 3.19 (td, J= 12.4,5.0 Hz, 1H), 2.36-2.28 (m, 
2H), 2.01 (qd, J = 13.6, 11.9, 4.9 Hz, 1H), 1.387 (s, 3H), 1.34 (s, 3H) ppm; l3C 
NMR (150 MHz, CDCh) 0: 165.2,158.4, 151.1, 146.8, 135.4, 131.8, 128.2, 123.1, 
113.7, 109.5, 108.6, 104.2, 101.6, 78.1, 75.9, 66.6, 61.6, 61.9, 55.3, 46.3, 32.3, 
21.0, 28.0, 26.1 ppm; HRMS-EI Calcd for C2sH2SN07 (M+): 453.1788, Found: 
453.1787. 
o 
(3 as,3bR, 1 ObR,12aR)-4-( 4-methoxybenzyl)-2,2-dimethyl-
3a,3b,4,7,8,9,lOb,12a-octahydro-5H-cyciopentalll[1,3]diox010[4,5-
c]phenanthridin-5-one (285).49k 
To a solution of alcohol 284 (15 mg, 0.033 mmol) in THF (1 mL) at 0 °C was 
added a spatula tip of NaH (60 % dispersion in mineral oil). The reaction was 
stirred at 0 °C for 10 min before being allowed to warm to rt and stir for 45 min. 
The reaction was cooled externally to 0 °C again before CS2 (12 JlL, 0.198 mmol) 
was added. After stirring for 1 h at 0 °C Mel (25 JlL, 0.397 mmol) was added and 
the reaction was allowed to warm to rt slowly over 5 h before being quenched 
with sat. N~CI (2 mL). The reaction was concentrated to remove THF, the aq 
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residue was extracted with EtOAc (3 x 30 mL), and the organic phases combined 
and dried over sodium sulfate. Following filtration, the EtOAc was removed 
under reduced pressure, the residue taken up in o-zylene (2 mL) and heated at 
reflux for 21 h. The reaction was concentrated under reduced pressure at 50°C 
and the crude residue loaded onto silica (100 mg). The final product was isolated 
by flash column chromatography (hexanes : ethyl acetate, 4:1). Yield: 5 mg, 35%, 
white solid; mp 172-174 °C (ethyl acetateihexanes), lit:49k 171-173 °C; Rf 0.51 
(hexanes:ethyl acetate, 1:1); [a]D22+ 37.48 (c 0.20, CHCh); IR (film) v 2920, 1647, 
1511, 1451 em-I; IH NMR (600 MHz, CDCh) b: 7.67 (s, IH), 7.27 (d, J = 8.6 Hz, 
2H), 6.92 (s, IH), 6.84 (d, J = 8.6 Hz, 2H), 6.34 (d, J = 10.2 Hz, IH), 6.11 (dt, J = 
10.0 Hz, 3.1 Hz, IH), 6.05 (s, 2H), 5.43 (d, J= 15.6 Hz, IH), 4.98 (d, J= 15.5 Hz, 
IH), 4.64-4.61 (m, IH), 4.39 (dd J= 9.3, 7.1 Hz, IH), 3.80 (s, 3H), 3.66 (dd, J = 
11.9, 9.3 Hz, IH), 3.49 (d, J = 12.1, IH), 1.38 (s, 3H), 1.35 (s, 3H) ppm; l3C 
NMR (150 MHz, CDCh) b: 165.5, 158.3, 151.1, 146.9, 133.6, 132.6, 128.2, 
127.9, 126.1, 123.7, 113.7, 109.3, 109.2, 103.8, 101.7, 74.8, 71.9, 60.8, 55.3,45.8, 
38.6, 27.6, 25.3 ppm; HRMS-EI Calcd for C2SH2SN06 (M+): 435.1682, Found: 
435.1683 
Etbyl6-oxo-3a,4,6,6a-tetrabydro-lH-furo[3,4-c]pyrazole-3-carboxylate (302). 
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To a solution of crotonolactone 301 (1.0 g, 12 mmol) in dioxane (7 mL) was 
added ethyldiazoacetate (1.5 mL, 14 mmol). The reaction mixture was heated at 
95°C for 12 hours before being allowed to cool to rt and concentrated to a thick 
oil. Trituration with CHCh provided a crude yellow solid. The final product was 
purified by recrystallization from EhO. Yield: 0.796g, 48%, off white solid, mp 
132-134 °C (diethyl ether); Rf 0.26 (hexanes:ethyl acetate, 1:1); IH NMR (300 
MHz, CDCh) 8: 6.86 (bs, IH), 4.77-4.60 (m, 3H), 4.37 (q, J= 8.6 Hz, 2H), 4.22 
(ddd, J= 10.8 Hz, 6.8 Hz, 1.9 Hz, 2H), 1.39 (t, J= 7.14 Hz, 3H) ppm; 13C NMR 
(75 MHz, CDCh) 8: 175.2, 161.5, 141.7, 70.7, 61.8, 61.2, 45.7, 14.2 ppm; 
HRMS-EI Calcd for CSHlON204 (M+): 198.0641, Found: 198.0638. 
)l}J=0 
/'0 
Ethyl 2-(5-oxo-2,5-dihydrofuran-3-yl)acetate (303) 
Pyrazole 302 (2.8 g, 14.13 mmol) suspended in toluene (75 mL) in a Schlenk tube 
equipet with a teflon stopper and a magnetic stirring bar. The tube was sealed and 
heated to 150°C for 12 h. The crude reaction mixture was filtered through a 
silica plug and eluted with a mixture of hexane:ethyl acetate (2:1). Yield: 2.135 
g, 89 %, clear and colorless oil; Rf 0.41 (hexanes:ethyl acetate, 1: 1); IR (film) v 
3626,3515,3478,3119,2984,2939,1919,1735,1641,1448, 1372,1160 cm-I ; IH 
NMR (300 MHz, CDCh) 8: 6.06 (m, IH), 4.91 (m, 2H), 4.21 (q, J= 7.1 Hz,2H), 
3.52 (s, 2H), 1.29 (t, J = 7.13 Hz, 3H) ppm; 13C NMR (75 MHz, CDCb) 8: 173.1, 
167.9, 161.1, 118.8, 73.0, 61.8, 34.4, 14.1 ppm; HRMS-EI Calcd for CSHlO04 
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(M+): 170.0579, Found: 170.0578; Anal. calcd CgHlO04 C, 56.47; H, 6.84; found 
C, 56.32; H, 6.01. 
o 'sX )If}-d " 
/'0 
Ethyl 2-(5-(tert-butyldimethylsilyloxy)furan-3-yl)acetate (305) 
Lactone 303 (980 mg, 5.79 mmol) was taken up in CH2Ch (20 mL) and cooled 
externally in an ice bath while NEt3 (1.21 mL, 8.69 mmol) was added. The 
reaction was stirred for 15 min before TBSOTf (1.66 mL, 7.24 mmol) was added 
dropwise over 10 min. The reaction was allowed to wann to room temperature 
over 2 hours before being quenched with H20 (20 mL). The two layers were 
separated and the aqueous phase was extracted with CH2Ch (3 x 60 mL). The 
organic phase was washed with a 10% solution of citric acid (2 x 10 mL), H20 
(10 mL), drided over sodium sulfate and filtered/concentrated. The fmal product 
was isolated by flash column chromatography (hexanesl ethyl acetate, 4: 1). Yield: 
1.103 g, 67 %, slight yellow oil; Rf 0.7 (hexanes:ethyl acetate, 1:1); IR (film) v 
3127,2932, 2860, 2744, 2715, 1743, 1625, 1573, 1524, 1472, 1392, 1366, 1287 
em-I; IH NMR (300 MHz, CDC13) 0: 6.77 (d, J = 0.92, IH), 5.15 (d, J = 0.92, 
IH), 4.16 (q, J= 7.1 Hz, 2H), 3.45 (s, 2H), 1.27 (t, J= 7.14 Hz, 3H), 0.97 (s, 9H), 
0.24 (s, 6H) ppm; BC NMR (75 MHz, CDC13) 0: 171.2, 156.8, 129.6, 118.7, 
85.5, 60.7, 31.8, 25.4, 18.0, 14.2, -4.9 ppm; HRMS-EI Calcd for CI4H2404Si 
(M+): 284.1444, Found: 284.1440; Anal. calcd CI4H2404Si C, 59.12; H, 8.51; 
found C, 58.61; H, 8.37. 
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I 
-Si-
II 
........ 0 
3-Methoxy-6-( (trimethylsilyl)ethynyl)pyridazine (296). 
To a solution of pyridazine 7 (1 g, 4 mmol) in THF (10 mL) was added 
triethylamine (3.55 mL, 25.53 mL). The reaction mixture was cooled externally 
in an ice bath and trimethylsilylacetylene (0.662 mL, 4.68 mmol) added, followed 
by CI (41 mg, 0.21 mmol) and PdClz(Ph3)2 (150 mg, 0.213 mmol). The reaction 
mixture was maintained at 0 °C for 1 hour then allowed to warm to room 
temperature and stir for 4 hours. The reaction was concentrated to dryness, taken 
up in CH2Clz, and filtered through a silica plug (CH2Clz: Et3N 400:1). Silica (4g) 
was added and the filtrate was concentrated to dryness. The final product was 
isolated by flash column chromatography (hexanes : ethyl acetate, 4:1). Yield: 
0.737 g, 84%, slight orange oil; Rf 0.55 (hexanes:ethyl acetate, 2:1); IR (film) v 
3081, 3016,2935,2898,2877,2634,2616,2574,2498,2167, 1589, 1538, 1461, 
1403, 1328, 1290, 1251, 1164, 1010 em-I; IH NMR (300 MHz, CDCb)~: 7.45 (d, 
J = 9.1 Hz, IH), 6.92 (d, J = 9.3 Hz, IH), 4.16 (s, 3H), 0.30 (s, 9H) ppm; 13C 
NMR (75 MHz, CDCb) ~: 163.4, 143.4, 132.4, 116.4, 100.6, 98.2, 55.0, -0.4 
ppm; HRMS-EI Ca1cd for ClOH14N20Si (M+): 206.0875, Found: 206.0875; Anal. 
calcd ClOHl~20Si C, 58.21; H, 6.84; found C, 57.72; H, 6.67. 
185 
II 
/0 
3-Ethynyl-6-methoxypyridazine (307). 
To a solution ofpyridazine 296 (0.262 g, 1.27 mmol) in THF (10 mL) was added 
TBAF (1.9 mL, 1.905 mmol). The reaction was immediately quenched with sat. 
~CI (5 mL) and concentrated to remove THF. The crude mixture was 
extracted with EtOAc (3 x 20 mL) and the organic extracts combined, washed 
with brine (5 mL), dried over magnesium sulfate, filtered, and concentrated. The 
final product was isolated by flash column chromatography (hexanes : ethyl 
acetate, 4:1). Yield: 0.118 g, 69%, slight yellow crystals; mp 51-53°C (ethyl 
acetate/hexanes); Rf 0.27 (hexanes:ethyl acetate, 2:1); IR (film) v 3272, 3060, 
2991,2950, 1587, 1467, 1442, 1403, 1328 cm-1 IH NMR (300 MHz, CDCb) 8: 
7.47 (d, J = 9.1 Hz, IH), 6.92 (d, J = 9.1 Hz, IH), 4.15 (s, 3H), 3.31 (s, IH) ppm; 
13C NMR (75 MHz, CDCb) 8: 163.7, 142.6, 132.5, 116.6, 80.2, 79.9, 55.1 ppm; 
HRMS-EI Calcd for C7H6N20 (M+): 134.0480, Found: 134.0482; Anal. calcd. 
C7H~20 C, 62.68; H, 4.51; found C, 62.73; H, 4.40. 
CI N? II  d-
0 ........ 
3-Chloro-6-methoxypyridazine (313) 
186 
To a solution of 3,6-dichloropyridazine (8) (1.5 g, 10.07 mmol) in MeOH (100 
mL) was added K2C03 (1.67 g, 12.08 mmol). The resulting suspension was 
brought to reflux and heated for 11 h. The reaction was allowed to cool to rt 
before being concentrated to a thick slurry which was quickly added to H20 (40 
mL). The resulting white precipitate was filtered and washed with ice cold H20 
(10 mL). Yield: 0.598 g, 41%, white solid; mp 88-90 °c (methanol/water); Rf 
0.29 (hexanes:ethyl acetate, 2:1); IR (film) v 3272, cm-I; IH NMR (300 MHz, 
CDCb)~: 7.38 (d, J = 9.1 Hz, IH), 6.97 (d, J = 9.1 Hz, IH), 4.13 (s, 3H; BC 
NMR (75 MHz, CDC13) ~: 1.64.4, 151.1, 130.7, 120.0, 55.2 ppm; HRMS-EI 
Calcd for CsHsCIN20 (M+): 144.0090, Found: 144.0092; Anal. calcd CsHsCIN20 
C, 41.54; H, 3.49; found C, 41.49; H, 3.39. 
1,2-his( 6-Methoxypyridazin-3-yJ)ethyne (6) 
To a solution of Pd(Ac)2 (119 mg, 0.53 mmol), PPh3 (280 mg, 1.06 mmol), and 
CuI (203 mg, 1.06 mmol) in a mixture of acetonitril:water (3:1, 50 mL) was 
added iodopyridazine (7) (5 g, 21.28 mmol) followed by NEt3 (8.87 mL, 63.82 
mmol). The reaction was flushed with acetylene gas using a balloon. The reaction 
was stirred under an atmosphere of acetylene for 10 h before being concentrated 
and dried under vacuum for 6h. The black residue was taken up in CH2Ch (300 
mL), washed with H20 (4 x 30 mL), dried over sodium sulfate, and 
filtered/concentrated. The final product was isolated by recrystalizations from 
chloroform: ether. Yield: 2.01 g, 78%, light brown solid; decomposition point 220 
187 
°c (chlorofonn:ether); Rf 0.60 (methylene chloride:methanol, 10:1); IR (film) v 
3058, 1589, 1543, 1472, 1422, 1350, 1291 cm\ IH NMR (300 MHz, CDCh) 8: 
7.64 (d, J = 9.2 Hz, IH), 7.01 (d, J = 9.2 Hz, IH), 4.21 (s, 3H) ppm; BC NMR 
(75 MHz, CDCh) 8: 163.8, 142.8, 132.6, 116.7,87.9,55.2 ppm; HRMS-EI Calcd 
for Cl2HION202 (M+): 242.0803, Found: 242.0807; Anal. calcd C12HION20 2 C, 
59.50; H, 4.16; found C, 59.32; H, 4.16. 
MeO 
H 
N, 
N 
II 
N 
OMe 
1,2-his(6-methoxypyridazin-3-yl)-N-methylethanamine (309). 
Pyridazine 6 (0.5 g, 2.06 mmol) in a Schlenk tube was suspended in toluene (20 
mL) and cooled externally to -78°C. Freshly generated methylamine was 
condensed into the tube by bubbling through the cold solution. Approximately 5 
mL of methyl amine was added in this way. Ind2TiMe2 was added to the tube 
before it was sealed and allowed to wann to room temperature. The reaction was 
placed in a preheated oil bath at 110 °c and stirred for 4.5 h before being removed 
from heat and being allowed to cool to room temperature overnight. The reaction 
was cooled externally to -10°C and argon was bubbled through until methyl 
amine was no longer detected by Alkacid paper. MeOH (10 mL) was added 
followed by ZnCh (0.419 g, 3.09 mmol) and NaBH3CN (127 mg, 2.06 mmol). 
After 1 h another portion of and NaBH3CN (120 mg) was added and the reaction 
was allowed to warm to room temperature over 10 h. The reaction cooled in an 
188 
ice bath and quenched with the slow addition of sat. Na2C03 solution (10 mL). 
The reaction mixture was diluted with CH2Ch (200 mL) and separate. The 
aqueous phase was extracted with CH2Ch (3 x 100 mL). The organic phase was 
dried over Na2S04 and treated with deactivate charcoal before being filtered and 
concentrated. The fmal product was isolated by flash column chromatography 
(methylene chloride:methanol, 10:1). Yield: 0.385 g, 68%, off white solid; mp 
125-127 °C (chloroform/ether); RfO.11 (methylene chloride:methanol, 10:1); IR 
(film) v 3308, 3063, 2952, 2925, 2855, 2797, 1724, 1598, 1553, 1468, 1415, 1306 
cm-I ; IH NMR (300 MHz, CDCb) 8: 7.51 (d, J= 9.0 Hz, IH), 7.22 (d, J= 9.0 
Hz, IH), 6.94 (d, J = 9.0 Hz, IH), 6.88(d, J = 9.0 Hz, IH), 4.34 (t, J = 6.9 Hz, 
IH), 4.12 (s, 3H), 4.10 (s, 3H), 3.34 (d, J= 4.3 Hz, IH), 3.32 (d, J= 2.8 Hz, IH), 
2.35 (s, 3H) ppm; 13C NMR (75 MHz, CDCb) 8: 164.7, 164.1, 159.6, 156.1, 
13004, 128.9, 117.7, 117.6, 63.5, 54.7, 54.6,41.2,34.3 ppm; HRMS-EI Calcd for 
C13H17N502 (M+): 275.1382, Found: 275.1382; Anal. calcd C13H17N502 C, 56.71; 
H, 6.22; found C, 56.66; H, 6.15. 
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